{
  "topicName": "Asthma",
  "topicId": "2a0a90e6-1c4e-4b6a-9ce2-3379dd122594",
  "exportId": "5630bad0-fca7-4c91-85ca-aa5700e2147d",
  "dataId": "ecfa8284-a76d-4a3c-aec4-aa5b00cd85cb",
  "number": 6,
  "dateOfExport": "2019-05-28T12:28:16.0935447+00:00",
  "nextPlannedReviewBy": "2023-12-31T23:59:59+00:00",
  "topicSummary": "Asthma is a chronic inflammatory condition of the airways.The airways are hyper-responsive and constrict easily in response to a wide range of stimuli",
  "lastRevised": "Last revised in April 2018",
  "terms": [
    {
      "code": "D001249",
      "term": "Asthma"
    }
  ],
  "clinicalSpecialties": ["Allergies", "Child health", "Respiratory"],
  "topicHtmlObjects": [
    {
      "itemId": "f161063e-ec35-49f0-9a35-397396abb944",
      "parentId": null,
      "rootId": "f161063e-ec35-49f0-9a35-397396abb944",
      "fullItemName": "Summary",
      "htmlHeader": "<!-- begin field 294d3498-a991-495f-983a-f58c3e390308 --><h1>Asthma: Summary</h1><!-- end field 294d3498-a991-495f-983a-f58c3e390308 -->",
      "htmlStringContent": "<section aria-labelledby='topical-treatment'><div class='ChapterBody-module--section--2d0kz'><h2 id='topical-treatment' class='visually-hidden'>Scenario: Topical treatment</h2><!-- begin item abcce840-02bc-4871-8c18-225e1b02265e --><!-- begin field b27861cb-ce61-460a-a48d-ac070090ec1d --><p>From birth onwards.</p><!-- end field b27861cb-ce61-460a-a48d-ac070090ec1d --><!-- end item abcce840-02bc-4871-8c18-225e1b02265e --></div><section aria-labelledby='initiation'><div class='ChapterBody-module--section--2d0kz'><h3 id='initiation'>What should I consider when initiating topical corticosteroids?</h3><!-- begin item 714989ff-b037-4e62-8cff-0a8511ea2c5a --><!-- begin field 9c0b9e06-9888-446c-9693-52fadf887ca7 --><ul><li>Topical corticosteroids are effective and have few adverse effects if they are used appropriately.</li><li>The choice of topical corticosteroid depends on the condition being treated, the area of the body affected, and the age of the person.<ul><li>Mild eczema may only require a mild topical corticosteroid, whereas more potent topical corticosteroids may be required as part of the treatment strategy for psoriasis.<ul><li>Prescribe the least&nbsp;<a class='topic-reference internal-reference' href='#30f839a5-9ee0-4141-8786-fdfc171a890c'>potent</a>&nbsp;corticosteroid that relieves symptoms, and an&nbsp;<a class='topic-reference internal-reference' href='#d3c0cd13-7615-4485-b699-7843c4f5e471'>appropriate quantity</a>.</li><li>If the treatment is for a flare-up of disease activity, taper the treatment by using a less potent corticosteroid once the flare-up is under control.</li></ul></li><li>Areas where the skin is thin or flexural (such as the face, scrotum, groin, axillae, and submammary area) usually require a&nbsp;<a class='topic-reference internal-reference' href='#30f839a5-9ee0-4141-8786-fdfc171a890c'>mild or moderately potent</a>&nbsp;corticosteroid preparation.</li><li>Areas where the skin is thick, owing to either site (palms of the hands and soles of the feet) or from constant scratching (lichenification), usually require more <a class='topic-reference internal-reference' href='#30f839a5-9ee0-4141-8786-fdfc171a890c'>potent corticosteroid preparations.</a></li><li>Children and older people are more susceptible to the adverse effects of topical corticosteroids because they have a thinner epidermis. Older people also have decreased dermal collagen (owing to age and sun damage).</li></ul></li><li>Discuss the variety of <a class='topic-reference internal-reference' href='#b1b41362-7958-4866-9c4b-41e6348f5ce2'>formulations</a> available with the person.</li><li>Consider prescribing an emollient with the topical corticosteroid to moisturize the skin. For more information, see the section on&nbsp;<a class='topic-reference external-reference' href='/Topic/ViewTopic/68307f26-e94a-48b4-9595-fadcb2fdee8a#360726fd-6332-4162-82b4-a93a01cb034a'>Emollients</a>&nbsp;in the CKS&nbsp;on&nbsp;<a class='topic-reference external-reference' href='/Topic/ViewTopic/68307f26-e94a-48b4-9595-fadcb2fdee8a'>Eczema - atopic</a>.</li></ul><!-- end field 9c0b9e06-9888-446c-9693-52fadf887ca7 --><!-- end item 714989ff-b037-4e62-8cff-0a8511ea2c5a --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item dc52e3ff-5ec5-4562-a8f8-87946a06b0a1 --><!-- begin field 1dfd10f5-7faf-49a1-bf19-bf1d96ada040 --><p>These recommendations are based on expert opinion in narrative reviews <em>Topical steroids for skin disease&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Coulson, 1996</a>], <em>Guidelines of care for the management of psoriasis and psoriatic arthritis&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>], and <em>Choosing topical corticosteroids</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Ference, 2009</a>]; the National Institute for Health and Care Excellence (NICE) guideline <em>Psoriasis: assessment and management</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2017</a>]; the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>]; and the <em>British National Formulary</em> (BNF) [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>].</p><!-- end field 1dfd10f5-7faf-49a1-bf19-bf1d96ada040 --><!-- end item dc52e3ff-5ec5-4562-a8f8-87946a06b0a1 --></div></section></section><section aria-labelledby='length-of-treatment'><div class='ChapterBody-module--section--2d0kz'><h3 id='length-of-treatment'>How long can I prescribe topical corticosteroids for?</h3><!-- begin item 4d7555c6-6e3b-436b-8401-050e57f166cb --><!-- begin field 4d08d02c-c353-4d5d-b664-e89a90ae4627 --><ul><li>The length of treatment depends on the condition being treated — where possible treatment with topical corticosteroids should be intermittent to treat exacerbations of eczema or to reduce the size and thickness of plaques in psoriasis.&nbsp;</li><li>If symptoms do not improve 3–7 days after initiating a topical corticosteroid, reassess the condition and consider other potential causes:&nbsp;<ul><li><strong>Infection </strong>— such as impetigo, herpes simplex, or tinea corporis, which can be worsened by topical corticosteroids. See the CKS topics on <a class='topic-reference external-reference' href='/Topic/ViewTopic/08c2a82c-2e88-477a-a00d-e75b47770e61'>Impetigo</a>,&nbsp;<a class='topic-reference external-reference' href='/Topic/ViewTopic/501ea0cd-acdf-4cd7-bab7-e2043816027a'>Herpes simplex - genital</a>,&nbsp;<a class='topic-reference external-reference' href='/Topic/ViewTopic/5f875f0c-db78-44fb-b672-bd54c9216205'>Herpes simplex - oral</a>, and&nbsp;<a class='topic-reference external-reference' href='/Topic/ViewTopic/0a9103d8-0e5e-4e22-8ed1-df6caa2888c6'>Fungal skin infection - body and groin</a> for information on further management.&nbsp;</li><li><strong>Hypersensitivity reaction </strong>— consider switching to a corticosteroid with a different active ingredient or refer the person to a dermatologist if suspected hypersensitive reactions have occurred on multiple occasions.&nbsp;</li><li><strong>Non-adherence </strong>— this could be due to concerns about the safety of corticosteroids. Reassure the person that adverse effects are rare when topical corticosteroids are applied thinly to the affected areas only, and no more frequently than twice daily.</li><li><strong>Tolerance </strong>—&nbsp;consider switching to another topical corticosteroid of the same&nbsp;<a class='topic-reference internal-reference' href='#30f839a5-9ee0-4141-8786-fdfc171a890c'>potency</a>.</li></ul></li><li><strong>In people with psoriasis:</strong><ul><li>Arrange a review 4 weeks after starting a new topical treatment in adults, and 2 weeks after starting a new topical treatment in children.&nbsp;</li><li>Offer a review at least annually for adults using intermittent or short-term courses of potent or very potent topical corticosteroids, and for children using topical corticosteroids of any potency to assess for steroid atrophy and other adverse effects.&nbsp;<ul><li>More frequent monitoring is required for people using topical corticosteroids in intertriginous areas, on the face and neck, or under occlusion as adverse effects due to increased systemic absorption are more likely.&nbsp;</li></ul></li><li>Very potent corticosteroids should not be used continuously at any site for more than 4 weeks.<ul><li>Where a longer duration is required, consider seeking specialist advice, and monitor the person more frequently to detect possible <a class='topic-reference internal-reference' href='#9b2e08b5-68e7-4a5f-bb05-4cceffe15481'>adverse effects</a> early.</li><li>Once symptoms improve, gradually taper down to a less potent topical corticosteroid to avoid a relapse of the condition.&nbsp;</li></ul></li><li>Potent corticosteroids should not be used continuously at any site for longer than 8 weeks.&nbsp;</li><li>Aim for a break of 4 weeks between courses of treatment with potent or very potent corticosteroids.&nbsp;</li></ul></li><li><strong>In people with eczema:</strong><ul><li>Treatment is generally short term (3–7 days) to control flares, and for up to 2 weeks in moderate to severe disease.&nbsp;</li><li>If using moderate or potent preparations for flares in vulnerable sites, such as axillae and groin, limit use to short periods (7–14 days).</li><li>Consider treating problem areas with topical corticosteroids for 2 consecutive days per week to prevent flares, instead of treating flares as they arise, in people with frequent flares.&nbsp;<ul><li>Review people receiving intermittent treatment every 3–6 months depending on the potency and site of application.</li></ul></li></ul></li><li>Once a clinical response has been seen, long-term topical corticosteroid treatment should be <a class='topic-reference internal-reference' href='#d382c057-0b3a-4cdd-9add-dd674ab870a0'>withdrawn</a> gradually in a stepwise manner.</li><li>For more information on managing eczema and psoriasis, see the CKS topics on <a class='topic-reference external-reference' href='/Topic/ViewTopic/68307f26-e94a-48b4-9595-fadcb2fdee8a'>Eczema - atopic</a> and <a class='topic-reference external-reference' href='/Topic/ViewTopic/c8702cb0-6f30-44e4-832b-ab9161ee384a'>Psoriasis</a>.</li></ul><!-- end field 4d08d02c-c353-4d5d-b664-e89a90ae4627 --><!-- end item 4d7555c6-6e3b-436b-8401-050e57f166cb --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item e728c565-4332-4797-a62a-5238530cb2e6 --><!-- begin field e631e7d9-fb51-4414-9912-7880308e3f65 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Psoriasis: assessment and management</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2017</a>]&nbsp;and <em>Atopic eczema in under 12s: diagnosis and management</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2007</a>]; the Scottish Intercollegiate Guidelines Network (SIGN) guideline<em>&nbsp;Management of atopic eczema in primary care </em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>SIGN, 2011</a>]; the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>]; and expert opinion in narrative reviews <em>Guidelines of care for the management of psoriasis and psoriatic arthritis</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>] and <em>Guidance on the diagnosis and clinical management of atopic eczema </em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Baron, 2012</a>].</p><p><strong>Monitoring</strong></p><ul><li>The recommendation to monitor people more frequently if they are using topical corticosteroids in intertriginous areas, on the face or neck, or under occlusion is pragmatic and what CKS considers good medical practice, as adverse effects are more likely due to increased systemic absorption.&nbsp;&nbsp;</li></ul><p><strong>Length of treatment</strong></p><ul><li>The recommendations on length of treatment are based on the MeReC bulletin [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>], the NICE guidelines for psoriasis [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2017</a>] and eczema [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2007</a>], and expert opinion in a narrative review&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Baron, 2012</a>].&nbsp;</li><li>The Australian College of Dermatologists&nbsp;<em>Adverse effects of topical corticosteroids&nbsp;in paediatric eczema:&nbsp;Australasian consensus statement</em> advises that there is no requirement for intervals without therapy — the topical corticosteroid should be applied to all inflamed skin until eczema is cleared [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Mooney, 2015</a>].&nbsp;</li></ul><!-- end field e631e7d9-fb51-4414-9912-7880308e3f65 --><!-- end item e728c565-4332-4797-a62a-5238530cb2e6 --></div></section></section><section aria-labelledby='potency'><div class='ChapterBody-module--section--2d0kz'><h3 id='potency'>What potency of topical corticosteroids should I prescribe?</h3><!-- begin item 30f839a5-9ee0-4141-8786-fdfc171a890c --><!-- begin field f5e66272-ea8a-46e7-9309-71231d7f1515 --><ul><li>Topical corticosteroids are available in four potencies: mildly potent, moderately potent, potent, and very potent (see Table 1 for more details).<ul><li>The potency of a topical corticosteroid is determined by the amount of vasoconstriction it produces and the degree to which it inhibits inflammation.</li><li>Prescribe the least potent preparation that is effective, and avoid dilution if possible.&nbsp;</li><li>Application of corticosteroid immediately on top of, or before, an emollient may dilute the product and transfer corticosteroid to areas that do not require treatment. For information on the application of corticosteroids and emollients together, see the section on <a class='topic-reference internal-reference' href='#c07af8fb-0a8a-48d7-a6d3-0fb200454f48'>Information and advice</a>.</li></ul></li></ul><p><strong>Table 1.</strong> Topical corticosteroids listed by potency class.</p><table><thead><tr><th style='width: 122.778px;'>Potency class</th><th style='width: 312.778px;'>Non-proprietary names and strengths</th><th style='width: 346.111px;'>Proprietary names*</th><th style='width: 457.222px;'>Formulations</th></tr></thead><tbody><tr><td style='width: 122.778px;'>Mild</td><td style='width: 312.778px;'>Hydrocortisone 0.1%, 0.5%, 1.0%, 2.5%</td><td style='width: 346.111px;'>Dioderm, Mildison, Synalar 1 in 10 dilution</td><td style='width: 457.222px;'>Cream and ointment</td></tr><tr><td style='width: 122.778px;' rowspan='5'>Moderate</td><td style='width: 312.778px;'>Alclometasone dipropionate 0.05%</td><td style='width: 346.111px;'>Modrasone</td><td style='width: 457.222px;'>Cream and ointment</td></tr><tr><td style='width: 312.778px;'>Betamethasone valerate 0.025%</td><td style='width: 346.111px;'>Betnovate-RD</td><td style='width: 457.222px;'>Cream and ointment</td></tr><tr><td style='width: 312.778px;'>Clobetasone butyrate 0.05%</td><td style='width: 346.111px;'>Eumovate</td><td style='width: 457.222px;'>Cream and ointment</td></tr><tr><td style='width: 312.778px;'>Fluocinolone acetonide 0.00625%</td><td style='width: 346.111px;'>Synalar 1 in 4 dilution</td><td style='width: 457.222px;'>Cream and ointment</td></tr><tr><td style='width: 312.778px;'>Fludroxycortide 0.0125%</td><td style='width: 346.111px;'>Haelan</td><td style='width: 457.222px;'>Cream, ointment, and tape</td></tr><tr><td style='width: 122.778px;' rowspan='9'>Potent</td><td style='width: 312.778px;'>Beclometasone dipropionate 0.025%</td><td style='width: 346.111px;'>Generic</td><td style='width: 457.222px;'>Cream and ointment</td></tr><tr><td style='width: 312.778px;'>Betamethasone dipropionate 0.05%</td><td style='width: 346.111px;'>Diprosone</td><td style='width: 457.222px;'>Cream, ointment, and lotion</td></tr><tr><td style='width: 312.778px;'>Betamethasone valerate 0.1%</td><td style='width: 346.111px;'>Betnovate</td><td style='width: 457.222px;'>Cream, ointment, lotion, scalp application, and foam&nbsp;</td></tr><tr><td style='width: 312.778px;'>Diflucortolone valerate 0.1%</td><td style='width: 346.111px;'>Nerisone</td><td style='width: 457.222px;'>Cream, ointment, and oily cream</td></tr><tr><td style='width: 312.778px;'>Fluocinolone acetonide 0.025%</td><td style='width: 346.111px;'>Synalar</td><td style='width: 457.222px;'>Cream, ointment, and gel</td></tr><tr><td style='width: 312.778px;'>Fluocinonide 0.05%</td><td style='width: 346.111px;'>Metosyn</td><td style='width: 457.222px;'>Cream and ointment</td></tr><tr><td style='width: 312.778px;'>Fluticasone propionate 0.05%</td><td style='width: 346.111px;'>Cutivate</td><td style='width: 457.222px;'>Cream&nbsp;</td></tr><tr><td style='width: 312.778px;'>Hydrocortisone butyrate 0.1%</td><td style='width: 346.111px;'>Locoid</td><td style='width: 457.222px;'>Cream, ointment, and scalp application</td></tr><tr><td style='width: 312.778px;'>Mometasone furoate 0.1%</td><td style='width: 346.111px;'>Elocon</td><td style='width: 457.222px;'>Cream, ointment, and scalp application</td></tr><tr><td style='width: 122.778px;' rowspan='2'>Very potent</td><td style='width: 312.778px;'>Clobetasol propionate 0.0525%</td><td style='width: 346.111px;'>Dermovate, Clarelux</td><td style='width: 457.222px;'>Cream, ointment, scalp application and foam</td></tr><tr><td style='width: 312.778px;'>Diflucortolone valerate 0.3%</td><td style='width: 346.111px;'>Nerisone Forte</td><td style='width: 457.222px;'>Ointment and oily cream</td></tr><tr><td style='width: 1280.56px;' colspan='4'><strong>Data from:</strong> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>].&nbsp; *Note: generic products may also be available for some of these products.</td></tr></tbody></table><p>&nbsp;</p><!-- end field f5e66272-ea8a-46e7-9309-71231d7f1515 --><!-- end item 30f839a5-9ee0-4141-8786-fdfc171a890c --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item 6fb3249e-105b-45c5-abd5-9d3595483722 --><!-- begin field e25b6100-32ef-4507-8764-ea93eccddba0 --><p>This information is based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>], the <em>British National Formulary </em>(BNF) [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>], and the National Institute for Health and Care Excellence (NICE) technology appraisal <em>Frequency of application of topical corticosteroids for atopic eczema </em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2004</a>].&nbsp;</p><!-- end field e25b6100-32ef-4507-8764-ea93eccddba0 --><!-- end item 6fb3249e-105b-45c5-abd5-9d3595483722 --></div></section></section><section aria-labelledby='formulations'><div class='ChapterBody-module--section--2d0kz'><h3 id='formulations'>What formulation of topical corticosteroids should I prescribe?</h3><!-- begin item b1b41362-7958-4866-9c4b-41e6348f5ce2 --><!-- begin field 27418074-4948-4bb2-963a-937431fba6bd --><ul><li>Topical corticosteroids are available in several formulations, including creams, ointments, lotions, gels, tapes, mousses, and solutions.</li><li>The choice of formulation depends on the condition being treated, its severity and location, cosmetic acceptability, and the person's preference.&nbsp;</li><li><strong>Solutions</strong><ul><li>Solutions are low viscosity, alcohol- or water-based liquids.</li><li>They are easy to apply and are non-greasy.</li><li>They are very drying if alcohol is the base, and can sting sore skin.</li></ul></li><li><strong>Lotions</strong><ul><li>Lotions are similar to solutions, but thicker.</li><li>They are useful for treating large or hairy areas and contain alcohol, which has a drying effect on exudative lesions.&nbsp;</li></ul></li><li><strong>Creams</strong><ul><li>Creams are thicker than lotions and are suitable for moist or weepy lesions.</li><li>Creams are generally less potent than ointments with the same active ingredient.&nbsp;&nbsp;</li><li>They are moisturizing without being greasy. Many people prefer them, especially for use on the face and palms of the hands.</li></ul></li><li><strong>Ointments</strong><ul><li>Ointments are preferred for dry, lichenified, or scaly conditions, or where a more occlusive effect is required.&nbsp;</li><li>The occlusive effects can increase the penetration of the steroid.&nbsp;</li><li>They have a more prolonged emollient effect and tend to increase the potency of the corticosteroid.&nbsp;</li><li>They are less likely to cause irritation as they are usually preservative free.&nbsp;</li></ul></li><li><strong>Gels and mousses</strong><ul><li>Gels are thicker than solutions, and can be drying.</li><li>Mousses are stable, non-greasy foams.</li><li>Gels and mousses can be useful for scalp conditions.</li></ul></li><li><strong>Tapes and bandages</strong><ul><li>Potent and very potent topical corticosteroids used under occlusion should be under specialist supervision, used for only a short period of time, and for areas of very thick skin (such as the palms of the hands and soles of the feet).<ul><li>Occlusive polythene or hydrocolloid dressings increase the absorption of the corticosteroid and the risk of adverse effects.</li></ul></li></ul></li><li><strong>Compound preparations&nbsp;</strong>contain other substances such as:<ul><li>Antibacterials and antifungals — for infected skin.&nbsp;</li><li>Salicylic acid, calcipotriol, or coal tar — for psoriasis and other dry skin conditions.<ul><li>Some of these substances (for example urea and salicylic acid) may increase the penetration of the corticosteroid.</li></ul></li></ul></li></ul><!-- end field 27418074-4948-4bb2-963a-937431fba6bd --><!-- end item b1b41362-7958-4866-9c4b-41e6348f5ce2 --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item 340169e9-8e21-418f-87fc-7cd693c612bf --><!-- begin field d1cf1c43-ea38-409b-afbc-50df2ac6ef91 --><p>This information is based on the <em>British National Formulary</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>]; the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>]; the National Institute for Health and Care Excellence and (NICE) guideline <em>Psoriasis: assessment and management</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2017</a>];&nbsp;and expert opinion in narrative reviews <em>Topical steroids for skin disease&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Coulson, 1996</a>], <em>Guidelines of care for the management of psoriasis </em><em>and psoriatic arthritis&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>], and <em>Choosing topical corticosteroids</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Ference, 2009</a>].</p><!-- end field d1cf1c43-ea38-409b-afbc-50df2ac6ef91 --><!-- end item 340169e9-8e21-418f-87fc-7cd693c612bf --></div></section></section><section aria-labelledby='application'><div class='ChapterBody-module--section--2d0kz'><h3 id='application'>How should topical corticosteroids be applied?</h3><!-- begin item da14da63-9354-44dd-8ecc-1d2ba0d9c7e9 --><!-- begin field 6f4d7eb9-17c2-4f2f-bb34-8f818e80ff70 --><ul><li>A thin layer of topical corticosteroid should be applied once or twice daily, adjusting the potency to control symptoms. For many conditions, once daily application is usually sufficient. Increase to twice daily application only if the condition does not respond adequately.&nbsp;<ul><li>Avoid the use of the phrase 'use sparingly' to avoid undertreatment.</li></ul></li><li>Topical corticosteroids should typically be used in bursts of 3–7 days in order to achieve control. Once a clinical response is seen, <a class='topic-reference internal-reference' href='#d382c057-0b3a-4cdd-9add-dd674ab870a0'>withdraw</a> the corticosteroid gradually.&nbsp;</li><li>If an emollient is also being used, advise the person to wait 20–30 minutes between applications.&nbsp;</li><li>Most products are supplied with an information leaflet specifying the number of fingertip units (FTUs) needed to treat specific body areas.<ul><li>One FTU is the length of cream or ointment expelled from a tube with a standard 5 mm diameter nozzle equivalent to the distance from the tip of the adult index finger to the first crease. One FTU is about 500 mg and is sufficient to treat a skin area about twice that of the flat of the hand with the fingers together.</li></ul></li><li>See the sections on <a class='topic-reference internal-reference' href='#62a85c90-fe82-4ff3-9175-a74a00aa84fa'>Fingertip units (FTUs) for adults</a>&nbsp;and <a class='topic-reference internal-reference' href='#88bf764a-41f8-4064-b72c-a7a700edd191'>Fingertip units (FTUs) for children</a>&nbsp;for the approximate amount of topical corticosteroid that should be applied to different areas of the body.</li></ul><!-- end field 6f4d7eb9-17c2-4f2f-bb34-8f818e80ff70 --><!-- end item da14da63-9354-44dd-8ecc-1d2ba0d9c7e9 --></div><section aria-labelledby='fingertip-units-ftus-for-children'><div class='ChapterBody-module--section--2d0kz'><h4 id='fingertip-units-ftus-for-children'>Fingertip units (FTUs) for children</h4><!-- begin item 88bf764a-41f8-4064-b72c-a7a700edd191 --><!-- begin field 32f32bbd-ae0d-4f2e-a82b-a7a700edd42e --><ul><li>The fingertip unit (FTU) is measured on an adult index finger.</li><li>The approximate amount of topical corticosteroid that should be applied to children, for each area of the body, is listed in Table 2.</li></ul><p><strong>Table 2.</strong> Amount of topical preparation (in FTUs) for different areas of a child's body.</p><table><thead><tr><th colspan='1'>Age of child</th><th colspan='1'>Entire face and neck</th><th colspan='1'>Entire arm and hand</th><th colspan='1'>Entire leg and foot</th><th colspan='1'>Entire front of chest and abdomen</th><th colspan='1'>Entire back including buttocks</th></tr></thead><tbody><tr><td colspan='1'>3–12 months</td><td colspan='1'>1</td><td colspan='1'>1</td><td colspan='1'>1.5</td><td colspan='1'>1</td><td colspan='1'>1.5</td></tr><tr><td colspan='1'>1–2&nbsp;years</td><td colspan='1'>1.5</td><td colspan='1'>1.5</td><td colspan='1'>2</td><td colspan='1'>2</td><td colspan='1'>3</td></tr><tr><td colspan='1'>3–5&nbsp;years</td><td colspan='1'>1.5</td><td colspan='1'>2</td><td colspan='1'>3</td><td colspan='1'>3</td><td colspan='1'>3.5</td></tr><tr><td colspan='1'>6–10&nbsp;years</td><td colspan='1'>2</td><td colspan='1'>2.5</td><td colspan='1'>4.5</td><td colspan='1'>3.5</td><td colspan='1'>5</td></tr><tr><td colspan='6'><strong>Data from:</strong>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Long, 1998</a>; <a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>]</td></tr></tbody></table><!-- end field 32f32bbd-ae0d-4f2e-a82b-a7a700edd42e --><!-- end item 88bf764a-41f8-4064-b72c-a7a700edd191 --></div></section><section aria-labelledby='fingertip-units-ftus-for-adults'><div class='ChapterBody-module--section--2d0kz'><h4 id='fingertip-units-ftus-for-adults'>Fingertip units (FTUs) for adults</h4><!-- begin item 62a85c90-fe82-4ff3-9175-a74a00aa84fa --><!-- begin field 87b43142-a8f9-40ed-840d-a74a00aa8529 --><ul><li>The approximate amount of topical corticosteroid that should be applied to adults, for each area of the body, is listed in Table 3.</li></ul><p><strong>Table 3.</strong> Amount of topical preparation (in FTUs) for different areas of an adult's body.</p><table><tbody><tr><td><strong>Body area</strong></td><td><strong>Number of FTUs</strong></td></tr><tr><td>Scalp</td><td>3</td></tr><tr><td>Face and neck</td><td>2.5</td></tr><tr><td>One hand (front and back including fingers)</td><td>1</td></tr><tr><td>One arm (including entire hand)</td><td>4</td></tr><tr><td>Elbows (large plaque)</td><td>1</td></tr><tr><td>Both soles of feet</td><td>1.5</td></tr><tr><td>One foot (dorsum and sole) including toes</td><td>1.5</td></tr><tr><td>One leg (including entire foot)</td><td>8</td></tr><tr><td>Buttocks</td><td>4</td></tr><tr><td>Knees (large plaque)</td><td>1</td></tr><tr><td>Trunk (front)</td><td>8</td></tr><tr><td>Trunk (back)</td><td>8</td></tr><tr><td>Genitalia</td><td>0.5</td></tr><tr><td colspan='2'><strong>Data from:</strong>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>]</td></tr></tbody></table><!-- end field 87b43142-a8f9-40ed-840d-a74a00aa8529 --><!-- end item 62a85c90-fe82-4ff3-9175-a74a00aa84fa --></div></section><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item 9678856e-fe3a-4d52-a447-a7a700ee5b08 --><!-- begin field 392194d4-ab02-474a-9ea7-a7a700ee5c8f --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Atopic eczema in under 12s: diagnosis and management</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2007</a>], the NICE technology appraisal <em>Frequency of application of topical corticosteroids for atopic eczema</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2004</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of atopic eczema in primary care</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>SIGN, 2011</a>], the National Prescribing Centre Bulletin&nbsp;<em>Using topical corticosteroids in general practic</em>e [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>], the <em>British National Formulary</em> (BNF) [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>], and the manufacturer's summary of product characteristics for Betnovate cream [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>ABPI, 2019c</a>].</p><p><strong>Frequency of application</strong></p><ul><li>The recommendation on frequency of application of topical corticosteroids is based on a NICE Technology Appraisal that identified 10 randomized controlled trials (RCTs). The evidence suggested that, overall, there was little difference in effectiveness between once daily and more frequent application of topical corticosteroids, although a difference could not be ruled out [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2004</a>].<ul><li>A total of 10 RCTs compared once daily application with more frequent use of topical corticosteroids within the same potency group for the treatment of eczema. None of the studies found clear evidence that application more than once a day produced better overall clinical outcomes.</li><li>Taking into account evidence on cost-effectiveness, NICE recommends that topical corticosteroids should be prescribed 'for application only once or twice daily'.</li></ul></li><li>SIGN recommends that in people with atopic eczema topical corticosteroids should be applied once daily and if there is an inadequate response to increase to twice daily application [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>SIGN, 2011</a>].</li><li>The recommendation to use topical corticosteroids in bursts of 3–7 days is based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>], and expert opinion in a narrative review <em>Atopic Dermatitis&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Williams, 2005</a>].</li><li>The Australasian College of Dermatologists&nbsp;<em>Adverse effects of&nbsp;topical corticosteroids&nbsp;in paediatric eczema:&nbsp;Australasian consensus statement</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Mooney, 2015</a>]&nbsp;advises that the phrase 'use sparingly' should be avoided as it is nonsensical and has no value, and it promotes inadequate use of topical corticosteroids. It recommends that people are advised to use topical steroids liberally and then carefully rubbed or massaged into inflamed skin, but to avoid very thick application.</li></ul><p><strong>Combining topical corticosteroids and emollient therapy</strong></p><ul><li>There is no evidence or consensus in the literature to help decide in which order preparations should be applied and the length of time people should wait before applying the second preparation.&nbsp;</li><li>The NICE guidance&nbsp;<em>Atopic eczema in under 12s: diagnosis and management</em>&nbsp;advises that products should be applied one at time with several minutes between applications where practical, and that the preferences of the child and parents or carers should determine which product should be applied first [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2007</a>].</li><li>A British Association for Dermatologists patient information leaflet advises that people should wait 20–30 minutes between the two treatments to avoid diluting the topical steroid and reducing its effectiveness, but does not advise which preparation should be applied first [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>BAD, 2019</a>].&nbsp;</li><li>The manufacturer of Betnovate cream advises that adequate time should be allowed for absorption of the corticosteroid after each application before applying an emollient, but does not specify an amount of time to wait [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>ABPI, 2019c</a>].</li><li>The British National Formulary advises that mixing topical preparations on the skin should be avoided where possible and recommends that several minutes should elapse between application of different preparations [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>].</li><li>In the expert opinion of previous external reviewers of this CKS topic, some recommend that the corticosteroid should be applied first. This is also a reasonable strategy, provided that sufficient time is allowed before the emollient is applied, to prevent dilution and unnecessary spreading of the corticosteroid. Waiting for 1 hour is suggested by some external reviewers.</li></ul><!-- end field 392194d4-ab02-474a-9ea7-a7a700ee5c8f --><!-- end item 9678856e-fe3a-4d52-a447-a7a700ee5b08 --></div></section></section><section aria-labelledby='quantity-to-prescribe'><div class='ChapterBody-module--section--2d0kz'><h3 id='quantity-to-prescribe'>How much topical corticosteroid should I prescribe?</h3><!-- begin item d3c0cd13-7615-4485-b699-7843c4f5e471 --><!-- begin field c2d034dd-17d5-4c94-babc-362646678900 --><ul><li>It is important that the appropriate quantity of topical corticosteroid is prescribed to avoid undertreatment. For suitable quantities of topical corticosteroid creams and ointments to prescribe, see Table 4.</li><li>For the weekly dose of topical corticosteroids unlikely to cause systemic adverse effects in adults, see Table 5.</li></ul><p><strong>Table 4.</strong> Suitable quantities of topical corticosteroids to prescribe (single daily application for 2 weeks).</p><table><thead><tr><th colspan='1'>Area of the body</th><th colspan='1'>Suitable quantity to prescribe</th></tr></thead><tbody><tr><td colspan='1'>Face and neck</td><td colspan='1'>15–30&nbsp;g</td></tr><tr><td colspan='1'>Both hands</td><td colspan='1'>15–30&nbsp;g</td></tr><tr><td colspan='1'>Scalp</td><td colspan='1'>15–30&nbsp;g</td></tr><tr><td colspan='1'>Both arms</td><td colspan='1'>30–60&nbsp;g</td></tr><tr><td colspan='1'>Both legs</td><td colspan='1'>100&nbsp;g</td></tr><tr><td colspan='1'>Trunk</td><td colspan='1'>100&nbsp;g</td></tr><tr><td colspan='1'>Groin and genitalia</td><td colspan='1'>15–30&nbsp;g</td></tr><tr><td colspan='2'><strong>Data from:</strong> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>]</td></tr></tbody></table><p><strong>Table 5. </strong>Weekly dose of topical corticosteroids unlikely to cause systemic adverse effects in adults.</p><table><thead><tr><th colspan='1'>Treatment period</th><th colspan='1'>Moderately potent</th><th colspan='1'>Potent</th><th colspan='1'>Very potent</th></tr></thead><tbody><tr><td colspan='1'>Less than 2 months</td><td colspan='1'>100g</td><td colspan='1'>50g</td><td colspan='1'>30g</td></tr><tr><td colspan='1'>2–6&nbsp;months</td><td colspan='1'>50g</td><td colspan='1'>30g</td><td colspan='1'>15g</td></tr><tr><td colspan='1'>6–12&nbsp;months</td><td colspan='1'>25g</td><td colspan='1'>15g</td><td colspan='1'>7.5g</td></tr><tr><td colspan='4'><strong>Data from:</strong>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Coulson, 1996</a>]</td></tr></tbody></table><!-- end field c2d034dd-17d5-4c94-babc-362646678900 --><!-- end item d3c0cd13-7615-4485-b699-7843c4f5e471 --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item 51b60107-593c-44a6-81b4-492444d71ba6 --><!-- begin field 57cf5543-7fc4-4528-9e37-551ab486f562 --><p>These recommendations are based on the <em>British National Formulary</em> (BNF) [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>], and expert opinion in narrative reviews <em>Topical steroids for skin disease&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Coulson, 1996</a>]&nbsp;and&nbsp;<em>Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Beattie, 2003</a>].</p><ul><li>Undertreatment is a significant problem in primary care. It is caused by several factors, including under-prescribing and failure to use a sufficient quantity [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Beattie, 2003</a>].</li></ul><!-- end field 57cf5543-7fc4-4528-9e37-551ab486f562 --><!-- end item 51b60107-593c-44a6-81b4-492444d71ba6 --></div></section></section><section aria-labelledby='withdrawal'><div class='ChapterBody-module--section--2d0kz'><h3 id='withdrawal'>How should I withdraw or stop topical corticosteroid treatment?</h3><!-- begin item d382c057-0b3a-4cdd-9add-dd674ab870a0 --><!-- begin field 41383c39-21a8-44cf-9e20-74b81624d0ac --><ul><li>Once a clinical response has been seen, withdraw long term topical corticosteroid treatment gradually in a stepwise manner. Abrupt withdrawal can cause a relapse or rebound of the condition being treated (for example psoriasis or eczema).&nbsp;</li><li>Consider the following options:<ul><li>Reduce the application frequency of the current corticosteroid.&nbsp;</li><li>Step down to a lower potency corticosteroid.&nbsp;</li><li>Use a lower potency corticosteroid together with other topical treatments (such as a vitamin D or coal tar preparation used in the treatment of psoriasis. For more information, see the CKS topic on <a class='topic-reference external-reference' href='/Topic/ViewTopic/c8702cb0-6f30-44e4-832b-ab9161ee384a'>Psoriasis</a>).&nbsp;</li><li>Use a lower potency corticosteroid intermittently.</li></ul></li></ul><!-- end field 41383c39-21a8-44cf-9e20-74b81624d0ac --><!-- end item d382c057-0b3a-4cdd-9add-dd674ab870a0 --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item ed28ab69-7551-4809-9d41-4660aee127f6 --><!-- begin field 30acb69c-2031-4858-b4a7-848e74da3333 --><p>These recommendations are based on the National Prescribing Centre Bulletin&nbsp;<em>Using topical corticosteroids in general practice&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>]; the National Institute for Health and Care Excellence (NICE) guideline <em>Psoriasis: assessment and management</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2017</a>]; and expert opinion in narrative reviews <em>Topical steroids for skin disease&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Coulson, 1996</a>], <em>Guidelines of care for the management of psoriasis </em><em>and psoriatic arthritis&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>], and <em>Choosing topical corticosteroids</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Ference, 2009</a>].</p><ul><li>Flares of eczema may occur if corticosteroids are stopped abruptly. Topical corticosteroids should be withdrawn gradually, decreasing the potency in a stepwise manner [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>].<ul><li>CKS is aware that some previous external reviewers of this CKS topic stated that gradual withdrawal is unnecessary, and may adversely influence adherence, especially when treating children.</li></ul></li></ul><!-- end field 30acb69c-2031-4858-b4a7-848e74da3333 --><!-- end item ed28ab69-7551-4809-9d41-4660aee127f6 --></div></section></section><section aria-labelledby='contraindications-cautions'><div class='ChapterBody-module--section--2d0kz'><h3 id='contraindications-cautions'>What contraindications and cautions are associated with topical corticosteroids?</h3><!-- begin item 94f63eb2-e36d-4860-b8df-4d9f1b141365 --><!-- begin field 6b364b04-0f9a-460c-9793-6adb6f1a4712 --><ul><li><strong>Contraindications</strong><ul><li>Avoid prescribing topical corticosteroids in people with:<ul><li>Bacterial, fungal, or viral skin infections.&nbsp;</li><li>Rosacea.&nbsp;</li><li>Perioral dermatitis.&nbsp;</li><li>Acne vulgaris.&nbsp;</li><li>Anogenital pruritus.&nbsp;</li></ul></li><li>Topical corticosteroids should not be used indiscriminately for treating pruritus.</li></ul></li><li><strong>Cautions</strong><ul><li>Avoid prolonged use of corticosteroids, particularly on the face.&nbsp;</li><li>Potent corticosteroids should generally be avoided on the face and skin flexures.&nbsp;</li><li>Use topical corticosteroids with caution in the periocular area.</li></ul></li></ul><!-- end field 6b364b04-0f9a-460c-9793-6adb6f1a4712 --><!-- end item 94f63eb2-e36d-4860-b8df-4d9f1b141365 --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item a789d059-af60-466c-9d9c-80eddc3dc311 --><!-- begin field 2ece0b1c-35eb-430a-a81b-234c63d33c2a --><p>These recommendations are based on the <em>British National Formulary</em> (BNF), the manufacturers' summaries of product characteristics for Betnovate cream [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>ABPI, 2019c</a>] and hydrocortisone 1% cream [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>ABPI, 2020a</a>], and the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of atopic eczema in primary care </em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>SIGN, 2011</a>].</p><!-- end field 2ece0b1c-35eb-430a-a81b-234c63d33c2a --><!-- end item a789d059-af60-466c-9d9c-80eddc3dc311 --></div></section></section><section aria-labelledby='pregnancy-breastfeeding'><div class='ChapterBody-module--section--2d0kz'><h3 id='pregnancy-breastfeeding'>Can I prescribe topical corticosteroids to a woman who is pregnant or breastfeeding?</h3><!-- begin item d0fc17b7-8c1c-4623-b522-450b27dfd174 --><!-- begin field db997193-c5d2-424a-a5a6-3098c9db6b4f --><p><strong>Pregnancy</strong></p><ul><li>Topical exposure to corticosteroids in pregnancy is expected to pose a low risk to the developing fetus.</li><li>However, factors affecting systemic absorption of the corticosteroid should be taken into account, including surface area, frequency of application, condition of skin, and the potency of preparation.&nbsp;</li></ul><p><strong>Breastfeeding</strong></p><ul><li>Topical corticosteroids pose a negligible risk to breastfeeding infants.</li><li>Before breastfeeding, the topical corticosteroid should be removed from all areas of the breast (especially nipples and areola areas) with warm water and reapplied after feeding — this is to prevent the infant’s mouth coming into direct contact with the topical corticosteroid.&nbsp;</li><li>When applied to the breast, the use of creams are preferred to ointments owing to ease of removal before breastfeeding — use the least potent preparations for the shortest duration where possible.&nbsp;<ul><li>Hydrocortisone (mild potency) and clobetasone (moderate potency) are preferred for application to the nipple and areola area –&nbsp;avoid application of high potency steroids to these areas.&nbsp;</li></ul></li></ul><!-- end field db997193-c5d2-424a-a5a6-3098c9db6b4f --><!-- end item d0fc17b7-8c1c-4623-b522-450b27dfd174 --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item a48de57e-04f3-4be5-8d89-685c0e5faaa7 --><!-- begin field d9f67431-6bae-4b07-9dc4-05bd70513ca0 --><p><strong>Pregnancy</strong></p><ul><li>These recommendations are largely based on the UK Teratology Information Service (UKTIS) document <em>Use of topical corticosteroids in pregnancy</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>UKTIS, 2016a</a>] and a Cochrane systematic review <em>Safety of topical corticosteroids in pregnancy</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Chi, 2015</a>].<ul><li>Topical exposure to corticosteroids in pregnancy is expected to pose a low risk to the developing fetus. However, factors affecting systemic absorption of the corticosteroid should be taken into account, including surface area, frequency of application, condition of skin, and the potency of preparation [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>UKTIS, 2016a</a>].&nbsp;<ul><li>If topical use is extensive or significant systemic absorption is expected, information relating to systemic exposure of corticosteroids in pregnancy should be considered. For more information, see the section on&nbsp;<a class='topic-reference external-reference' href='/Topic/ViewTopic/72c594bc-4c91-4d24-acdb-dda9812ea656#8b69af62-c22d-42e3-9e1a-620517fc9d87'>Pregnancy and breastfeeding</a>&nbsp;in the CKS topic on&nbsp;<a class='topic-reference external-reference' href='/Topic/ViewTopic/72c594bc-4c91-4d24-acdb-dda9812ea656'>Corticosteroids - oral</a>.</li></ul></li><li>A Cochrane systematic review that assessed the effects of topical corticosteroids on pregnancy outcomes in five cohorts and nine case-control studies (n = 1,601,515) found [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Chi, 2015</a>]:<ul><li>No association between maternal use of topical corticosteroids of any potency and an increase in adverse pregnancy outcomes, including mode of delivery, congenital abnormality, preterm delivery, fetal death, and low Apgar score.&nbsp;</li><li>A probable association between low birth weight and maternal use of potent to very potent topical corticosteroids, especially when the cumulative dosage of topical corticosteroids throughout the pregnancy is very large.&nbsp;</li></ul></li><li>The manufacturer of Betnovate cream advises that if it is used in pregnancy the minimum quantity should be used for the minimum duration [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>ABPI, 2019c</a>].&nbsp;</li></ul></li></ul><p><strong>Breastfeeding</strong></p><ul><li>These recommendations are based on information published by the Specialist Pharmacy Service (SPS) document <em>Safety in lactation: topical corticosteroids</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>SPS, 2016a</a>].</li></ul><!-- end field d9f67431-6bae-4b07-9dc4-05bd70513ca0 --><!-- end item a48de57e-04f3-4be5-8d89-685c0e5faaa7 --></div></section></section><section aria-labelledby='adverse-effects'><div class='ChapterBody-module--section--2d0kz'><h3 id='adverse-effects'>What are the adverse effects of topical corticosteroids?</h3><!-- begin item 9b2e08b5-68e7-4a5f-bb05-4cceffe15481 --><!-- begin field b12381a7-e7c1-48fd-aae9-82f5f5624250 --><ul><li><strong>When used correctly, topical corticosteroids rarely cause serious adverse effects.</strong></li><li><strong>The likelihood of adverse effects is directly related to:</strong><ul><li>Duration of treatment — long term treatment is likely to result in systemic absorption.</li><li>Area of the skin being treated — treating large areas of skin increases the risk of systemic absorption.&nbsp;</li><li>Condition of the skin — absorption is greatest in thin skin (for example, the face) and inflamed skin.&nbsp;</li><li>Potency of the topical corticosteroid — the greater the potency, the greater the risk of systemic absorption.</li><li>Occlusion — use of topical corticosteroids under occlusion increases the risk of systemic absorption.</li><li>Age — children (especially babies) and older people are more susceptible to adverse effects.&nbsp;</li></ul></li><li><strong>Local adverse effects are more common</strong> — they mostly occur on the face, in skin folds, and in areas that are treated over the long term. Local adverse effects include:<ul><li>Acne vulgaris.</li><li>Folliculitis.&nbsp;</li><li>Skin atrophy (thinning).&nbsp;</li><li>Telangiectasia.</li><li>Transient burning or stinging.</li><li>Permanent striae.&nbsp;</li><li>Allergic contact dermatitis.</li><li>Exacerbation of rosacea, perioral dermatitis, or tinea infections.&nbsp;</li><li>Skin depigmentation — usually reversible.&nbsp;</li><li>Excessive hair growth at the site of application (hypertrichosis).&nbsp;</li><li>Vasodilation.&nbsp;</li></ul></li><li><strong>Systemic adverse effects&nbsp;</strong>are rare, and more likely to occur when potent or very potent topical corticosteroids are used over a large surface area for a prolonged period (or when they are used under occlusion). Any of the adverse effects of oral corticosteroids may also occur with topical corticosteroids, especially in children, including:&nbsp;<ul><li>Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on&nbsp;<a class='topic-reference external-reference' href='/Topic/ViewTopic/72c594bc-4c91-4d24-acdb-dda9812ea656#8e8b34c5-9cb9-41f5-a3c6-a7a700ec79a6'>Adrenal insufficiency</a>&nbsp;in the CKS topic on&nbsp;<a class='topic-reference external-reference' href='/Topic/ViewTopic/72c594bc-4c91-4d24-acdb-dda9812ea656'>Corticosteroids - oral</a>.</li><li>Cushing's syndrome.</li><li>Growth suppression.</li><li>Visual disturbance — if a person presents with symptoms such as blurred vision or other visual disturbances, consider referral to an ophthalmologist for evaluation of possible causes that may include cataract, glaucoma, or rare diseases such as central serous chorioretinopathy.&nbsp;</li></ul></li></ul><!-- end field b12381a7-e7c1-48fd-aae9-82f5f5624250 --><!-- end item 9b2e08b5-68e7-4a5f-bb05-4cceffe15481 --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item b19cd3bf-a8b4-45f7-ac1d-95d7798b6eef --><!-- begin field c284baa2-6143-4eff-9481-3d0262ed16e5 --><p>This information is largely based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practic</em>e&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>], expert opinion in a narrative review <em>Guidelines of care for the management of psoriasis&nbsp;and psoriatic arthritis</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>], the Australasian College of Dermatology consensus statement <em>Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Mooney, 2015</a>], expert opinion in a narrative review <em>Choosing topical corticosteroids</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Ference, 2009</a>],&nbsp;and the summary of product characteristics for Betnovate cream [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>ABPI, 2019c</a>].</p><p><strong>Systemic adverse effects</strong></p><ul><li>An Australasian College of Dermatology consensus statement on the adverse effects of topical corticosteroids in paediatric eczema [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Mooney, 2015</a>] states that physiological hypothalamic-pituitary-adrenal (HPA) axis suppression can occur with very widespread and prolonged, or occlusive use of potent/superpotent topical corticosteroids. However, this recovers quickly, and clinically significant/pathological adrenal suppression is very rare in the treatment of paediatric eczema with topical corticosteroids.&nbsp;<ul><li>In a review of 16 topical corticosteroid trials that recorded HPA suppression, only one reported pathological adrenal suppression: five adult psoriasis patients who used more than 100 g clobetasol propionate a week for between 10 weeks to 18 months developed features of Cushing’s syndrome.&nbsp;</li><li>In the literature there are 25 paediatric case reports of HPA axis suppression. These children had mostly used super-potent topical steroids (clobetasol propionate) for 1–17 months for diaper eczema.&nbsp;</li></ul></li><li>While severe adverse effects of topical corticosteroids, such as Cushing syndrome and permanent skin atrophy, are well known, they rarely occur when they are used properly [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Li, 2017</a>; <a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Mooney, 2015</a>].</li><li>A systematic review and meta-analysis that assessed the risk of adrenal insufficiency with short term use of low to moderate potency topical corticosteroids for treatment of atopic dermatitis in children and adolescents found a low prevalence of adrenal insufficiency in people treated for a short term (2–4 weeks) [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Davallow Ghajar, 2019</a>].&nbsp;</li><li>Topically applied high and ultra high potency corticosteroids can be absorbed well enough to cause systemic side effects, including decreased growth rate [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Ference, 2009</a>; <a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>].</li><li>There is a rare risk of central serous chorioretinopathy with local as well as systemic administration of corticosteroids [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MHRA, 2017</a>].&nbsp;<ul><li>People should be advised to report any blurred vision or other visual disturbances during corticosteroid treatment.</li></ul></li></ul><!-- end field c284baa2-6143-4eff-9481-3d0262ed16e5 --><!-- end item b19cd3bf-a8b4-45f7-ac1d-95d7798b6eef --></div></section></section><section aria-labelledby='minimizing-adverse-effects'><div class='ChapterBody-module--section--2d0kz'><h3 id='minimizing-adverse-effects'>How should I minimize the risks of adverse effects in people using topical corticosteroids?</h3><!-- begin item 34acd612-b53c-4561-a460-b604590af3fb --><!-- begin field 411dd1a6-9156-42aa-b1ff-1b16763ec8e7 --><ul><li><strong>To minimize the adverse effects of topical corticosteroids:</strong><ul><li>Prescribe the least potent formulation that relieves the symptoms and advise the person to apply it thinly to affected areas, no more than twice daily.&nbsp;</li><li>Limit the <a class='topic-reference internal-reference' href='#4d7555c6-6e3b-436b-8401-050e57f166cb'>length of treatment</a> and <a class='topic-reference internal-reference' href='#d3c0cd13-7615-4485-b699-7843c4f5e471'>quantity</a> used per week depending on the potency of the topical steroid, the indication, and the affected areas.&nbsp;&nbsp;</li><li>Avoid prescribing potent corticosteroids for use on the face and skin flexures.&nbsp;<ul><li>If they are used in people with eczema, limit use to short periods only.</li></ul></li><li>Limit use of mild or moderate potency corticosteroids to a maximum of 2 weeks for people with psoriasis of the face, flexure, or genitals.</li><li>Avoid using occlusive dressings with potent or very potent topical corticosteroids.</li><li>Consider prescribing an appropriate quantity of an emollient for use alongside the topical corticosteroid.&nbsp;</li><li>If a topical corticosteroid is needed for maintenance therapy, consider intermittent use, with time periods when emollients are used on their own.&nbsp;</li></ul></li><li><strong>If the person is using large amounts of topical corticosteroid regularly, </strong>monitor them for signs of systemic adverse effects (such as adrenal suppression) and local adverse effects (such as thinning of the skin or striae).&nbsp;</li><li><strong>Monitor the height of children </strong>who are using large amounts of topical corticosteroid. Refer the child to a paediatrician if growth suppression is suspected.&nbsp;</li></ul><!-- end field 411dd1a6-9156-42aa-b1ff-1b16763ec8e7 --><!-- end item 34acd612-b53c-4561-a460-b604590af3fb --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item c2bf0824-b8b2-4445-b6e8-40b31ffb2066 --><!-- begin field 4ce6b9bc-2071-4b99-8076-848d16bb33b8 --><p>These recommendations are based&nbsp;on the National Prescribing Centre Bulletin&nbsp;<em>Using topical corticosteroids in general practice</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>]; the <em>British National Formulary</em> (BNF) [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>]; the National Institute for Health and Care Excellence (NICE) guidelines <em>Psoriasis: assessment and management&nbsp;</em>[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2017</a>]&nbsp;and&nbsp;<em>Atopic eczema in under 12s: diagnosis and management</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2007</a>]; the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of atopic eczema in primary care</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>SIGN, 2011</a>]; expert opinion in narrative reviews <em>Guidelines of care for the management of psoriasis and psoriatic arthritis</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>] and&nbsp;<em>Choosing topical corticosteroids</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Ference, 2009</a>]; and the summary of product characteristics for Betnovate cream [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>ABPI, 2019c</a>].</p><p><strong>Monitoring growth of children</strong></p><ul><li>Topically applied high- and ultra-high potency corticosteroids can be absorbed well enough to cause systemic side effects, including decreased growth rate [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Ference, 2009</a>; <a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>].</li><li>The recommendation to monitor growth in children is based on expert opinion in a narrative review [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>] that recommends assessing growth of children using topical corticosteroids long term, and is what CKS considers good medical practice, as rarely, topical corticosteroids can cause system adverse effects, particularly in children.&nbsp;</li></ul><!-- end field 4ce6b9bc-2071-4b99-8076-848d16bb33b8 --><!-- end item c2bf0824-b8b2-4445-b6e8-40b31ffb2066 --></div></section></section><section aria-labelledby='information-advice'><div class='ChapterBody-module--section--2d0kz'><h3 id='information-advice'>What information and advice should I give to a person receiving topical corticosteroids?</h3><!-- begin item c07af8fb-0a8a-48d7-a6d3-0fb200454f48 --><!-- begin field 9c018f1e-760d-448e-9ad8-5b7e5b83493e --><ul><li>Explain about the potency of each topical corticosteroid that has been prescribed, and if possible provide a written treatment plan, outlining the:&nbsp;<ul><li><strong>Quantity </strong>— explain&nbsp;<a class='topic-reference internal-reference' href='#62a85c90-fe82-4ff3-9175-a74a00aa84fa'>Fingertip units (FTUs) for adults</a>, and advise the person to apply the topical corticosteroid thinly to the affected area. It should cover the inflamed skin even if it is excoriated.&nbsp;</li><li><strong>Duration of treatment&nbsp; </strong>— advise the person not to use topical corticosteroids for longer than prescribed.</li><li><strong>Frequency </strong>— once daily (or sometimes twice daily).&nbsp;</li><li><strong>Location </strong>— people may be prescribed more than one topical corticosteroid, of different potencies, to be applied on different parts of the body.&nbsp;</li><li><strong>Method </strong>— topical corticosteroids should not be mixed with other topical preparations. Advise the person to:<ul><li>Wait 20–30 minutes between applications of the topical corticosteroid and emollient to avoid diluting the corticosteroid and reducing its effectiveness.</li><li>Rub gently into the skin — the corticosteroid should be applied gently in the direction of hair growth to prevent occlusion folliculitis.&nbsp;</li></ul></li></ul></li><li>Reassure the person that, when used correctly, topical corticosteroids rarely cause serious adverse effects. However, advise that they should seek medical review if they notice any adverse effects (such as thinning of the skin, striae, or acne vulgaris).&nbsp;</li><li>Advise the person to carry a steroid treatment card if they are receiving long term treatment (several weeks) with a potent or very potent topical corticosteroid.&nbsp;</li><li>Warn the person to keep away from fire or other naked flames (for example, candles, cigarettes) — if topical corticosteroids come into contact with dressings, clothing and bedding, the fabric can be easily ignited.&nbsp;</li><li>Remind the person not to use an out of date topical preparation as reuse of a microbially contaminated corticosteroid can be harmful.&nbsp;</li></ul><!-- end field 9c018f1e-760d-448e-9ad8-5b7e5b83493e --><!-- end item c07af8fb-0a8a-48d7-a6d3-0fb200454f48 --></div><section aria-labelledby='basis-for-recommendation'><div class='ChapterBody-module--section--2d0kz'><h4 id='basis-for-recommendation'>Basis for recommendation</h4><!-- begin item c7e0edf0-0c2d-4a8d-8b26-bdb080f18578 --><!-- begin field abb9c1da-d444-4f60-b3cd-6debbacbf114 --><p>These recommendations are largely based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MeReC, 1999</a>]; the <em>British National Formulary</em>&nbsp;(BNF)&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>]; the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of atopic eczema in primary care</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>SIGN, 2011</a>]; expert opinion in narrative reviews <em>Guidelines of care for the management of psoriasis and psoriatic arthritis</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Menter, 2009</a>]&nbsp;and <em>Choosing topical corticosteroids</em>&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Ference, 2009</a>]; a British Association of Dermatologists (BAD) patient information leaflet <em>Topical corticosteroids</em> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>BAD, 2019</a>]; and the summary of product characteristics for Betnovate cream [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>ABPI, 2019c</a>].</p><p><strong>Applying corticosteroids</strong> [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Mooney, 2015</a>]</p><ul><li>The Australian College of Dermatologists advises that there is no requirement:&nbsp;<ul><li>To use topical corticosteroids sparingly — an ample volume of cream should be applied that is sufficient to cover the entire affected area.</li><li>For intervals without therapy — the topical corticosteroid should be applied to all inflamed skin until eczema is cleared.&nbsp;&nbsp;</li></ul></li><li>It also advises that the phrase 'use sparingly' should be avoided as it is nonsensical and has no value, and it promotes inadequate use of topical corticosteroids. It recommends that people are advised to use topical steroids liberally and then carefully rubbed or massaged into inflamed skin, but to avoid very thick application.</li><li>Underutilization of topical corticosteroids due to the widespread fear of side effects leads to worse outcomes for children with eczema in both the short and long term.</li></ul><p><strong>Timing of application of emollients and topical corticosteroids</strong></p><ul><li>There is no evidence or consensus in the literature to help decide in which order preparations should be applied and the length of time people should wait before applying the second preparation.&nbsp;</li><li>The NICE guidance&nbsp;<em>Atopic eczema in under 12s: diagnosis and management</em> advises that products should be applied one at a time with several minutes between applications where practical, and that the preferences of the child and parents or carers should determine which product should be applied first&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>NICE, 2007</a>].</li><li>A British Association for Dermatologists (BAD) patient information leaflet advises that people should wait 20–30 minutes between the two treatments to avoid diluting the topical steroid and reducing its effectiveness, but does not advise which preparation should be applied first [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>BAD, 2019</a>].&nbsp;</li><li>The manufacturer of Betnovate cream advises that adequate time should be allowed for absorption of the corticosteroid after each application before applying an emollient, but does not specify an amount of time to wait&nbsp;[<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>ABPI, 2019c</a>].</li><li>The British National Formulary recommends that mixing topical preparations on the skin should be avoided where possible; several minutes should elapse between application of different preparations [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Joint Formulary Committee, 2020</a>].</li><li>In the expert opinion of previous external reviewers of this CKS topic, some recommend that the corticosteroid should be applied first. This is also a reasonable strategy, provided that sufficient time is allowed before the emollient is applied, to prevent dilution and unnecessary spreading of the corticosteroid. Waiting for 1 hour is suggested by some external reviewers.</li></ul><p><strong>Steroid treatment card</strong></p><ul><li>The recommendation to issue a steroid treatment card if the person is receiving long term treatment (for several weeks) with a potent or very potent topical corticosteroid, is based on what CKS considers to be good clinical practice.<ul><li>Most topical corticosteroids may, under certain circumstances, be absorbed in sufficient amounts to cause systemic adverse effects [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>Brayfield, 2020</a>].</li><li>The Medicines and Healthcare products Regulatory Agency (MHRA) advises that in addition to issuing a steroid treatment card to people on high dose inhaled corticosteroids, one may be issued to other people at high risk of systemic adverse effects at the discretion of the prescriber or pharmacist [<a class='bibliography-reference internal-reference' href='#d1bdc0c9-c003-4877-aa9e-fff27dc8b2ee'>MHRA, 2006</a>].</li></ul></li></ul><!-- end field abb9c1da-d444-4f60-b3cd-6debbacbf114 --><!-- end item c7e0edf0-0c2d-4a8d-8b26-bdb080f18578 --></div></section></section></section>",
      "containerElement": "topicSummary",
      "children": [],
      "depth": 1,
      "pos": 0
    },
    {
      "itemId": "60caeda7-f2b3-4195-8d1a-bcabbe2c02b0",
      "parentId": null,
      "rootId": "60caeda7-f2b3-4195-8d1a-bcabbe2c02b0",
      "fullItemName": "Have I got the right topic?",
      "htmlHeader": "<!-- begin field 259ec64d-dae0-4e8e-8756-a90cf629ee37 --><h1>Have I got the right topic?</h1><!-- end field 259ec64d-dae0-4e8e-8756-a90cf629ee37 -->",
      "htmlStringContent": "<!-- begin item 60caeda7-f2b3-4195-8d1a-bcabbe2c02b0 --><!-- begin field ec14bbaf-6f5c-4086-9b7d-aa5b00cd848f --><p>From age 1 month onwards.</p><!-- end field ec14bbaf-6f5c-4086-9b7d-aa5b00cd848f --><!-- begin field a7c545ff-6eb4-4749-9c9c-7fbb10f6afa7 --><p>This CKS&nbsp;topic covers the primary care management of acute and chronic asthma in adults and children.</p><p>This CKS&nbsp;topic is based on the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) <em>British guideline on the management of asthma</em> [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>], and the National Institute of Health and Care Excellence guideline&nbsp;<em>Asthma: diagnosis, monitoring and chronic asthma management</em> [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</p><p>There are separate CKS&nbsp;topics on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/473ddaff-d0fe-4ba6-950d-21174782d383\">Chest infections - adult</a>, <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/e48489e8-63d1-4a04-bc5b-07e36a76af58\">Chronic obstructive pulmonary disease</a>, <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/5aee85d5-d8d1-479b-bfa3-a30835b97d6e\">Common cold</a>&nbsp;and <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/d067f8f3-0954-4f6f-aa2d-7367538e4d66\">Smoking cessation</a>.</p><p>The target audience for this CKS&nbsp;topic is healthcare professionals working within the NHS in the UK, and providing first contact or primary health care.</p><!-- end field a7c545ff-6eb4-4749-9c9c-7fbb10f6afa7 --><!-- end item 60caeda7-f2b3-4195-8d1a-bcabbe2c02b0 -->",
      "containerElement": "rightTopic",
      "children": [],
      "depth": 1,
      "pos": 1
    },
    {
      "itemId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
      "parentId": null,
      "rootId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
      "fullItemName": "How up-to-date is this topic?",
      "htmlHeader": "<!-- begin field 84de3e78-8250-482a-af86-84e0840a6c6e --><h1>How up-to-date is this topic?</h1><!-- end field 84de3e78-8250-482a-af86-84e0840a6c6e -->",
      "htmlStringContent": "<!-- begin item e64ca0fe-509a-4022-ba1d-0850fb07be46 --><!-- end item e64ca0fe-509a-4022-ba1d-0850fb07be46 -->",
      "containerElement": "uptodate",
      "children": [
        {
          "itemId": "a3f17739-8081-47cc-a71e-19a61fcc1b02",
          "parentId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
          "rootId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
          "fullItemName": "Changes",
          "htmlHeader": "<!-- begin field eeaeb8c9-c497-4d17-a92a-ab0529701025 --><h2>Changes</h2><!-- end field eeaeb8c9-c497-4d17-a92a-ab0529701025 -->",
          "htmlStringContent": "<!-- begin item a3f17739-8081-47cc-a71e-19a61fcc1b02 --><!-- begin field 3d213d55-9047-4c72-a58a-3f51620d1036 --><p><strong>April 2018</strong> &mdash; minor update. <a class=\"topic-reference internal-reference\" href=\"#ccba3ee6-8ec7-4867-b4d6-d9d150b81fcc\">New product availability</a> Spiriva Respimat is now licensed as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.</p><p><strong>March 2018</strong> &mdash; reviewed and updated. A literature search was conducted in March 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field 3d213d55-9047-4c72-a58a-3f51620d1036 --><!-- end item a3f17739-8081-47cc-a71e-19a61fcc1b02 -->",
          "containerElement": "changes",
          "children": [
            {
              "itemId": "81bf6b86-e61e-487d-a644-cea483a74251",
              "parentId": "a3f17739-8081-47cc-a71e-19a61fcc1b02",
              "rootId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
              "fullItemName": "Previous changes",
              "htmlHeader": "<!-- begin field f843999f-44f8-45d7-a399-94891802c30c --><h3>Previous changes</h3><!-- end field f843999f-44f8-45d7-a399-94891802c30c -->",
              "htmlStringContent": "<!-- begin item 81bf6b86-e61e-487d-a644-cea483a74251 --><!-- begin field 94c45a69-5659-48bc-b1d6-7f5a12d7dfff --><p><strong>February 2018 </strong>&mdash; minor update. Systematic review from Cochrane library - Anti-IL5 therapies for asthma added to new evidence section.&nbsp;</p><p><strong>October to December 2016&nbsp;</strong>&mdash; reviewed and updated. A literature search was conducted in October&nbsp;2016&nbsp;to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone&nbsp;restructuring. No major changes to the recommendations have been made.</p><p><strong>December 2013</strong>&nbsp;&mdash;&nbsp;minor update. A broken link to the Children&#39;s Asthma Control Test has been fixed.</p><p><strong>July 2013</strong>&nbsp;&mdash; minor update. Links to the DVLA website have been updated.</p><p><strong>June 2013</strong>&nbsp;&mdash; minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>May 2013</strong>&nbsp;&mdash;&nbsp;minor update. Minor change to the text to improve the clarity managing&nbsp;people awaiting hospital admission.</p><p><strong>February 2013&nbsp;</strong>&mdash; minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong>&nbsp;&mdash; minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>March 2012</strong>&nbsp;&mdash; minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2012</strong>&nbsp;&mdash; minor update. A recommendation to advise people inhaling terbutaline via a turbohaler to rinse their mouth after each use to minimize systemic adverse effects has been added, following an update to the manufacturer&#39;s Summary of Product Characteristics. Issued in March 2012.</p><p><strong>November 2011</strong>&nbsp;&mdash; minor update. The black triangle has been removed from Serevent Evohaler<sup>&reg;</sup>&nbsp;(salmeterol cfc-free inhaler); prescriptions have been amended to reflect this. Issued in December 2011.</p><p><strong>June&nbsp;2011</strong>&nbsp;&mdash; annual updates from the&nbsp;<em>British guideline on the management of asthma: a national clinical guideline</em>&nbsp;by SIGN/BTS are now included. Issued in June 2011.</p><p><strong>May 2011</strong>&nbsp;&mdash; minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>April 2011&nbsp;</strong>&mdash;&nbsp;minor update. Pulmicort pMDI inhalers have been removed from this topic as they have been discontinued. Issued in June 2011.</p><p><strong>March 2011</strong>&nbsp;&mdash; topic structure revised to ensure consistency across CKS topics &mdash; no changes to clinical recommendations have been made.</p><p><strong>February 2011</strong>&nbsp;&mdash; minor update. The range of dry powder inhaler devices included as prescriptions has been updated. Issued in February 2011.</p><p><strong>December 2010</strong>&nbsp;&mdash; minor update. The Flixotide Diskhaler<sup>&reg;</sup>&nbsp;(fluticasone) range has been discontinued. The prescription has been removed. Issued in December 2010.</p><p><strong>October 2010&nbsp;</strong>&mdash; minor update. Information on fitness to drive from the Driver and Vehicle Licensing Agency&#39;s guidance for medical practitioners,&nbsp;<em>At a glance guide to the current medical standards of fitness to drive</em>&nbsp;has been added. Issued in November 2010.</p><p><strong>September 2010</strong>&nbsp;&mdash; minor update. The Medicines and Healthcare products Regulatory Agency has issues a reminder to prescribers that, for most children, a daily dose of 24&nbsp;micrograms formoterol is sufficient. Issued in September 2010.</p><p><strong>March 2010</strong>&nbsp;&mdash; minor update. All strengths of Beclazone<sup>&reg;</sup>&nbsp;inhalers have been discontinued. Prescriptions removed. For advice regarding switching from CFC beclometasone to CFC-free beclometasone.&nbsp;Issued in March 2010.</p><p><strong>January 2010</strong>&nbsp;&mdash; minor update. Ciclesonide (Alvesco<sup>&reg;</sup>) is no longer a black triangle product. Minor addition to text regarding drug interactions with theophylline. Issued in January 2010.</p><p><strong>December 2009</strong>&nbsp;&mdash; minor update. Clenil Modulite<sup>&reg;</sup>&nbsp;(beclometasone CFC-free) is no longer a black triangle product. Prescription updated. Issued in December 2009.</p><p><strong>November 2009</strong>&nbsp;&mdash; minor update. The&nbsp;<em>Supporting evidence&nbsp;</em>section on&nbsp;Symbicort Smart&reg;&nbsp;has been reworded to make it clear that the data summarized are from a single Cochrane review. Issued in November 2009.</p><p><strong>August 2009</strong>&nbsp;&mdash; minor update. The annual updates from the&nbsp;<em>British guideline on the management of asthma: a national clinical guideline</em>&nbsp;by SIGN/BTS are now included. Issued in August 2009.</p><p><strong>May 2009</strong>&nbsp;&mdash; updated to include information and prescriptions for budesonide CFC-free pMDI. The Nebuhaler<sup>&reg;</sup>&nbsp;spacer device has been discontinued. The prescription has been replaced with the NebuChamber<sup>&reg;</sup>&nbsp;spacer device. Issued in June 2009.</p><p><strong>April 2009</strong>&nbsp;&mdash; minor update. The Quality and Outcomes Framework (QOF) indicators for stopping smoking that relate to asthma have been added to the&nbsp;<em>Goals and outcome measures</em>&nbsp;section. Issued in May 2009.</p><p><strong>February 2009</strong>&nbsp;&mdash; minor update. Flixotide<sup>&reg;</sup>&nbsp;50&nbsp;microgram diskhaler and all strengths of the Aerobec<sup>&reg;</sup>&nbsp;breath-actuated inhaler have been discontinued. Prescriptions removed. Issued March 2009.</p><p><strong>August 2008</strong>&nbsp;&mdash; update to the diagnosis and assessment sections following the publication of the&nbsp;<em>British guideline on the management of asthma: a national clinical guideline</em>&nbsp;by SIGN/BTS. Issued in November 2008.</p><p><strong>March 2008</strong>&nbsp;&mdash; minor update to include advice from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding the use of short-acting beta<sub>2</sub>-agonists in people who have a history of heart disease. Issued in March 2008.</p><p><strong>September to December 2007&nbsp;</strong>&mdash; converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.&nbsp;This CKS topic includes revisions in the 2007 update to the SIGN/BTS British Guideline on the Management of Asthma.</p><p><strong>June 2007</strong>&nbsp;&mdash; updated. Nebuhaler<sup>&reg;</sup>&nbsp;discontinued. Prescriptions replaced with Nebuhaler<sup>&reg;</sup>&nbsp;+ mask, which continues to be available. Issued in June 2007.</p><p><strong>May 2007</strong>&nbsp;&mdash; updated. Becotide<sup>&reg;</sup>&nbsp;and Becloforte<sup>&reg;</sup>&nbsp;discontinued. Prescriptions removed. Issued in May 2007.</p><p><strong>March 2007</strong>&nbsp;&mdash; updated. Prescriptions and dosing information for Clenil Modulite<sup>&reg;</sup>&nbsp;(CFC-free beclometasone) and CFC-free formoterol included. Information on spacer device compatibilities also updated. Issued in March 2007.</p><p><strong>July to September 2006</strong>&nbsp;&mdash; updated. Validated in December 2006 and issued in January 2007.</p><p><strong>July 2006&nbsp;</strong>&mdash; minor update. All strengths of Ventodisks<sup>&reg;</sup>&nbsp;(salbutamol dry powder Diskhaler<sup>&reg;</sup>) will be discontinued from the end of September 2006 and prescriptions have been removed. Issued in July 2006.</p><p><strong>April 2006&nbsp;</strong>&mdash; minor update. Prescriptions for CFC-free nedocromil and salmeterol pressurized metered dose inhalers have replaced those for CFC-containing inhalers. Information on changing to CFC-free inhalers included in Medicines Management. Issued in May 2006.</p><p><strong>January 2006</strong>&nbsp;&mdash; minor update. Volumatic<sup>&reg;</sup>&nbsp;spacer device re-introduced and prescriptions included; terbutaline pressurized metered dose inhalers have been discontinued and prescriptions removed. Issued in February 2006.</p><p><strong>August 2005</strong>&nbsp;&mdash; updated to include revisions in the 2005 update to the SIGN/BTS British Guideline on the Management of Asthma, and the new CMO recommendations on the pneumococcal immunization programme. Volumatic<sup>&reg;</sup>&nbsp;spacer device discontinued and prescriptions removed; advice for using alternative spacer devices included. Validated in September 2005 and issued in November 2005.</p><p><strong>August 2004&nbsp;</strong>&mdash; updated to include revisions in the 2004 update to the SIGN/BTS British Guideline on the Management of Asthma. Validated in September 2004 and issued in November 2004.</p><p><strong>April 2003</strong>&nbsp;&mdash; reviewed. Validated in September 2003 and issued in October 2003. This guidance supersedes the CKS guidance&nbsp;<em>Asthma &mdash; age under 5&nbsp;years</em>, which has been withdrawn.</p><p><strong>April 2002</strong>&nbsp;&mdash; reviewed and updated to incorporate&nbsp;<em>Inhaler devices for routine treatment of chronic asthma in older children (aged 5&ndash;15&nbsp;years)</em>, technology appraisal guidance no. 38, issued by the National Institute for Health and Care Excellence (April 2002).</p><p><strong>April 1999</strong>&nbsp;&mdash; reviewed. Validated in July 1999 and issued in August 1999.</p><p><strong>June 1998</strong>&nbsp;&mdash; written.</p><!-- end field 94c45a69-5659-48bc-b1d6-7f5a12d7dfff --><!-- end item 81bf6b86-e61e-487d-a644-cea483a74251 -->",
              "containerElement": "previousChanges",
              "children": [],
              "depth": 3,
              "pos": 0
            }
          ],
          "depth": 2,
          "pos": 0
        },
        {
          "itemId": "2ffa2492-015d-4b65-97d4-25a6a535c449",
          "parentId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
          "rootId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
          "fullItemName": "Update",
          "htmlHeader": "<!-- begin field 11cbb9d8-5b51-44e4-a524-b7e240dfdf11 --><h2>Update</h2><!-- end field 11cbb9d8-5b51-44e4-a524-b7e240dfdf11 -->",
          "htmlStringContent": "<!-- begin item 2ffa2492-015d-4b65-97d4-25a6a535c449 --><!-- end item 2ffa2492-015d-4b65-97d4-25a6a535c449 -->",
          "containerElement": "annualKnowUpd",
          "children": [
            {
              "itemId": "ccba3ee6-8ec7-4867-b4d6-d9d150b81fcc",
              "parentId": "2ffa2492-015d-4b65-97d4-25a6a535c449",
              "rootId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
              "fullItemName": "New evidence",
              "htmlHeader": "<!-- begin field 85cc18d3-794f-4ac7-85c7-89b7c2f3a7b9 --><h3>New evidence</h3><!-- end field 85cc18d3-794f-4ac7-85c7-89b7c2f3a7b9 -->",
              "htmlStringContent": "<!-- begin item ccba3ee6-8ec7-4867-b4d6-d9d150b81fcc --><!-- begin field d4ac5b43-f76e-4bb7-a782-2cf3b178fb22 --><h3>Evidence-based guidelines</h3><!-- end field d4ac5b43-f76e-4bb7-a782-2cf3b178fb22 --><!-- begin field 2ecf291a-a6ac-4cae-bf7a-120ba845bbfb --><ul><li>Gonem, S., Cumella, A., and Richardson, M. (2019)&nbsp;<em>Asthma admission rates and patterns of salbutamol and inhaled corticosteroid prescribing in England from 2013 to 2017.&nbsp;</em>BMJ Journals. <a href=\"https://thorax.bmj.com/\" data-hyperlink-id=\"8313f3f3-a9b2-4dde-83df-a9de00a44c58\">www.throrax.bmj.com</a> [<a href=\"https://thorax.bmj.com/content/early/2019/01/10/thoraxjnl-2018-212723\" data-hyperlink-id=\"77ac9640-cd35-4202-a1e3-a9de00a44c72\">Free Full-text</a>]</li></ul><!-- end field 2ecf291a-a6ac-4cae-bf7a-120ba845bbfb --><!-- begin field 6f9164f0-9a49-4d29-a6cf-577f3c2f7c18 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 6f9164f0-9a49-4d29-a6cf-577f3c2f7c18 --><!-- begin field 376d4673-5268-489e-a713-361578d59e14 --><ul><li>NICE (2019) <em>TA565:&nbsp;Benralizumab for treating severe eosinophilic asthma. </em>National Institute for Health and Care Excellence. <a href=\"https://www.nice.org.uk/\" data-hyperlink-id=\"4f25976e-5faa-4d65-b31e-aa1400fdaabd\">www.nice.org.uk</a> [<a href=\"https://www.nice.org.uk/guidance/ta565\" data-hyperlink-id=\"6c97a9b1-fa6e-440f-b80b-aa1400fdaae6\">Free Full-text</a>]</li></ul><!-- end field 376d4673-5268-489e-a713-361578d59e14 --><!-- begin field 28caae71-77ac-4f16-876f-e39ab0370d0f --><h3>Economic Appraisals</h3><!-- end field 28caae71-77ac-4f16-876f-e39ab0370d0f --><!-- begin field 9b5e8257-d218-4f01-b85b-843b29ac76da --><p>No new economic appraisals relevant to England since 1 March 2018.</p><!-- end field 9b5e8257-d218-4f01-b85b-843b29ac76da --><!-- begin field d010b39d-e314-421d-b607-8bedeb8acf23 --><h3>Systematic reviews and meta-analyses</h3><!-- end field d010b39d-e314-421d-b607-8bedeb8acf23 --><!-- begin field 878f5ba4-b08c-4bd4-83c1-1e667a7d2995 --><ul><li>Asthma UK (2018) <em>UK asthma death rates among worst in Europe.</em> Asthma UK. <a data-hyperlink-id=\"dfc1792b-fbef-4172-8929-a8f70155eb8d\" href=\"https://www.asthma.org.uk//\">www.asthma.org.uk</a> [<a data-hyperlink-id=\"54671c84-5307-48ad-a258-a8f70155ebfa\" href=\"https://www.asthma.org.uk/about/media/news/press-release-uk-asthma-death-rates-among-worst-in-europe/\">Free Full-text</a>]</li><li>BMJ (2018) <em>Two pathways, one patient; UK asthma guidelines</em>. British Medical Journal. <a data-hyperlink-id=\"d7083764-35c0-452e-8c14-a8f70155ec36\" href=\"http://journals.bmj.com/\">www.bmj.com</a> [<a data-hyperlink-id=\"3504c43f-f5a3-4dfa-a6b5-a8f70155ec44\" href=\"http://thorax.bmj.com/content/early/2018/05/02/thoraxjnl-2018-211703\">Free Full-text</a>]</li><li>BMJ (2018) <em>Improving the global diagnosis and management of asthma in children</em>. British Medical Journal. <a data-hyperlink-id=\"139b6155-9001-40e0-bcde-a90000ad25ce\" href=\"https://journals.bmj.com/\">www.bmj.com</a> [<a data-hyperlink-id=\"37f051ff-df5d-48fe-974f-a90000ad25d3\" href=\"http://thorax.bmj.com/content/73/7/662\">Free Full-text</a>]</li><li>Busse, W., et al. (2018) Combined analysis of asthma safety trails of long-acting&nbsp;&szlig;<sub>2</sub>-agonists. The New England Journal of Medicine. <a data-hyperlink-id=\"ba3e256a-52be-4229-80e3-a915009caf6f\" href=\"https://www.nejm.org/\">www.nejm.org</a> [<a data-hyperlink-id=\"e52796f8-f97e-4059-8aeb-a915009cb104\" href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1716868\">Free Full-text</a>]</li><li>NIHR (2018) Increasing inhaled steroids for short periods reduces asthma exacerbations. National Institute for Health Research [<a data-hyperlink-id=\"130338e3-c5ac-4b67-8dac-a92700cb13c4\" href=\"https://discover.dc.nihr.ac.uk/content/signal-000619/asthma-exacerbations-can-be-reduced-by-increasing-inhaled-steroids-for-short-periods\">Free Full-text</a>]</li><li>Connett, G., Connett, L., and Thomas, M. (2019)&nbsp;<em>Determining the reasons for poorly controlled asthma in an adolescent.</em>&nbsp;British Medical Journal. <a data-hyperlink-id=\"5f871a76-41c3-4ecc-8224-a9e400a6af24\" href=\"https://www.bmj.com/\">www.bmj.com</a> [<a data-hyperlink-id=\"d6ea5fc6-c64b-4e05-8883-a9e400a6af31\" href=\"https://www.bmj.com/content/364/bmj.l75\">Free Full-text</a>]</li><li>Stefan, M., Shieh, M-S., and Spitzer, K. (2019)&nbsp;<em>Association of Antibiotic Treatment With Outcomes in Patients Hospitalized for an Asthma Exacerbation Treated With Systemic Corticosteroids. </em>JAMA Internal Medicine. <a href=\"https://jamanetwork.com/\" data-hyperlink-id=\"2f0a8b09-ce8a-485a-966d-a9fc00b3d2bf\">www.jamanetwork.com</a> [<a href=\"https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2721036\" data-hyperlink-id=\"26aefe49-015c-42a3-8c99-a9fc00b3d366\">Free Full-text</a>]</li></ul><!-- end field 878f5ba4-b08c-4bd4-83c1-1e667a7d2995 --><!-- begin field d6921492-b70d-4710-8132-c7fff72e16e7 --><h3>Primary evidence</h3><!-- end field d6921492-b70d-4710-8132-c7fff72e16e7 --><!-- begin field 5eeb24b3-ecd0-447d-8d1d-9529901869b8 --><ul><li>NEJM (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. The New England Journal of Medicine. <a href=\"https://www.nejm.org/\" data-hyperlink-id=\"4b2d057e-7152-4207-999c-a8f701555ba1\">www.nejm.org</a> [<a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1804092\" data-hyperlink-id=\"2365fe0f-0a32-4a88-99eb-a8f701555d59\">Free Full-text</a>]</li><li>Biospace Inc. (2018) GSK announces long-term data on mepolizumab in patients with severe asthma. Biospace Inc. <a href=\"https://www.biospace.com/\" data-hyperlink-id=\"f30bdce7-26c2-4f84-8bb3-a8f701555f18\">www.biospace.com</a> [<a href=\"https://www.biospace.com/article/gsk-unveils-positive-long-term-nucala-data-for-patients-with-severe-asthma/?keywords=MEPOLIZUMAB\" data-hyperlink-id=\"1ad06d27-716f-45e7-9e5c-a8f701555fb2\">Free Full-text</a>]</li></ul><!-- end field 5eeb24b3-ecd0-447d-8d1d-9529901869b8 --><!-- end item ccba3ee6-8ec7-4867-b4d6-d9d150b81fcc -->",
              "containerElement": "annualKnowNewEvidence",
              "children": [],
              "depth": 3,
              "pos": 0
            },
            {
              "itemId": "45f88529-1d86-428f-a15c-16786d01b685",
              "parentId": "2ffa2492-015d-4b65-97d4-25a6a535c449",
              "rootId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
              "fullItemName": "New policies",
              "htmlHeader": "<!-- begin field 4e3749ed-2b76-45af-b0a9-f4ec4e067624 --><h3>New policies</h3><!-- end field 4e3749ed-2b76-45af-b0a9-f4ec4e067624 -->",
              "htmlStringContent": "<!-- begin item 45f88529-1d86-428f-a15c-16786d01b685 --><!-- begin field 3cbff26b-704b-4d88-bef4-90ab9b7271f9 --><p>No new national policies or guidelines since&nbsp;1 March 2018.</p><!-- end field 3cbff26b-704b-4d88-bef4-90ab9b7271f9 --><!-- end item 45f88529-1d86-428f-a15c-16786d01b685 -->",
              "containerElement": "annualKnowPolicies",
              "children": [],
              "depth": 3,
              "pos": 1
            },
            {
              "itemId": "7017c19c-71fa-4b79-9195-554804021d1c",
              "parentId": "2ffa2492-015d-4b65-97d4-25a6a535c449",
              "rootId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
              "fullItemName": "New safety alerts",
              "htmlHeader": "<!-- begin field 647f87e3-4264-4eee-9072-b3ac62ac67f6 --><h3>New safety alerts</h3><!-- end field 647f87e3-4264-4eee-9072-b3ac62ac67f6 -->",
              "htmlStringContent": "<!-- begin item 7017c19c-71fa-4b79-9195-554804021d1c --><!-- begin field 74539bdf-ef7f-44e2-92be-0888d85fb494 --><p>No new safety alerts since 1 March 2018.</p><!-- end field 74539bdf-ef7f-44e2-92be-0888d85fb494 --><!-- end item 7017c19c-71fa-4b79-9195-554804021d1c -->",
              "containerElement": "annualKnowSafety",
              "children": [],
              "depth": 3,
              "pos": 2
            },
            {
              "itemId": "09c12594-d1ed-47f4-8faf-1c4bc3a69d8f",
              "parentId": "2ffa2492-015d-4b65-97d4-25a6a535c449",
              "rootId": "e64ca0fe-509a-4022-ba1d-0850fb07be46",
              "fullItemName": "Changes in product availability",
              "htmlHeader": "<!-- begin field 866df228-f9ab-4341-8761-cd96551e03ab --><h3>Changes in product availability</h3><!-- end field 866df228-f9ab-4341-8761-cd96551e03ab -->",
              "htmlStringContent": "<!-- begin item 09c12594-d1ed-47f4-8faf-1c4bc3a69d8f --><!-- begin field 72cbd259-65b4-4346-a11d-792e6b742b34 --><ul><li>Spiriva Respimat 2.5 microgram, inhalation solution is now licensed as an add-on maintenance&nbsp;bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year. See more <a data-hyperlink-id=\"9b4529f6-fabf-4540-b807-a8f7014d6f94\" href=\"https://www.medicines.org.uk/emc/product/407/smpc\">here</a>.</li><li>UK launch of Flutiform k-haler for asthma.&nbsp;Flutiform k-haler is the first breath-actuated inhaled corticosteroid long-acting &beta;2-agonist combination aerosol inhaler for adults and adolescents. The device is activated by a low breathing-in force that makes it easier to use correctly. See more <a data-hyperlink-id=\"81266755-f5b5-413f-9a48-a96700ad146c\" href=\"http://www.pharmatimes.com/news/uk_first_eu_nation_to_launch_flutiform_k-haler_for_asthma_1251730\">here</a>.&nbsp;</li><li>The SPC for Fostair&nbsp;(beclomethasone and formoterol) NEXThaler 100/6 has been updated to add maintenance and reliever treatment (MART) posology in asthma. The MART regimen is in line with the Fostair 100/6 aerosol device (1 puff as needed as rescue treatment, up to a maximum daily dose of 8 inhalations). See more <a data-hyperlink-id=\"7e4304de-0234-4703-9c4a-a98f009c390d\" href=\"https://www.medicines.org.uk/emc/product/3317/smpc\">here</a>.&nbsp;</li><li>The SPCs for Flutiform 50/5 and 125/5 microgram (fluticasone/formoterol) actuation pressurised inhalation, suspension&nbsp;have been updated following the addition of a new paediatric indication for children aged 5 to less than 12 for the treatment of asthma. See more <a data-hyperlink-id=\"cb4e30f3-d4cf-4f8a-9f60-a9d600f62e3c\" href=\"https://www.medicines.org.uk/emc/product/7649/smpc\">here</a>.&nbsp;</li><li>European CHMP recommends dupilumab for adult and adolescent (12 years and older) patients with certain forms of severe asthma. See more <a data-hyperlink-id=\"c21503b6-6a60-4691-b33d-aa1400ce6126\" href=\"https://www.ema.europa.eu/en/news/new-add-treatment-patients-severe-asthma\">here</a>.&nbsp;</li><li>mepolizumab (Nucala&reg;) accepted for restricted use in children over 6 yrs within NHSScotland -&nbsp;SMC has accepted mepolizumab as add-on treatment for severe refractory eosinophilic asthma in children &gt;6yrs. Use is restricted to those who have &gt;150cells/microlitre eosinophils at initiation and &gt;4 exacerbations in preceding year or receiving maintenance oral corticosteroids. See more <a data-hyperlink-id=\"50d74f16-61bb-4a3d-a5eb-aa5500d00041\" href=\"https://www.scottishmedicines.org.uk/medicines-advice/mepolizumab-nucala-abbreviated-smc2139/\">here</a>.</li><li>Dupilumab is now licensed for patients &gt;12yrs as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or FeNO, who are inadequately controlled with high dose ICS+another medicinal product for maintenance treatment. See more <a href=\"https://www.medicines.org.uk/emc/product/8553/smpc\" data-hyperlink-id=\"1ac11324-6454-4f27-83e4-aa57009249ed\">here</a>.&nbsp;</li></ul><!-- end field 72cbd259-65b4-4346-a11d-792e6b742b34 --><!-- end item 09c12594-d1ed-47f4-8faf-1c4bc3a69d8f -->",
              "containerElement": "annualKnowProduct",
              "children": [],
              "depth": 3,
              "pos": 3
            }
          ],
          "depth": 2,
          "pos": 1
        }
      ],
      "depth": 1,
      "pos": 2
    },
    {
      "itemId": "148142b7-b9dd-4951-a154-32ed71242cae",
      "parentId": null,
      "rootId": "148142b7-b9dd-4951-a154-32ed71242cae",
      "fullItemName": "Goals and outcome measures",
      "htmlHeader": "<!-- begin field dcca9aad-d928-4ded-b893-5be9863e5202 --><h1>Goals and outcome measures</h1><!-- end field dcca9aad-d928-4ded-b893-5be9863e5202 -->",
      "htmlStringContent": "<!-- begin item 148142b7-b9dd-4951-a154-32ed71242cae --><!-- end item 148142b7-b9dd-4951-a154-32ed71242cae -->",
      "containerElement": "goalOutcomes",
      "children": [
        {
          "itemId": "c4509460-f916-4698-af66-050e14bf92b8",
          "parentId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "rootId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "fullItemName": "Goals",
          "htmlHeader": "<!-- begin field 616928b8-19c7-4992-9e7c-7dd662d3f504 --><h2>Goals</h2><!-- end field 616928b8-19c7-4992-9e7c-7dd662d3f504 -->",
          "htmlStringContent": "<!-- begin item c4509460-f916-4698-af66-050e14bf92b8 --><!-- begin field 2697c2b6-1565-43d4-99a2-daafd8b1e399 --><p>To support primary healthcare professionals to:</p><ul><li>Make an accurate diagnosis of asthma and assess its severity.</li><li>Offer treatment to manage symptoms.</li><li>Advise on smoking cessation, if applicable.</li><li>Provide a self-management plan for recognizing and managing deterioration of symptoms.</li><li>Provide advice on nutrition and&nbsp;exercise.</li><li>Refer to specialist services where appropriate.</li></ul><!-- end field 2697c2b6-1565-43d4-99a2-daafd8b1e399 --><!-- end item c4509460-f916-4698-af66-050e14bf92b8 -->",
          "containerElement": "goals",
          "children": [],
          "depth": 2,
          "pos": 0
        },
        {
          "itemId": "413df63c-6df4-4e67-91ab-99009cf6de39",
          "parentId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "rootId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "fullItemName": "Outcome measures",
          "htmlHeader": "<!-- begin field 1674bd05-6fb7-4da0-bdd5-e0654babf154 --><h2>Outcome measures</h2><!-- end field 1674bd05-6fb7-4da0-bdd5-e0654babf154 -->",
          "htmlStringContent": "<!-- begin item 413df63c-6df4-4e67-91ab-99009cf6de39 --><!-- begin field 73abca56-0ed8-47eb-85d9-9a925ba87100 -->No outcome measures were found during the review of this topic.<!-- end field 73abca56-0ed8-47eb-85d9-9a925ba87100 --><!-- end item 413df63c-6df4-4e67-91ab-99009cf6de39 -->",
          "containerElement": "outcomeMeasures",
          "children": [],
          "depth": 2,
          "pos": 1
        },
        {
          "itemId": "c1008927-b81a-4e8a-816f-a2361ec88792",
          "parentId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "rootId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "fullItemName": "Audit criteria",
          "htmlHeader": "<!-- begin field a68b88be-2830-4697-8cc7-e9f53d2bd232 --><h2>Audit criteria</h2><!-- end field a68b88be-2830-4697-8cc7-e9f53d2bd232 -->",
          "htmlStringContent": "<!-- begin item c1008927-b81a-4e8a-816f-a2361ec88792 --><!-- begin field faec2e0f-96d5-4e5a-8e96-d211e567a6ac -->No audit criteria were found during the review of this topic.<!-- end field faec2e0f-96d5-4e5a-8e96-d211e567a6ac --><!-- end item c1008927-b81a-4e8a-816f-a2361ec88792 -->",
          "containerElement": "cksAuditCriteria",
          "children": [],
          "depth": 2,
          "pos": 2
        },
        {
          "itemId": "6d630d5c-f301-416f-975b-f3a197fde6e5",
          "parentId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "rootId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "fullItemName": "QOF indicators",
          "htmlHeader": "<!-- begin field 18b48d51-e553-48fc-953b-7e069fd67f41 --><h2>QOF indicators</h2><!-- end field 18b48d51-e553-48fc-953b-7e069fd67f41 -->",
          "htmlStringContent": "<!-- begin item 6d630d5c-f301-416f-975b-f3a197fde6e5 --><!-- begin field 97836eba-520e-4c0e-b93a-ae7d2ba4b64a --><p><strong>Table 1.</strong> Indicators from the Quality and Outcomes Framework (QOF) for asthma in the General Medical Services (GMS) contract.</p><table><tbody><tr><th>Quality indicator</th><th>Points</th><th>Threshold</th></tr><tr><td><strong>AST001</strong>&nbsp;The contractor establishes and maintains a register of patients with asthma, excluding patients with asthma who have been prescribed no asthma-related drugs in the preceding 12 months</td><td>4</td><td>&mdash;</td></tr><tr><td><strong>AST002</strong>&nbsp;The percentage of patients aged 8 or over with asthma (diagnosed on or after 1 April 2006), on the register, with measures of variability or reversibility recorded between 3 months before and anytime after diagnosis</td><td>15</td><td>45&ndash;80%</td></tr><tr><td><strong>AST003</strong>&nbsp;The percentage of patients with asthma, on the register, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control using the 3 RCP questions</td><td>20</td><td>45&ndash;70%</td></tr><tr><td><strong>AST004</strong>&nbsp;The percentage of patients with asthma aged 14 or over who have not attained the age of 20, on the register, in whom there is a record of smoking status in the preceding 12 months</td><td>6</td><td>45&ndash;80%</td></tr><tr><td><strong>SMOK002</strong>&nbsp;The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months</td><td>25</td><td>50&ndash;90%</td></tr><tr><td><strong>SMOK005</strong>&nbsp;The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months</td><td>25</td><td>56&ndash;96%</td></tr><tr><td colspan=\"3\"><strong>Data from:</strong>&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BMA and NHS Employers, 2017</a>] </td></tr></tbody></table><!-- end field 97836eba-520e-4c0e-b93a-ae7d2ba4b64a --><!-- end item 6d630d5c-f301-416f-975b-f3a197fde6e5 -->",
          "containerElement": "cksGmsQuality",
          "children": [],
          "depth": 2,
          "pos": 3
        },
        {
          "itemId": "0e3b55ff-ba11-4be3-8a53-48f17f3a6bca",
          "parentId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "rootId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "fullItemName": "QIPP - Options for local implementation",
          "htmlHeader": "<!-- begin field 44e7b41e-50b2-4195-90b4-2b9fbc28b7df --><h2>QIPP -&nbsp;Options for local implementation</h2><!-- end field 44e7b41e-50b2-4195-90b4-2b9fbc28b7df -->",
          "htmlStringContent": "<!-- begin item 0e3b55ff-ba11-4be3-8a53-48f17f3a6bca --><!-- begin field e55754c0-1683-4058-8b90-c86f2940dea5 --><p>No QIPP indicators were found during the review of this topic.</p><!-- end field e55754c0-1683-4058-8b90-c86f2940dea5 --><!-- end item 0e3b55ff-ba11-4be3-8a53-48f17f3a6bca -->",
          "containerElement": "cksQIPP",
          "children": [],
          "depth": 2,
          "pos": 4
        },
        {
          "itemId": "ac9e10ec-4591-45e9-97ad-0c00fb1092c9",
          "parentId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "rootId": "148142b7-b9dd-4951-a154-32ed71242cae",
          "fullItemName": "NICE quality standards",
          "htmlHeader": "<!-- begin field b088ff22-7d1e-465f-a7b6-3fe8162cfe67 --><h2>NICE quality standards</h2><!-- end field b088ff22-7d1e-465f-a7b6-3fe8162cfe67 -->",
          "htmlStringContent": "<!-- begin item ac9e10ec-4591-45e9-97ad-0c00fb1092c9 --><!-- begin field cf22eec9-26c9-4caa-bca3-a6fd008a7a57 --><p><strong>Quality standards that directly relate to the diagnosis and management of asthma include:</strong></p><ul><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-1-diagnosis#quality-statement-1-diagnosis\" data-hyperlink-id=\"29d6dda1-bc7f-4a01-988d-a8f7015b5fd2\">Statement 1</a>&nbsp;People with newly diagnosed asthma are diagnosed in accordance with NICE guidance.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-2-diagnosing-occupational-asthma#quality-statement-2-diagnosing-occupational-asthma\" data-hyperlink-id=\"aa0cfa96-35f5-4601-a7b2-a8f7015b5fd7\">Statement 2</a>&nbsp;Adults with new onset asthma are assessed for occupational causes.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-3-written-personalised-action-plans#quality-statement-3-written-personalised-action-plans\" data-hyperlink-id=\"deb3f68a-61d2-4874-8515-a8f7015b5ff3\">Statement 3</a>&nbsp;People with asthma receive a written personalised action plan.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-4-inhaler-technique#quality-statement-4-inhaler-technique\" data-hyperlink-id=\"2721b9cd-7508-473e-9828-a8f7015b5ff3\">Statement 4</a>&nbsp;People with asthma are given specific training and assessment in inhaler technique before starting any new inhaler treatment.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-5-review#quality-statement-5-review\" data-hyperlink-id=\"27817b6c-e87b-4336-b043-a8f7015b5ff8\">Statement 5</a>&nbsp;People with asthma receive a structured review at least annually.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-6-assessing-asthma-control#quality-statement-6-assessing-asthma-control\" data-hyperlink-id=\"973f5d87-026b-4521-8440-a8f7015b5ffc\">Statement 6</a>&nbsp;People with asthma who present with respiratory symptoms receive an assessment of their asthma control.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-7-assessing-severity#quality-statement-7-assessing-severity\" data-hyperlink-id=\"6ce7a7dc-990e-4b33-8ad8-a8f7015b6001\">Statement 7</a>&nbsp;People with asthma who present with an exacerbation of their symptoms receive an objective measurement of severity at the time of presentation.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-8-treatment-for-acute-asthma#quality-statement-8-treatment-for-acute-asthma\" data-hyperlink-id=\"60374806-bcef-4cfe-9c87-a8f7015b6006\">Statement 8</a>&nbsp;People aged 5&nbsp;years or older presenting to a healthcare professional with a severe or life-threatening acute exacerbation of asthma receive oral or intravenous steroids within 1&nbsp;hour of presentation.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-9-specialist-review#quality-statement-9-specialist-review\" data-hyperlink-id=\"231d0c8a-b25e-44e6-b9c0-a8f7015b6006\">Statement 9</a>&nbsp;People admitted to hospital with an acute exacerbation of asthma have a structured review by a member of a specialist respiratory team before discharge.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-10-follow-up-in-primary-care#quality-statement-10-follow-up-in-primary-care\" data-hyperlink-id=\"e0dc6a00-262b-4282-a0ed-a8f7015b600a\">Statement 10</a>&nbsp;People who received treatment in hospital or through out-of-hours services for an acute exacerbation of asthma are followed up by their own GP practice within 2&nbsp;working days of treatment.</li><li><a href=\"https://www.nice.org.uk/guidance/qs25/chapter/quality-statement-11-difficult-asthma#quality-statement-11-difficult-asthma\" data-hyperlink-id=\"7e46a9f2-6568-4887-8a88-a8f7015b600f\">Statement 11</a>&nbsp;People with difficult asthma are offered an assessment by a multidisciplinary difficult asthma service.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017b</a>] </p><p><strong>Additional quality standards that should also be considered when commissioning and providing a high-quality asthma service include:</strong></p><ul><li><a href=\"http://www.nice.org.uk/guidance/qs43/chapter/quality-statement-1-identifying-people-who-smoke\" data-hyperlink-id=\"3edd8f75-32bb-4858-b69b-a8f7015b6014\">Statement 1</a>&nbsp;People are asked if they smoke by their healthcare practitioner, and those who smoke are offered advice on how to stop.</li><li><a href=\"http://www.nice.org.uk/guidance/qs43/chapter/quality-statement-2-referral-to-smoking-cessation-services\" data-hyperlink-id=\"a267b941-f2a1-450a-8e1b-a8f7015b601d\">Statement 2</a>&nbsp;People who smoke are offered a referral to an evidence-based smoking cessation service.</li><li><a href=\"http://www.nice.org.uk/guidance/qs43/chapter/quality-statement-3-behavioural-support-with-pharmacotherapy\" data-hyperlink-id=\"9947e615-21dd-43a1-84cc-a8f7015b6027\">Statement 3</a>&nbsp;People who smoke are offered behavioural support with pharmacotherapy by an evidence-based smoking cessation service.</li><li><a href=\"http://www.nice.org.uk/guidance/qs43/chapter/quality-statement-4-pharmacotherapy\" data-hyperlink-id=\"7b7763c2-d744-414f-ae38-a8f7015b602b\">Statement 4</a>&nbsp;People who seek support to stop smoking and who agree to take pharmacotherapy are offered a full course.</li><li><a href=\"http://www.nice.org.uk/guidance/qs43/chapter/quality-statement-5-outcome-measurement\" data-hyperlink-id=\"13eccbd2-384c-4d9c-8fd5-a8f7015b6035\">Statement 5</a>&nbsp;People who smoke who have set a quit date with an evidence-based smoking cessation service are assessed for carbon monoxide levels 4 weeks after the quit date.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2013</a>]</p><!-- end field cf22eec9-26c9-4caa-bca3-a6fd008a7a57 --><!-- end item ac9e10ec-4591-45e9-97ad-0c00fb1092c9 -->",
          "containerElement": "cksNICEQuality",
          "children": [],
          "depth": 2,
          "pos": 5
        }
      ],
      "depth": 1,
      "pos": 3
    },
    {
      "itemId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
      "parentId": null,
      "rootId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
      "fullItemName": "Background information",
      "htmlHeader": "<!-- begin field 661113db-3f58-4e98-991a-6d3ab749ac28 --><h1>Background information</h1><!-- end field 661113db-3f58-4e98-991a-6d3ab749ac28 -->",
      "htmlStringContent": "<!-- begin item 56990625-0a95-4124-8bf0-03dc5a21dfb9 --><!-- end item 56990625-0a95-4124-8bf0-03dc5a21dfb9 -->",
      "containerElement": "background",
      "children": [
        {
          "itemId": "0986f770-bd9e-4c87-9f95-19731213b6e4",
          "parentId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "rootId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "fullItemName": "Definition",
          "htmlHeader": "<!-- begin field 336bea12-ae71-45cd-95f0-7a209ba6e39d --><h2>What is it?</h2><!-- end field 336bea12-ae71-45cd-95f0-7a209ba6e39d -->",
          "htmlStringContent": "<!-- begin item 0986f770-bd9e-4c87-9f95-19731213b6e4 --><!-- begin field e271ffce-0dd2-49e2-9a99-0c42adb4590a --><ul><li><strong>Asthma is a chronic respiratory condition associated with airway inflammation and hyper-responsiveness</strong>.<ul><li>The disease is heterogeneous, with different underlying disease processes and variations&nbsp;in severity, clinical course, and response to treatment.</li></ul></li><li><strong>Asthma is characterized by symptoms including</strong>&nbsp;<strong>cough, wheeze, chest tightness, and shortness of breath, and variable expiratory airflow limitation,&nbsp;that can vary over time and in intensity. </strong><ul><li>Symptoms can be triggered by factors including exercise, allergen or irritant exposure, changes in weather, and viral respiratory infections.</li><li>Symptoms may resolve spontaneously or in response to medication, and may sometimes be absent for weeks or months at a time.&nbsp;</li></ul></li><li><strong>Acute asthma exacerbation</strong>&nbsp;is a term used to describe the onset of severe asthma symptoms, which can be life-threatening.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">GINA, 2016</a>]</p><!-- end field e271ffce-0dd2-49e2-9a99-0c42adb4590a --><!-- end item 0986f770-bd9e-4c87-9f95-19731213b6e4 -->",
          "containerElement": "backgroundSub",
          "children": [],
          "depth": 2,
          "pos": 0
        },
        {
          "itemId": "b6ef091b-d1d2-4bb0-8850-a6b700e86949",
          "parentId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "rootId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "fullItemName": "Prevalence",
          "htmlHeader": "<!-- begin field f2b1906f-614d-4745-b6eb-a6b700e86ac5 --><h2>What is the prevalence of asthma?</h2><!-- end field f2b1906f-614d-4745-b6eb-a6b700e86ac5 -->",
          "htmlStringContent": "<!-- begin item b6ef091b-d1d2-4bb0-8850-a6b700e86949 --><!-- begin field ecf4e394-1944-430b-83f6-a6b700e86ac5 --><ul><li>Asthma affects more than 300 million people worldwide including 11.6% of children aged 6 to 7 years.</li><li>In the UK, over 8 million people, or approximately 12% of the population, have been diagnosed with asthma. However, some&nbsp;may have grown out of the condition, and 5.4 million people are receiving asthma&nbsp;treatment.</li><li>Approximately 160,000 people in the UK are diagnosed with asthma each year, however, incidence rates went down by&nbsp;around 10% between 2008 and 2012.</li><li>The incidence of asthma is higher in children than in adults.</li><li>In early childhood, asthma is more common in boys than in girls, but by adulthood, the sex ratio is reversed.</li><li>Asthma accounts for 2-3% of primary care consultations, 60,000 hospital admissions, and 200,000 bed days per year in the UK.</li><li>Occupational asthma may account for 9&ndash;15% of adult-onset asthma. It is reported to be the most common industrial lung disease in the developed world.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Olin, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Mukherjee et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">British Lung Foundation, 2018</a>]</p><!-- end field ecf4e394-1944-430b-83f6-a6b700e86ac5 --><!-- end item b6ef091b-d1d2-4bb0-8850-a6b700e86949 -->",
          "containerElement": "backgroundSub",
          "children": [],
          "depth": 2,
          "pos": 1
        },
        {
          "itemId": "6ef7283e-7bd6-43b1-a34d-a6b700e8717a",
          "parentId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "rootId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "fullItemName": "Risk factors",
          "htmlHeader": "<!-- begin field 5b2b6110-1743-47f6-b909-a6b700e872fd --><h2>What are the risk factors for asthma?</h2><!-- end field 5b2b6110-1743-47f6-b909-a6b700e872fd -->",
          "htmlStringContent": "<!-- begin item 6ef7283e-7bd6-43b1-a34d-a6b700e8717a --><!-- begin field aa75a1a8-0f16-4c7b-aac8-a6b700e872fd --><ul><li><strong>Various risk factors</strong>&nbsp;<strong>may increase the likelihood of development or persistence of asthma, including:</strong><ul><li>Personal or family history of atopic disease (for example asthma, eczema, allergic rhinitis, or allergic conjunctivitis) [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">GINA, 2016</a>].</li><li>Male sex for pre-pubertal asthma&nbsp;and female sex for persistence of asthma from childhood to adulthood&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>].</li><li>Respiratory infections&nbsp;in infancy&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">DynaMed Plus, 2016</a>].</li><li>Exposure (including prenatally) to tobacco smoke&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">DynaMed Plus, 2016</a>].</li><li>Premature birth and associated low birth weight&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">GINA, 2016</a>].</li><li>Obesity&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">GINA, 2016</a>].</li><li>Social deprivation [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">British Lung Foundation, 2018</a>].<ul><li>In 2012, incidence rates were 36% higher in the most&nbsp;deprived communities compared to the least&nbsp;deprived. This may be due to higher levels of damp housing, fungal spores, pollution, and exposure to tobacco smoke&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">British Lung Foundation, 2018</a>].</li></ul></li><li>Exposure to inhaled particulates [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Olin, 2014</a>].</li><li>Workplace exposures including flour dust and isocyanates from paint [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Subbarao et al, 2015</a>].</li></ul></li></ul><!-- end field aa75a1a8-0f16-4c7b-aac8-a6b700e872fd --><!-- end item 6ef7283e-7bd6-43b1-a34d-a6b700e8717a -->",
          "containerElement": "backgroundSub",
          "children": [],
          "depth": 2,
          "pos": 2
        },
        {
          "itemId": "d9245eef-0ab3-4d3a-b89a-a6b700ec2dfb",
          "parentId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "rootId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "fullItemName": "Prognosis",
          "htmlHeader": "<!-- begin field 935cb95c-be92-4bbd-847a-a6b700ec3405 --><h2>What is the prognosis of asthma?</h2><!-- end field 935cb95c-be92-4bbd-847a-a6b700ec3405 -->",
          "htmlStringContent": "<!-- begin item d9245eef-0ab3-4d3a-b89a-a6b700ec2dfb --><!-- begin field 8254eea5-0489-4e59-99ab-a6b700ec3405 --><ul><li>Male children are more likely to grow out of asthma in the transition to adulthood&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>].</li><li>The earlier the onset of asthma, the better the prognosis; most children who present under 2 years of age become asymptomatic by mid-childhood (6&ndash;11 years of age) [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>].</li><li>However, early-onset asthma in atopic children may be associated with a worse prognosis [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Warner, Personal Communication, 2006</a>].</li><li>The Melbourne Epidemiological Study of Childhood Asthma was a 1964&ndash;1999 longitudinal study which suggested that in most children with asthma, significant wheezing continued into adult life. The study found that the more severe or frequent symptoms were in childhood, the more likely it was that symptoms would continue into adulthood&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Phelan et al, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Horak et al, 2003</a>].<ul><li>The study recruited children at age 7 years and followed them up through adolescence to adulthood. The proportion of people with no recent asthma increased steadily from 20% at age 14 years to 40% at age 42 years.</li><li>Episodic asthma in childhood tends to resolve in adolescence and early adulthood.</li><li>The study concluded that the pattern of asthma during childhood tends to predict&nbsp;outcome in later life.</li></ul></li></ul><!-- end field 8254eea5-0489-4e59-99ab-a6b700ec3405 --><!-- end item d9245eef-0ab3-4d3a-b89a-a6b700ec2dfb -->",
          "containerElement": "backgroundSub",
          "children": [],
          "depth": 2,
          "pos": 3
        },
        {
          "itemId": "85568542-65fa-4561-8772-a6b700ee8029",
          "parentId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "rootId": "56990625-0a95-4124-8bf0-03dc5a21dfb9",
          "fullItemName": "Complications",
          "htmlHeader": "<!-- begin field 2a4f58de-5a7a-4c85-9241-a6b700ee81c4 --><h2>What are the complications of asthma?</h2><!-- end field 2a4f58de-5a7a-4c85-9241-a6b700ee81c4 -->",
          "htmlStringContent": "<!-- begin item 85568542-65fa-4561-8772-a6b700ee8029 --><!-- begin field ba9782d8-9182-48ad-8766-a6b700ee81c4 --><p><strong>Complications of asthma include:</strong></p><ul><li><strong>Death</strong>&nbsp;&mdash;&nbsp;more than 1,200 people died of asthma in the UK in 2014 [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">British Lung Foundation, 2018</a>]. Annually, asthma causes an estimated 250,000 deaths worldwide [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Olin, 2014</a>].</li><li><strong>Respiratory complications</strong> &mdash;&nbsp; irreversible airway changes,<strong>&nbsp;</strong>pneumonia, pulmonary collapse (atelectasis caused by mucus plugging of the airways), respiratory failure, pneumothorax, and status asthmaticus (repeated asthma attacks without respite, or non-response to appropriate treatment)&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>].</li><li><strong>Impaired quality of life</strong>&nbsp;may result from suboptimal control of asthma. This may include:<ul><li>Fatigue.</li><li>Underperformance and time off school or work&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Olin, 2014</a>].</li></ul></li></ul><!-- end field ba9782d8-9182-48ad-8766-a6b700ee81c4 --><!-- end item 85568542-65fa-4561-8772-a6b700ee8029 -->",
          "containerElement": "backgroundSub",
          "children": [],
          "depth": 2,
          "pos": 4
        }
      ],
      "depth": 1,
      "pos": 4
    },
    {
      "itemId": "e02b2728-772c-4924-9a6f-0cc38e2d93c8",
      "parentId": null,
      "rootId": "e02b2728-772c-4924-9a6f-0cc38e2d93c8",
      "fullItemName": "Diagnosis",
      "htmlHeader": "<!-- begin field e01e8463-659e-4bcc-bdf4-5b8528c165bd --><h1>Diagnosis of asthma</h1><!-- end field e01e8463-659e-4bcc-bdf4-5b8528c165bd -->",
      "htmlStringContent": "<!-- begin item e02b2728-772c-4924-9a6f-0cc38e2d93c8 --><!-- end item e02b2728-772c-4924-9a6f-0cc38e2d93c8 -->",
      "containerElement": "diagnosis",
      "children": [
        {
          "itemId": "061adf6f-72fd-429f-aabd-677babba4efc",
          "parentId": "e02b2728-772c-4924-9a6f-0cc38e2d93c8",
          "rootId": "e02b2728-772c-4924-9a6f-0cc38e2d93c8",
          "fullItemName": "Diagnosis",
          "htmlHeader": "<!-- begin field cd8b9455-7bc9-4501-b9f7-4f6009fe9c06 --><h2>When should I suspect asthma?</h2><!-- end field cd8b9455-7bc9-4501-b9f7-4f6009fe9c06 -->",
          "htmlStringContent": "<!-- begin item 061adf6f-72fd-429f-aabd-677babba4efc --><!-- begin field 694c01c2-e920-4608-9714-0a108d23193c --><p><strong>Note:</strong> <a class=\"topic-reference internal-reference\" href=\"#300f160e-78dc-4bd7-92f6-a6be010679c1\">Treat</a> people immediately if they are acutely unwell at presentation, and perform objective tests for asthma (see below) if the equipment is available and testing will not compromise treatment of the acute episode. If objective tests cannot be done immediately, carry them out when acute symptoms have been controlled, and advise the person to seek immediate medical advice if they become unwell while waiting to have objective tests.</p><p><strong>Take a structured clinical history in people with suspected asthma, and ensure that&nbsp;all answers are recorded for later review.&nbsp;There is no single diagnostic test to&nbsp;confirm a diagnosis. Use clinical judgement to determine the probability of an asthma diagnosis,&nbsp;based on a combination of the following:</strong></p><ul><li><strong>Presence of more than one variable symptom&nbsp;of wheeze, cough, breathlessness, and chest tightness.</strong><ul><li>Symptoms are commonly episodic, diurnal (worse at night or in the early morning), and/or triggered or exacerbated by exercise, viral infection, and exposure to cold air&nbsp;or allergens.</li><li>In children, symptoms may also be triggered by emotion and laughter.</li><li>In adults, symptoms may be triggered by use of&nbsp;non-steroidal anti-inflammatory drugs and beta-blockers.</li><li>Ideally,&nbsp; expiratory polyphonic wheeze (with multiple pitches and tones heard over different areas of the lung when the person breathes out)&nbsp;will be confirmed on auscultation.&nbsp;</li><li><strong>Note: </strong>Occupational asthma&nbsp;may be suggested by&nbsp;adult-onset asthma,&nbsp;where&nbsp;symptoms improve when not at work. High-risk occupations include laboratory work, baking, animal handling, welding, and paint spraying.&nbsp;Check for possible occupational asthma by asking:<ul><li>Are symptoms better on days away from work?</li><li>Are symptoms better when on holiday?</li></ul></li></ul></li><li><strong>Personal/family history of other atopic conditions,</strong> particularly atopic eczema/dermatitis and/or allergic rhinitis.<ul><li>Use a previous record of skin-prick tests, blood eosinophilia of 4% or more, or a raised allergen-specific IgE to corroborate atopic status, but do not offer these tests routinely to support an asthma diagnosis.</li></ul></li><li><strong>The results of fractional exhaled nitric oxide (FeNO) testing</strong>&nbsp;&mdash; should be used where possible&nbsp;be used to confirm eosinophilic airway inflammation to support an asthma diagnosis in people aged 17 years and older. This test may be available in some primary care practices&nbsp;or may require referral to a&nbsp;specialist centre. In steroid-naive adults, a FeNO level of 40 parts per billion (ppb) or higher&nbsp;is considered a positive result.<ul><li>Consider FeNO testing in children and young people (aged 5&nbsp;to&nbsp;16 years)&nbsp;if there is diagnostic uncertainty after initial assessment, and they have either normal spirometry&nbsp;<em>or</em><strong>&nbsp;</strong>obstructive spirometry with a negative bronchodilator reversibility (BDR) test (see below). A&nbsp;FeNO&nbsp;level of 35ppb is considered a positive result in this group.&nbsp;<ul><li>Approximately 1 in 5 people with a negative result will have asthma.</li><li>Approximately 1 in 5 people with a positive result will not have asthma.</li><li>Be aware that the results of FeNO tests may be affected by empirical treatment&nbsp;with inhaled corticosteroids.</li></ul></li></ul></li><li><strong>The results of objective tests to detect&nbsp;airway&nbsp;obstruction,&nbsp;when the person is symptomatic:</strong><ul><li><strong>Spirometry</strong> should be offered to all symptomatic people over&nbsp;the age of five years. The FEV<sub>1</sub>/FVC ratio is normally greater than 70%. Any value&nbsp;less than this suggests airflow limitation. However, a normal spirometry result&nbsp;when the person is asymptomatic does not rule out asthma.&nbsp;<ul><li><strong>Note: </strong>FEV<sub>1</sub>/FVC&nbsp;lower limit of normal (LLN) values can also be used to detect airway obstruction.</li><li>Be aware that spirometry&nbsp;may be affected by empirical treatment&nbsp;with inhaled corticosteroids.</li></ul></li><li><strong>Bronchodilator reversibility (BDR)</strong> can also help to confirm a diagnosis of&nbsp;asthma, and should be offered, where&nbsp;available, to adults (aged 17&nbsp;and over), and considered in children and young people (aged 5&nbsp;to&nbsp;16 years) with obstructive spirometry (FEV1/FVC ratio less than 70%):<ul><li>In&nbsp;adults, an improvement in FEV<sub>1</sub> of 12% or more, together with an increase in volume of at least 200 mL in response to beta-<sub>2</sub> agonists or&nbsp;corticosteroids is regarded as a positive result. An improvement of greater than 400 mL in FEV<sub>1</sub> is strongly suggestive of asthma.</li><li>In children, an improvement in FEV<sub>1</sub> of 12% or more&nbsp;is regarded as a positive result.</li></ul></li><li><strong>Variable peak expiratory flow (PEF) readings</strong>&nbsp;can support an asthma&nbsp;diagnosis if there is diagnostic uncertainty after initial assessment, a FeNO test, and/or objective tests to detect airway&nbsp;obstruction. A&nbsp;value of more than 20% variability after monitoring at least twice daily for 2-4 weeks&nbsp;is regarded&nbsp;as a positive result:<ul><li>In adults, offer monitoring of peak flow variability&nbsp;if the person has&nbsp;either normal spirometry,&nbsp;<em>or</em>&nbsp;obstructive spirometry and positive BDR,&nbsp;with a FeNO level of 39&nbsp;ppb or less. Consider monitoring peak flow variability if the person has obstructive spirometry&nbsp;<em>and</em>&nbsp;negative BDR,&nbsp;<em>and&nbsp;</em>a FeNO level between 25&nbsp;and 39&nbsp;ppb.</li><li>In children (aged 5&nbsp;to&nbsp;16 years), offer&nbsp;monitoring of peak flow variability if they have either normal spirometry&nbsp;<em>or</em>&nbsp;obstructive spirometry, irreversible airways obstruction (negative BDR), and a FeNO level of 35&nbsp;ppb or greater.</li><li>PEF variability is usually calculated as the difference between the highest and lowest readings expressed as a percentage of the average PEF.</li><li>The upper limit of the normal range is approximately 20% using at least four PEF reading per day&nbsp;but may be lower when using twice daily readings.</li><li>PEF charting when asthma is &#39;inactive&#39; is unlikely to confirm variability.</li></ul></li></ul></li><li><strong>The results of a direct bronchial challenge test with histamine or methacholine &mdash; this test requires specialist referral. A PC20 value (provocative concentration causing a 20% drop in FEV1) of 8&nbsp;mg/ml or less is regarded as a positive result.</strong><ul><li>Offer this test (where available) to adults&nbsp;if there is diagnostic uncertainty after normal spirometry and either a FeNO level of 40&nbsp;ppb or more and no variability in peak flow readings&nbsp;or&nbsp;FeNO level of 39&nbsp;ppb or less with variability in peak flow readings.</li><li>Consider offering this test to adults with obstructive spirometry without bronchodilator reversibility&nbsp;and&nbsp;a FeNO level between 25&nbsp;and 39&nbsp;ppb&nbsp;and&nbsp;no variability in peak flow readings (less than 20% variability over 2-4 weeks).</li></ul></li><li><strong>For symptomatic adults (aged over 17 years): </strong><ul><li>Diagnose asthma if there is a&nbsp;FeNO level of 40&nbsp;ppb or more with either&nbsp;positive bronchodilator reversibility, positive peak flow variability, or bronchial hyperreactivity, or&nbsp;a FeNO level between 25&nbsp;and 39&nbsp;ppb and a positive bronchial challenge test,&nbsp;or&nbsp;positive bronchodilator reversibility and positive peak flow variability irrespective of FeNO level.</li><li>Suspect asthma&nbsp;if there is&nbsp;obstructive spirometry with:&nbsp;negative bronchodilator reversibility, with either a FeNO level of 40&nbsp;ppb or higher, or a FeNO level between 25&nbsp;and 39&nbsp;ppb and positive peak flow variability, or&nbsp;positive bronchodilator reversibility with a FeNO level between 25&nbsp;and 39&nbsp;ppb and negative peak flow variability.</li><li>Consider an <a class=\"topic-reference internal-reference\" href=\"#d2ef7678-6881-4a6c-bd0e-a6b9011a90ba\">alternative diagnosis</a> or referral for a second opinion if there is&nbsp;a FeNO level below 40&nbsp;ppb, normal spirometry and positive peak flow variability,&nbsp;or&nbsp;a FeNO level of 40&nbsp;ppb or higher, but normal spirometry, negative peak flow variability, and negative bronchial challenge test,&nbsp;or&nbsp;obstructive spirometry with bronchodilator reversibility, but a FeNO level below 25&nbsp;ppb, and negative peak flow variability,&nbsp;or positive peak flow variability but normal spirometry, a FeNO level below 40&nbsp;ppb, and a negative bronchial challenge test,&nbsp;or&nbsp;obstructive spirometry with negative bronchodilator reversibility, a FeNO level below 25&nbsp;ppb, and negative peak flow variability (if measured).</li><li>Review the diagnosis after 6&nbsp;to&nbsp;10&nbsp;weeks by repeating spirometry and objective measures of asthma control and reviewing symptoms.</li></ul></li><li><strong>For symptomatic children&nbsp;(aged 5 to&nbsp;16&nbsp;years): </strong><ul><li>Diagnose asthma if there is a FeNO level of 35&nbsp;ppb or higher&nbsp;with positive peak flow variability, or&nbsp;obstructive spirometry with positive bronchodilator reversibility.</li><li>Suspect asthma&nbsp;if there is a&nbsp;FeNO level of 35&nbsp;ppb or higher&nbsp;with normal spirometry and negative peak flow variability, or a FeNO level of 35&nbsp;ppb or higher&nbsp;with obstructive spirometry but negative bronchodilator reversibility and no variability in peak flow readings, or normal spirometry, a FeNO level of 34&nbsp;ppb or less, and positive peak flow variability.</li><li>Consider an <a class=\"topic-reference internal-reference\" href=\"#d2ef7678-6881-4a6c-bd0e-a6b9011a90ba\">alternative diagnosis</a>, or referral for&nbsp;specialist assessment if there is normal spirometry with&nbsp;a FeNO level of 34&nbsp;ppb or less&nbsp;and negative peak flow variability.</li><li>Refer for specialist assessment if there is obstructive spirometry, negative bronchodilator reversibility and a FeNO level of 34&nbsp;ppb or less.</li><li>Review the diagnosis after 6&nbsp;weeks by repeating any abnormal tests and reviewing symptoms.</li></ul></li><li><strong>For children under the age of five years, or those who are unable to perform some or all objective tests, use clinical judgement based on any&nbsp;positive objective test results&nbsp;and&nbsp;noted signs and symptoms to determine the likelihood of asthma.</strong><ul><li>If the person cannot perform a particular test, attempt&nbsp;to perform at least 2&nbsp;other objective tests.</li><li>When a&nbsp;child reaches&nbsp;five years of age, carry out objective tests.</li></ul></li><li><strong>Record the basis for a diagnosis of asthma in a single entry in the person&#39;s medical records, alongside the coded diagnostic entry.</strong></li><li>Red-flag signs and symptoms that suggest an <a class=\"topic-reference internal-reference\" href=\"#d2ef7678-6881-4a6c-bd0e-a6b9011a90ba\">alternative diagnosis</a> and should prompt immediate referral to a respiratory physician for additional investigations include:<ul><li>In adults:<ul><li>Prominent systemic features (such as myalgia, fever, and weight loss).</li><li>Unexpected clinical findings (such as crackles, finger clubbing, cyanosis, evidence of cardiac disease, monophonic wheeze, or stridor).</li><li>Persistent, non-variable breathlessness.</li><li>Chronic sputum production.</li><li>Unexplained restrictive spirometry.</li><li>Chest X-ray shadowing.</li><li>Marked blood eosinophilia.</li></ul></li><li>In children:<ul><li>Failure to thrive.</li><li>Unexplained&nbsp;clinical findings (such as focal signs, abnormal voice or cry, dysphagia, and/or inspiratory stridor).</li><li>Symptoms that are present from birth.</li><li>Excessive vomiting or posseting.</li><li>Evidence of severe upper respiratory tract infection.</li><li>Persistent wet or productive cough.</li><li>A family history of unusual chest disease.</li><li>Nasal polyps.</li></ul></li></ul></li></ul><!-- end field 694c01c2-e920-4608-9714-0a108d23193c --><!-- end item 061adf6f-72fd-429f-aabd-677babba4efc -->",
          "containerElement": "diagnosisSub",
          "children": [
            {
              "itemId": "0671955d-4bb2-48c1-92be-a6be01014af6",
              "parentId": "061adf6f-72fd-429f-aabd-677babba4efc",
              "rootId": "e02b2728-772c-4924-9a6f-0cc38e2d93c8",
              "fullItemName": "Basis for recommendation",
              "htmlHeader": "<!-- begin field b057a366-bb8a-4948-9c8e-a6be01014b6e --><h3>Basis for recommendation</h3><!-- end field b057a366-bb8a-4948-9c8e-a6be01014b6e -->",
              "htmlStringContent": "<!-- begin item 0671955d-4bb2-48c1-92be-a6be01014af6 --><!-- begin field 7104fb57-aa76-440b-9f30-a6be01014b6e --><p>The recommendations on diagnosis of asthma&nbsp;are based on expert opinion in the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) <em>British guideline on the management of asthma </em>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>], the Global Initiative for Asthma (GINA) guideline on <em>Global strategy for asthma management and prevention</em> [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">GINA, 2016</a>], and the National Institute of Health and Care Excellence Guideline Asthma: diagnosis, monitoring and chronic asthma management [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</p><p><strong>FeNO testing</strong></p><ul><li><strong>The British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN) and the National Institute for Health and Care Excellence (NICE) have differing views on the importance of fractional exhaled nitric oxide testing (FeNO) in the diagnosis of asthma:</strong><ul><li>NICE states that this test should be offered to all people with suspected asthma [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</li><li>BTS/SIGN place less prominence on this test, suggesting it as a potentially useful adjunct to other tests and observations [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">White et al, 2017</a>].</li><li>CKS acknowledges that in practice, FeNO testing may not always be locally available, and advises that&nbsp;where this is the case,&nbsp;combinations of the other suggested tests/observations can be used to support or refute an&nbsp;asthma diagnosis.</li></ul></li></ul><p><strong>Spirometry results</strong></p><ul><li><strong>The British Thoracic&nbsp;Society (BTS)/Scottish Intercollegiate Guidelines&nbsp;Network (SIGN)&nbsp;and the National Institute for Health and Care Excellence (NICE) cite differing cut-off values for abnormal&nbsp;FEV1/FVC ratios:</strong><ul><li>BTS/SIGN recommend&nbsp;use of lower limit of normal (LLN) for FEV1/ FVC ratio to avoid under-diagnosis in children and over-diagnosis in elderly people.&nbsp;From a practical perspective, the spirometers widely used in clinical practice provide the lower and upper limits of the normal range of spirometry parameters&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>].</li><li>NICE acknowledges the advantages of using LLN (especially in children) and suggests it should be used &lsquo;if the value is available&rsquo; though specifically suggests the fixed ratio of 70% as the threshold for proceeding to bronchodilator reversibility testing&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</li><li>BTS/SIGN has&nbsp;responded to this by pointing out the significant limitations of the fixed ratio cut-off of 70% in children and&nbsp;emphasising the importance of using the LLN for defining airways obstruction&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">White et al, 2017</a>].</li></ul></li></ul><!-- end field 7104fb57-aa76-440b-9f30-a6be01014b6e --><!-- end item 0671955d-4bb2-48c1-92be-a6be01014af6 -->",
              "containerElement": "diagnosisBasis",
              "children": [],
              "depth": 3,
              "pos": 0
            }
          ],
          "depth": 2,
          "pos": 0
        },
        {
          "itemId": "d2ef7678-6881-4a6c-bd0e-a6b9011a90ba",
          "parentId": "e02b2728-772c-4924-9a6f-0cc38e2d93c8",
          "rootId": "e02b2728-772c-4924-9a6f-0cc38e2d93c8",
          "fullItemName": "Differential diagnosis",
          "htmlHeader": "<!-- begin field 9fb10e3b-96c1-477c-a385-a6b9011a92f9 --><h2>What are the differential diagnoses of asthma?</h2><!-- end field 9fb10e3b-96c1-477c-a385-a6b9011a92f9 -->",
          "htmlStringContent": "<!-- begin item d2ef7678-6881-4a6c-bd0e-a6b9011a90ba --><!-- begin field db843229-ef58-423b-860a-a6b9011a92f9 --><p><strong>The differential diagnoses of asthma include:</strong></p><ul><li><strong>Bronchiectasis </strong>&mdash; clinical features include copious sputum, frequent chest infections, a history of childhood pneumonia, and coarse lung crepitations. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/26fab339-e333-44ec-a481-de87a29052f3\">Bronchiectasis</a>.</li><li><strong>Chronic obstructive pulmonary disease (COPD)&nbsp;</strong>&mdash; asthma and COPD can be difficult to distinguish clinically and may co-exist. Clinical features of COPD include a productive cough and&nbsp;dyspnoea on exertion in a person over 35 years of age who&nbsp;is a current or previous smoker. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/e48489e8-63d1-4a04-bc5b-07e36a76af58\">Chronic obstructive pulmonary disease</a>.</li><li><strong>Ciliary dyskinesia&nbsp;</strong>&mdash; clinical features include persistent moist cough present from birth.</li><li><strong>Cystic fibrosis&nbsp;</strong>&mdash; clinical features include persistent moist cough&nbsp;and&nbsp;gastrointestinal symptoms that are often present from birth, and failure to thrive in children.</li><li><strong>Dysfunctional breathing&nbsp;</strong>&mdash; clinical features include breathlessness, dizziness, light-headedness, and peripheral tingling.</li><li><strong>Foreign body aspiration</strong>&nbsp;&mdash; suggested by sudden-onset cough, stridor (upper airway) or reduced chest wall movement on the affected side, bronchial breathing, and reduced or diminished breath sounds (lower airway).</li><li><strong>Gastro-oesophageal reflux&nbsp;</strong>&mdash; clinical features include cough, postural and food-related symptoms, and&nbsp;vomiting. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/8116d56b-de40-4191-af22-5152cc8f533c\">Dyspepsia - proven GORD</a>.</li><li><strong>Heart failure</strong> &mdash; clinical features include orthopnoea, oedema, a history of ischaemic heart disease, and fine lung crepitations. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/fdc42e20-2c4b-45ed-9093-6c2d4bde6e4d\">Heart failure - chronic</a>.</li><li><strong>Interstitial lung disease&nbsp;</strong>(asbestosis, pneumoconiosis, fibrosing alveolitis, sarcoidosis) &mdash; clinical features include a dry cough and fine lung crepitations.</li><li><strong>Lung cancer</strong> &mdash; clinical features&nbsp;include&nbsp;persistent cough, haemoptysis, weight loss, or persistent hoarse voice. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/2a330e0f-ed6b-480c-bb50-2b5e80aec564\">Lung and pleural cancers - recognition and referral</a>.</li><li><strong>Pertussis&nbsp;</strong>&mdash; clinical features include paroxysms of coughing. There may be vomiting after coughing, or an inspiratory whoop (especially in children, although this may be absent in infants). Occasionally the cough may persist for several months. For more information, see the CKS topic on&nbsp;<a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/aa36f776-3bec-44aa-ba6f-c147b57f7328\">Whooping cough</a>.</li><li><strong>Pulmonary embolism (PE)</strong>&nbsp;&mdash; suggested by acute-onset breathlessness, pleuritic pain, haemoptysis, crackles, and sinus tachycardia. For more information, see the CKS topic on&nbsp;<a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/6b233aab-5318-4abb-96fa-1877e917ef2c\">Pulmonary embolism</a>.</li><li><strong>Tuberculosis</strong> &mdash; clinical features include persistent productive cough, which may be associated with breathlessness and haemoptysis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/c1897d19-8ea9-40e5-84a7-c45a80747a3e\">Tuberculosis</a>.</li><li><strong>Upper airway cough syndrome&nbsp;</strong>&mdash; clinical features include&nbsp;frequent throat clearing and associated symptoms of chronic sinusitis (nasal blockage or discharge with facial pain or pressure over the affected sinus) or allergic rhinitis (nasal itching, sneezing, discharge, and blockage). For more information, see the CKS topic&nbsp;on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/fb5757b5-1fbb-4de4-88eb-dceaa28ff6a4\">Cough</a>.</li><li><strong>Vocal cord dysfunction&nbsp;</strong>&mdash; clinical features include dyspnoea and&nbsp;stridor.</li></ul><p>For detailed information on the differential diagnosis of people with cough or breathlessness, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/fb5757b5-1fbb-4de4-88eb-dceaa28ff6a4\">Cough</a>&nbsp;and <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/3816dff2-9844-4422-bc4f-062669a6f4d9\">Breathlessness</a>.</p><!-- end field db843229-ef58-423b-860a-a6b9011a92f9 --><!-- end item d2ef7678-6881-4a6c-bd0e-a6b9011a90ba -->",
          "containerElement": "diagnosisSub",
          "children": [
            {
              "itemId": "ccaa6389-5575-419c-94c5-a6be01015e7c",
              "parentId": "d2ef7678-6881-4a6c-bd0e-a6b9011a90ba",
              "rootId": "e02b2728-772c-4924-9a6f-0cc38e2d93c8",
              "fullItemName": "Basis for recommendation",
              "htmlHeader": "<!-- begin field 4e0de4e7-332c-4933-94e5-a6be01015ee8 --><h3>Basis for recommendation</h3><!-- end field 4e0de4e7-332c-4933-94e5-a6be01015ee8 -->",
              "htmlStringContent": "<!-- begin item ccaa6389-5575-419c-94c5-a6be01015e7c --><!-- begin field fda48776-5063-4bba-a2d0-a6be01015ee8 --><p>The information on differential&nbsp;diagnoses of asthma&nbsp;are based on expert opinion in the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines&nbsp;Network (SIGN)&nbsp;<em>British guideline on the management of asthma </em>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>] and the Global Initiative for Asthma (GINA) guideline on <em>Global strategy for asthma management and prevention&nbsp;</em>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">GINA, 2016</a>]<em>.</em></p><!-- end field fda48776-5063-4bba-a2d0-a6be01015ee8 --><!-- end item ccaa6389-5575-419c-94c5-a6be01015e7c -->",
              "containerElement": "diagnosisBasis",
              "children": [],
              "depth": 3,
              "pos": 0
            }
          ],
          "depth": 2,
          "pos": 1
        }
      ],
      "depth": 1,
      "pos": 5
    },
    {
      "itemId": "07e98755-62cf-4a2d-96c0-a297468b1000",
      "parentId": null,
      "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
      "fullItemName": "Management",
      "htmlHeader": "<!-- begin field 10740e2a-3249-49d4-a9d5-8f59401908e5 --><h1>Management</h1><!-- end field 10740e2a-3249-49d4-a9d5-8f59401908e5 -->",
      "htmlStringContent": "<!-- begin item 07e98755-62cf-4a2d-96c0-a297468b1000 --><!-- begin field 9438addd-93e0-478d-b4a3-a6d300a5121f --><ul><li><strong><a class=\"topic-reference internal-reference\" href=\"#44f59cc7-25d8-4bb0-b726-a6be01067965\">Scenario: Newly-diagnosed asthma</a>:</strong> covers the management of children and adults with newly diagnosed or suspected asthma.</li><li><strong><a class=\"topic-reference internal-reference\" href=\"#62e8b32d-7874-4cb1-9b5f-a6be0107cf35\">Scenario: Follow-up</a>:</strong> covers the appropriate follow-up of children and adults who have asthma.</li><li><strong><a class=\"topic-reference internal-reference\" href=\"#ce4b7218-e5ce-4b55-a34e-a6be0108fcc6\">Scenario: Acute exacerbation of asthma</a>:</strong> covers the management of an acute exacerbation of asthma.</li></ul><!-- end field 9438addd-93e0-478d-b4a3-a6d300a5121f --><!-- end item 07e98755-62cf-4a2d-96c0-a297468b1000 -->",
      "containerElement": "management",
      "children": [
        {
          "itemId": "44f59cc7-25d8-4bb0-b726-a6be01067965",
          "parentId": "07e98755-62cf-4a2d-96c0-a297468b1000",
          "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
          "fullItemName": "Scenario: Newly-diagnosed asthma",
          "htmlHeader": "<!-- begin field 706a8b33-1222-4f93-af50-a6be010679c1 --><h2>Scenario: Newly-diagnosed&nbsp;asthma</h2><!-- end field 706a8b33-1222-4f93-af50-a6be010679c1 -->",
          "htmlStringContent": "<!-- begin item 44f59cc7-25d8-4bb0-b726-a6be01067965 --><!-- begin field 76780fbe-4415-4284-80b7-aa5b00cd8494 --><p>From age 1 month onwards.</p><!-- end field 76780fbe-4415-4284-80b7-aa5b00cd8494 --><!-- end item 44f59cc7-25d8-4bb0-b726-a6be01067965 -->",
          "containerElement": "scenario",
          "children": [
            {
              "itemId": "300f160e-78dc-4bd7-92f6-a6be010679c1",
              "parentId": "44f59cc7-25d8-4bb0-b726-a6be01067965",
              "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
              "fullItemName": "How should I manage someone with newly-diagnosed or suspected asthma?",
              "htmlHeader": "<!-- begin field 6a6df86d-97ca-4f3c-a4cf-a6be010679c5 --><h3>How should I manage someone with newly-diagnosed or suspected&nbsp;asthma?</h3><!-- end field 6a6df86d-97ca-4f3c-a4cf-a6be010679c5 -->",
              "htmlStringContent": "<!-- begin item 300f160e-78dc-4bd7-92f6-a6be010679c1 --><!-- begin field 490f7e70-cb46-482b-9405-a6be010679c5 --><ul><li><strong>The aim of asthma management is control of the disease. Complete control is defined as:</strong><ul><li>No daytime symptoms.</li><li>No night-time waking due to asthma.</li><li>No need for rescue medication.</li><li>No asthma attacks.</li><li>No limitations on activity including exercise.</li><li>Normal lung function (FEV<sub>1</sub> and/or PEF &gt; 80% predicted or best). However, be aware that lung function measurements cannot be used reliably to guide asthma management in children under five years of age.</li><li>Minimal side-effects from medication.<ul><li>In practice, people may wish to balance the aims of asthma management against the potential side-effects or inconvenience of taking medication necessary to achieve perfect control.</li></ul></li></ul></li><li><strong>Assess the person&#39;s baseline asthma status</strong> using a validated questionnaire such as the Asthma Control Questionnaire or the Asthma Control Test, and/or lung function tests such as spirometry or peak expiratory flow (if not already carried out).</li><li><strong>Arrange specialist referral if occupational asthma is suspected.</strong></li><li><strong>Provide self-management education and a <a data-hyperlink-id=\"caeb1838-b4e6-49ac-85f2-a8f70161de32\" href=\"https://www.asthma.org.uk/advice/manage-your-asthma/action-plan/\">personalised asthma action plan</a></strong> (available from <a data-hyperlink-id=\"fe9e29a1-ddae-453b-8355-a8f70161de87\" href=\"https://www.asthma.org.uk/\">Asthma UK</a>) to the person or their parents/carers.</li><li><strong>Ensure that the person is up to date with all routine vaccinations,</strong> including all childhood immunizations, and the annual influenza vaccination. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/884b0998-c242-4b76-869c-7e1d7203ac34\">Immunizations - childhood</a>&nbsp;and&nbsp;<a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/92586dea-3104-4e8a-bc44-03b987a2edbd\">Immunizations - seasonal influenza</a>.</li><li><strong>Provide advice about sources of information and support</strong> for people with asthma, such as the <a data-hyperlink-id=\"1b4ebe19-d500-48ca-8ecd-a8f70161dee1\" href=\"https://www.blf.org.uk/\">British Lung Foundation</a> and <a data-hyperlink-id=\"114058ad-b6b5-4212-8c95-a8f70161dfad\" href=\"https://www.asthma.org.uk/\">Asthma UK.</a></li><li><strong>Advise the person on avoiding asthma trigger factors. </strong>These may include specific allergens, high levels of air pollution, smoke, beta-blockers, or non-steroidal anti-inflammatory drugs.</li><li><strong>Provide advice on weight loss and smoking cessation, if appropriate.</strong><ul><li>Parents and carers of children with asthma should also be advised about the dangers of smoking and offered support and treatment to stop.</li></ul></li><li><strong>Assess for the presence of anxiety or depression</strong>, as these are more common in people with asthma. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/135bad2d-5cd6-4df9-b7cf-450677581600\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/1b270734-f24e-4b58-8355-adaec350f356\">Depression</a>.</li><li><strong>Ensure that the person has their own peak flow meter</strong> and measures their peak flow regularly as part of their <a data-hyperlink-id=\"36276c3c-62ce-4543-903b-a8f70161dffd\" href=\"https://www.asthma.org.uk/advice/manage-your-asthma/action-plan/?gclid=CjwKEAiAyanCBRDkiO6M_rDroH0SJAAfZ4KLoI7yrkSyRkgoKVk2OQh3p92ZL_5_Eal-89_wAcxPSRoC2sHw_wcB&amp;gclid=CjwKEAiAyanCBRDkiO6M_rDroH0SJAAfZ4KLoI7yrkSyRkgoKVk2OQh3p92ZL_5_Eal-89_wAcxPSRoC2sHw_wcB\">personalised asthma action plan</a>.</li><li><strong>Initiate drug treatment at a level appropriate to the severity of the person&#39;s asthma.</strong> The aim is to abolish symptoms and optimise peak flow. Control is then maintained by increasing treatment as necessary and decreasing treatment when control is good. After any medication adjustments, review the response to treatment in 4 to 8 weeks.</li><li><strong>Explain when and how to use inhalers</strong>, and demonstrate the correct technique for using them. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"#d697784b-2cbb-4b02-b96d-a7a700c380d7\">delivery systems</a>.</li><li><strong>Prescribe an inhaled short-acting beta-<sub>2</sub> agonist (SABA) to all people with symptomatic asthma, to be used as reliever therapy as required.</strong> In a small minority of people with asthma with infrequent, short-lived wheeze, and normal lung function, occasional use of a SABA might be the only treatment necessary.<ul><li>Good asthma control is associated with little need for use of a SABA. Anyone prescribed more than one SABA per month should have their asthma control and symptoms assessed urgently and measures taken to improve their asthma control, if this is found to be poor.</li><li>For more information on prescribing a SABA, see the section <a class=\"topic-reference internal-reference\" href=\"#be2c12ab-d9dd-4ccf-bbda-a6d7016a5f43\">Which short-acting beta-2 agonists are available for asthma?</a></li></ul></li><li><strong>Prescribe an inhaled corticosteroid (ICS) as preventer therapy for all people who:</strong><ul><li>Use an inhaled SABA three times a week or more, <em>and/or</em></li><li>Have asthma symptoms three times a week or more, <em>and/or</em></li><li>Are woken at night by asthma symptoms once weekly or more.<ul><li>In addition, an ICS should be considered for adults and children over the age of 5 years who have had an asthma attack requiring treatment with oral corticosteroids in the past two years.</li></ul></li></ul></li><li><strong>Start ICS at a dose appropriate to the severity of the person&#39;s symptoms:</strong><ul><li>A reasonable starting dose is usually a low dose for adults, and a paediatric low dose for children aged 5 to 16 years. For dosages in children under the age of five years, see the advice below. The actual dosage will vary depending on the prescribed preparation, please see the section on <a class=\"topic-reference internal-reference\" href=\"#2941a4c0-4c3b-40cd-8090-a6d7016a8eeb\">Which inhaled corticosteroids are available for asthma?</a> for further details.</li><li>Higher doses may be required in people who are previous or current smokers as smoking reduces the effectiveness of ICS therapy.</li><li>ICS should initially be used twice daily (except ciclesonide, which is used once daily). There is little evidence of benefit from ICS dosing more than twice daily.</li><li>Adjust the dose of ICS over time, aiming for the lowest dose required for effective asthma control.</li><li>Once good control is established, once-daily ICS at the same daily dose can be considered as maintenance therapy.</li></ul></li><li><strong>If the person&#39;s asthma is not adequately controlled with low-dose ICS, consider a trial of an add-on therapy. </strong>Before initiating an add-on therapy, recheck adherence, inhaler technique, and elimination of trigger factors. The duration of the trial will depend on the desired outcome. For example, preventing nocturnal waking may require days or weeks of add-on treatment, while preventing asthma attacks or decreasing oral steroid use may require a longer trial. For more information on add-on therapies, please see the section on <a class=\"topic-reference internal-reference\" href=\"#baacfbc5-ee97-4d5f-a5a3-b492048eebab\">Prescribing information</a>.<ul><li><strong>For adults (aged 17 years and older):</strong><ul><li>Consider offering a leukotriene receptor antagonist (LTRA) in addition to the low dose ICS. Review the response to treatment in 4 to 8 weeks. Note: An LTRA is an oral therapy, taken only at night which may potentially affect adherence to the inhaled ICS therapy. Clinical judgement should therefore be used to determine whether a person is likely to adhere to treatment with a combination of inhaled ICS and oral LTRA. Where this may be problematic, consider offering a long-acting beta<sub>2</sub> agonist (LABA) in combination with the ICS as an alternative.</li><li>If asthma is uncontrolled on a low dose of ICS and a LTRA, offer a long-acting beta<sub>2</sub> agonist (LABA) in combination with the ICS. Use clinical judgement to decide whether to also continue treatment with the LTRA, taking into account the degree of response to LTRA treatment and the person&#39;s wishes.</li><li>If asthma is uncontrolled on a low dose of ICS and a LABA, with or without an LTRA, offer to change the person&#39;s ICS and LABA maintenance therapy to a maintenance and reliever therapy (MART) regimen with a low maintenance ICS dose. MART treatment consists of a single inhaler containing both ICS and a fast-acting LABA, which is used for both daily maintenance therapy and the relief of symptoms as required.</li><li>If asthma is uncontrolled on a MART regimen with a low maintenance ICS dose, with or without an LTRA, consider increasing the ICS to a moderate maintenance dose (either continuing on a MART regimen or changing to a fixed-dose of an ICS and a LABA, with a SABA as a reliever therapy.)</li><li>If asthma is uncontrolled on a moderate maintenance ICS dose with a LABA (either as MART or a fixed-dose regimen), with or without an LTRA, consider a trial of an additional drug (for example, a muscarinic receptor antagonist&nbsp;or theophylline). Alternatively, a high maintenance dose of ICS may be appropriate. Specialist supervision of high-dose ICS treatment may be advisable, depending on the experience of the prescriber. A specialist may also recommend continuous or frequent use of oral steroids (usually prednisolone) or additional steroid tablet-sparing treatments.</li></ul></li><li><strong>For children aged 5 to 16 years:</strong><ul><li>Consider offering a leukotriene receptor antagonist (LTRA) in addition to the paediatric low dose ICS, and reviewing the response to treatment in 4 to 8 weeks.</li><li>If asthma is uncontrolled on a paediatric low dose of ICS and a LTRA, consider stopping the LTRA and offering a long-acting beta<sub>2</sub> agonist (LABA) in combination with the ICS.</li><li>If asthma is uncontrolled on a paediatric low dose of ICS and a LABA, consider changing their ICS and LABA maintenance therapy to a maintenance and reliever therapy (MART) regimen with a paediatric low maintenance ICS dose. Ensure that the child is able to understand and comply with the MART regimen.</li><li>If asthma is uncontrolled on a MART regimen with a paediatric low maintenance ICS dose, consider increasing the ICS to a paediatric moderate maintenance dose (either continuing on a MART regimen or changing to a fixed-dose of an ICS and a LABA, with a SABA as a reliever therapy).</li><li>If asthma is uncontrolled on a paediatric moderate maintenance ICS dose with LABA (either as MART or a fixed-dose regimen), consider seeking advice from a healthcare professional with expertise in asthma. Increasing the ICS dose to paediatric high maintenance dose <em>or </em>a trial of an additional drug (for example, theophylline) may be advised but are usually carried out under specialist supervision.</li></ul></li><li><strong>For children under the age of five years with suspected asthma:</strong><ul><li>Offer an eight week trial of a paediatric moderate dose of ICS if there are symptoms that clearly indicate the need for maintenance therapy (occurring 3 times a week or more, or causing waking at night, or uncontrolled with a SABA alone). After 8 weeks, stop ICS treatment and continue to monitor the child&#39;s symptoms. If symptoms did not resolve during the trial period, consider an <a class=\"topic-reference internal-reference\" href=\"#d2ef7678-6881-4a6c-bd0e-a6b9011a90ba\">alternative diagnosis</a><strong>.</strong> If symptoms resolved then reoccurred within 4 weeks of stopping ICS treatment, restart the ICS at a paediatric low dose as first-line maintenance therapy. If symptoms resolved but reoccurred beyond 4 weeks after stopping ICS treatment, repeat the 8-week trial of a paediatric moderate dose of ICS.</li><li>If suspected asthma is uncontrolled in children under 5 on a paediatric low dose of ICS as maintenance therapy, consider an LTRA in addition to the ICS.</li><li>If suspected asthma is uncontrolled in children under 5 on a paediatric low dose of ICS and an LTRA as maintenance therapy, stop the LTRA and refer the child to a healthcare professional with expertise in asthma for further investigation and management.</li><li>Note: The evidence for treatment safety and efficacy is less clear for children under the age of two years than for other age groups, and the threshold for seeking specialist opinion should, therefore be lowest in this group.</li><li>An asthma diagnosis should be confirmed when the child is old enough/able to undergo <a class=\"topic-reference internal-reference\" href=\"#061adf6f-72fd-429f-aabd-677babba4efc\">objective tests</a>.</li></ul></li></ul></li><li><strong>If an inhaled ICS is contraindicated or not tolerated, alternative preventer medications include:</strong><ul><li>An LTRA for children under five years old.</li><li>Sodium cromoglicate, which is of some benefit in adults and is effective in children aged over five years.</li><li>Nedocromil sodium, which may be of benefit in adults and children aged over five years.</li><li>Theophyllines, which have some beneficial effect in all age groups.<ul><li>If there is doubt, seek specialist advice.</li></ul></li></ul></li><li><strong>If asthma control deteriorates:</strong><ul><li>Within a self-management programme, consider an increased dose of ICS for 7 days for children and young people (aged 5 to 16) who are using an ICS in a single inhaler. Clearly outline in the person&#39;s asthma action plan how and when to do this, and what to do if symptoms do not improve. When increasing ICS treatment:<ul><li>Consider quadrupling the regular ICS dose.</li><li>Do not exceed the maximum licensed daily dose.</li></ul></li><li>For people who report that their asthma is exacerbated by exercise, review regular treatment as this can indicate poorly-controlled asthma. In a person whose asthma is otherwise well-controlled:<ul><li>Alongside an ICS, consider use of an LTRA, a LABA, sodium cromoglicate or nedocromil sodium.</li><li>Advise use of a SABA immediately prior to exercise.</li></ul></li></ul></li><li><strong>Consider decreasing maintenance therapy once a person&#39;s asthma has been controlled with their current maintenance therapy for at least 3 months.</strong><ul><li>Discuss with the person (or their family or carer if appropriate) the potential risks and benefits of decreasing maintenance therapy.</li><li>When reducing maintenance therapy:<ul><li>Stop or reduce dose of medicines in an order that takes into account the clinical effectiveness when introduced, side effects and the person&#39;s preference.</li><li>Reductions in ICS dose should be slow as people deteriorate at different rates. Dose reductions should be considered every three months, decreasing by 25-50% each time. Only consider stopping ICS treatment completely for people who are using low dose ICS alone as maintenance therapy and are symptom-free.</li><li>Review and update the person&#39;s asthma action plan accordingly.</li><li>Decide with the person (or their family or carer if appropriate) how the effects of decreasing maintenance therapy will be monitored and reviewed, including self-monitoring and a follow-up with a healthcare professional.</li><li>Specialist advice should be sought if there is uncertainty, and with a lower threshold in children.</li></ul></li></ul></li><li><strong>Pregnant women should be managed in the same was as any other individual with asthma,</strong> and should be advised the importance of continuing their asthma medications (including systemic corticosteroids if applicable).</li><li><strong>For people of all ages with diagnosed or suspected asthma, consider an <a class=\"topic-reference internal-reference\" href=\"#d2ef7678-6881-4a6c-bd0e-a6b9011a90ba\">alternative diagnosis</a></strong> if symptom control remains poor after treatment.</li><li><strong>People with asthma should be <a class=\"topic-reference internal-reference\" href=\"#045c7ab2-0640-464c-b6e7-a6be0107cf94\">followed-up</a> at least annually. </strong>Closer monitoring of people with poor lung function and/or a history of an asthma attack within the last year should be considered. More regular follow-up is also required in people undergoing treatment adjustment, and may be advisable in people at increased risk of poor outcomes (such as those with non-adherence to asthma medicines, psychosocial problems, and repeated episodes of unscheduled care for asthma).</li></ul><!-- end field 490f7e70-cb46-482b-9405-a6be010679c5 --><!-- end item 300f160e-78dc-4bd7-92f6-a6be010679c1 -->",
              "containerElement": "scenarioRecommendation",
              "children": [
                {
                  "itemId": "d697784b-2cbb-4b02-b96d-a7a700c380d7",
                  "parentId": "300f160e-78dc-4bd7-92f6-a6be010679c1",
                  "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
                  "fullItemName": "Delivery systems",
                  "htmlHeader": "<!-- begin field 8ca3306c-3c9a-47d8-bf1f-a7a700c38351 --><h4>Delivery systems</h4><!-- end field 8ca3306c-3c9a-47d8-bf1f-a7a700c38351 -->",
                  "htmlStringContent": "<!-- begin item d697784b-2cbb-4b02-b96d-a7a700c380d7 --><!-- begin field aca0c0a6-9036-478b-98cf-a7a700c38351 --><ul><li><strong>Delivery systems for inhaled asthma medications include dry-powder inhalers (DPIs)&nbsp;and pressurized metered-dose inhalers (PMDIs).&nbsp;</strong><ul><li>In adults, a PMDI with or without a spacer is as effective as any other hand-held inhaler, but some people may prefer use of a DPI.</li><li>In children aged between 5 and 12 years, a&nbsp;PMDI with a spacer is recommended. A face mask is required until the child can breathe reproducibly using the spacer mouthpiece.</li><li>In children aged between 0 and 5 years, there is little or no evidence available on which to base recommendations, and specialist advice should&nbsp;therefore be sought if there is uncertainty.</li></ul></li><li><strong>Other factors to consider when choosing a delivery system include:</strong><ul><li>The ability of the person to develop and maintain an effective technique with the specific device &mdash; this may depend on such factors as age, dexterity, coordination, and inspiratory flow.</li><li>The suitability of the device to the person&#39;s (or carer&#39;s) lifestyle, considering such factors as portability and convenience.</li><li>The person&#39;s preference for, and willingness to use, a particular device.</li><li>The medication (and dose) being prescribed &mdash; a&nbsp;spacer&nbsp;should be used by all people on high-dose inhaled corticosteroids, and by most elderly&nbsp;people using PMDIs.</li></ul></li><li><strong>Good technique is essential in ensuring optimum use of inhaler devices.</strong><ul><li>Only prescribe the inhaler after the person (or their carer) has received training in its use and has demonstrated an acceptable technique.</li><li>Repeated checks are essential, as poor technique, even after training, is common. Reassess&nbsp;inhaler technique as part of a structured clinical review during <a class=\"topic-reference internal-reference\" href=\"#045c7ab2-0640-464c-b6e7-a6be0107cf94\">follow-up</a>.</li><li>Generic prescribing of inhalers should be avoided as this can lead to people with asthma being given an unfamiliar inhaler device with resultant problems of usage and compliance.&nbsp;</li></ul></li><li><strong>Spacers&nbsp;</strong>are plastic devices with a mouthpiece at one end and a hole for a pressurized metered-dose inhaler (pMDI) to be inserted at the other.<ul><li>They increase the proportion of the drug delivered to the airways and reduce the amount of drug deposited in the oropharynx (thereby reducing local adverse effects and reducing the amount of systemic absorption).</li><li>They are not interchangeable and must be compatible with the pMDI used.</li><li>The drug is administered by single-dose actuations from the pMDI into the spacer, with each actuation followed by inhalation.</li><li>There should be minimal delay between inhaler actuation and inhalation, as the drug aerosol is very short-lived.</li><li>Tidal breathing can be used, as it is as effective as single breaths.</li><li>Spacers should be washed&nbsp;monthly in detergent and allowed to dry in air.</li><li>Plastic spacers should be replaced at least every 12 months, although some manufacturers advise changing at 6&nbsp;months.</li></ul></li><li><strong>People requiring large doses of inhaled corticosteroids may require a specialised nebulizer.</strong>&nbsp;Use of such a device&nbsp;will usually be initiated by a respiratory specialist.</li></ul><!-- end field aca0c0a6-9036-478b-98cf-a7a700c38351 --><!-- end item d697784b-2cbb-4b02-b96d-a7a700c380d7 -->",
                  "containerElement": "scenarioClarification",
                  "children": [],
                  "depth": 4,
                  "pos": 1
                },
                {
                  "itemId": "f8b62898-36ee-4d78-90c6-a6be010679c5",
                  "parentId": "300f160e-78dc-4bd7-92f6-a6be010679c1",
                  "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
                  "fullItemName": "Basis for recommendation",
                  "htmlHeader": "<!-- begin field 7f0bfe70-516e-4c75-8980-a6be010679c5 --><h4>Basis for recommendation</h4><!-- end field 7f0bfe70-516e-4c75-8980-a6be010679c5 -->",
                  "htmlStringContent": "<!-- begin item f8b62898-36ee-4d78-90c6-a6be010679c5 --><!-- begin field 8edf0625-a96d-4cca-aed4-a6be010679c5 --><p>The information on management of people with newly-diagnosed or suspected asthma is based on expert opinion in the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines&nbsp;Network (SIGN)&nbsp;<em>British guideline on the management of asthma&nbsp;</em>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>]&nbsp;and the National Institute of Health and Care Excellence Guideline&nbsp;<em>Asthma: diagnosis, monitoring and chronic asthma management </em>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</p><p><strong>Use of a SABA alone to treat asthma</strong></p><ul><li><strong>The British Thoracic&nbsp;Society (BTS)/Scottish Intercollegiate Guidelines&nbsp;Network (SIGN)&nbsp;and the National Institute for Health and Care Excellence (NICE) have differing views on the use of short-acting beta-agonists (SABA) alone to treat asthma:</strong><ul><li>The BTS/SIGN guideline recommends initiation of treatment with low-dose ICS, explicitly stating that people&nbsp;should not be given short-acting beta-agonists (SABA) alone (except in the few with very occasional short-lived wheeze). This was a major revision from previous guidance. The motive for the change came following the National Review of Asthma Deaths&nbsp;which demonstrated that a proportion of these deaths occurred in patients only treated with SABA and highlighted this as an important preventable factor. &nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">White et al, 2017</a>].</li><li>The NICE guideline advocates&nbsp;the use of a SABA alone in its algorithm, though the detailed commentary reports this should only be prescribed for a small minority of patients&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</li><li>CKS has incorporated all of this information into its guidance and pragmatically suggests the use of careful clinical judgement to determine the need for additonal treatments in people with mild asthma symptoms.</li></ul></li></ul><p><strong>Leukotriene&nbsp;receptor antagonist&nbsp;(LTRA) versus long-acting beta-agonist&nbsp;(LABA)&nbsp;as first-line&nbsp;add-on therapy with&nbsp;inhaled corticosteroids&nbsp;(ICS):</strong></p><ul><li><strong>The British Thoracic&nbsp;Society (BTS)/Scottish Intercollegiate Guidelines&nbsp;Network (SIGN)&nbsp;and the National Institute for Health and Care Excellence (NICE) have issued differing advice on first-line&nbsp;add-on therapy to treatment&nbsp;with inhaled corticosteroids&nbsp;(ICS):</strong><ul><li>The NICE guidance advocates addition&nbsp;of a LTRA to ICS&nbsp;based on a cost-effectiveness model, but acknowledges that&nbsp;LABA&nbsp;has been demonstrated to be a&nbsp;more effective treatment&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</li><li>BTS/SIGN advise&nbsp;the addition of LABA to ICS, in line with international guidelines&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">GINA, 2016</a>]. The BTS/SIGN guideline cites head-to-head comparisons of ICS/LABA compared with ICS/LTRA which have favoured ICS/LABA for effectiveness in adults (inconclusive in children).&nbsp;BTS/SIGN also point out that on a practical level, following a change in&nbsp;therapy from ICS alone to ICS/LABA, in most cases, the person&nbsp;will continue&nbsp;to use&nbsp;a single inhaler as their preventer, while people given LTRA have to adapt to an oral therapy, taken only at night, potentially affecting adherence to the inhaled preventer therapy.&nbsp;&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">White et al, 2017</a>].</li><li>CKS suggests that when selecting first-line add-on therapy, clinical judgement should be used to determine whether a person is likely to adhere to treatment with a combination of inhaled ICS and oral LTRA, and where a LTRA is prescribed, NICE guidance regarding&nbsp;assessment of&nbsp;the response to LTRA treatment in 4&nbsp;to&nbsp;8&nbsp;weeks is followed to assess treatment efficacy should be strictly followed&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</li></ul></li></ul><p><strong>Inhaled corticosteroid dose in children</strong></p><ul><li><strong>The British Thoracic&nbsp;Society (BTS)/Scottish Intercollegiate Guidelines&nbsp;Network (SIGN)&nbsp;and the National Institute for Health and Care Excellence (NICE) use different terminologies relating to&nbsp;the dose of inhaled corticosteroids&nbsp;(ICS) in children:</strong><ul><li>NICE defines ICS doses for children as paediatric low (less than or equal to 200&nbsp;micrograms budesonide or equivalent),&nbsp;moderate (more than 200&nbsp;micrograms to 400 micrograms budesonide or equivalent) and high dose (more than 400&nbsp;micrograms budesonide or equivalent), and recommends the use of paediatric low dose as a starting maintenance dose&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</li><li>BTS/SIGN uses very low, low and medium categories&nbsp; to describe the same three&nbsp;budesonide or equivalent dose ranges, and therefore recommends the use of a very low dose as a starting maintenance dose&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">White et al, 2017</a>].</li><li>The age ranges used to define a child also differ. NICE defines children as under 16 years while for BTS/SIGN, children over 12 years are considered with adults&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">White et al, 2017</a>].</li><li>CKS has followed&nbsp;NICE guidance on these issues.</li><li>For more information on ICS doses and equivalence between different preparations, please seen the section on <a class=\"topic-reference internal-reference\" href=\"#2941a4c0-4c3b-40cd-8090-a6d7016a8eeb\">prescribing inhaled corticosteroids</a>.</li></ul></li></ul><p><strong>Use of high dose inhaled corticosteroids (ICS)</strong></p><ul><li><strong>The British Thoracic&nbsp;Society (BTS)/Scottish Intercollegiate Guidelines&nbsp;Network (SIGN)&nbsp;and the National Institute for Health and Care Excellence (NICE) offer different guidance on the need for specialist input when prescribing high dose ICS:</strong><ul><li>The NICE guideline states that&nbsp;If asthma is uncontrolled in adults (aged 17&nbsp;and over) on a moderate maintenance ICS dose with a LABA (either as MART or a fixed-dose regimen), with or without an LTRA, increasing the ICS to a high maintenance dose (only as part of a fixed-dose regimen, with a SABA used as a reliever therapy) can&nbsp;be considered prior to seeking advice from a healthcare professional with expertise in asthma&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</li><li>The BTS/SIGN guideline states that&nbsp;high doses of ICS in adults should be administered under specialist supervision&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>].</li><li>CKS has therefore suggested that it may be appropriate to seek&nbsp;specialist advice where high dose corticosteroid treatment is required, depending on the experience&nbsp;of the prescriber.</li></ul></li></ul><!-- end field 8edf0625-a96d-4cca-aed4-a6be010679c5 --><!-- end item f8b62898-36ee-4d78-90c6-a6be010679c5 -->",
                  "containerElement": "scenarioBasis",
                  "children": [],
                  "depth": 4,
                  "pos": 2
                }
              ],
              "depth": 3,
              "pos": 0
            }
          ],
          "depth": 2,
          "pos": 1
        },
        {
          "itemId": "62e8b32d-7874-4cb1-9b5f-a6be0107cf35",
          "parentId": "07e98755-62cf-4a2d-96c0-a297468b1000",
          "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
          "fullItemName": "Scenario: Follow-up",
          "htmlHeader": "<!-- begin field 2d1178f2-ec38-4dd1-b47b-a6be0107cf8f --><h2>Scenario: Follow-up</h2><!-- end field 2d1178f2-ec38-4dd1-b47b-a6be0107cf8f -->",
          "htmlStringContent": "<!-- begin item 62e8b32d-7874-4cb1-9b5f-a6be0107cf35 --><!-- begin field 60062d93-ba82-4935-a0ab-aa5b00cd8496 --><p>From age 1 month onwards.</p><!-- end field 60062d93-ba82-4935-a0ab-aa5b00cd8496 --><!-- end item 62e8b32d-7874-4cb1-9b5f-a6be0107cf35 -->",
          "containerElement": "scenario",
          "children": [
            {
              "itemId": "045c7ab2-0640-464c-b6e7-a6be0107cf94",
              "parentId": "62e8b32d-7874-4cb1-9b5f-a6be0107cf35",
              "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
              "fullItemName": "How should I follow-up a person with asthma?",
              "htmlHeader": "<!-- begin field 353e7fdb-daf9-4abe-82cd-a6be0107cf94 --><h3>How should I&nbsp;follow-up a person with asthma?</h3><!-- end field 353e7fdb-daf9-4abe-82cd-a6be0107cf94 -->",
              "htmlStringContent": "<!-- begin item 045c7ab2-0640-464c-b6e7-a6be0107cf94 --><!-- begin field 7e5fce9e-5997-41fa-94cd-a6be0107cf94 --><ul><li><strong>People with asthma should be followed up at least annually, to determine whether their treatment needs to be changed.&nbsp;</strong>Closer monitoring of people with poor lung function and/or a history of an asthma attack within the last year should be considered.</li><li>Monitor asthma control at each review in anyone aged 5 years and over using either spirometry or peak flow variability testing.</li><li>Do not routinely use FeNO to monitor asthma control, but consider FeNO measurement as an option to support asthma management in people who are symptomatic despite using inhaled corticosteroids.</li><li>Observe and give advice on the person&#39;s inhaler technique:<ul><li>At every consultation relating to an asthma attack.</li><li>When there is deterioration in asthma control.</li><li>When the inhaler device is changed.</li><li>At every annual review.</li><li>If the person asks for it to be checked.</li></ul></li><li><strong>In all people, monitor:</strong><ul><li>Number of asthma attacks, oral corticosteroid use, time off school/nursery/work due to asthma.</li><li>Nocturnal symptoms</li><li>Adherence (which can be assessed by reviewing prescription refill frequency).</li><li>Possession of/use of a self-management plan/written personalised asthma action plan.</li><li>Exposure to tobacco smoke.</li></ul></li><li><strong>In children, specific factors that should be monitored and recorded include:</strong><ul><li>Symptom score (best assessed using the&nbsp;<a href=\"http://www.asthma.com/additional-resources/childhood-asthma-control-test.html\" data-hyperlink-id=\"ee67a13d-0cc2-42ff-a5bc-a8f7015a58ca\">Childhood&nbsp;Asthma Control Test,</a> or <a href=\"https://www.qoltech.co.uk/acq.html\" data-hyperlink-id=\"4924c7ac-fecb-482e-b714-a8f7015a59da\">Asthma Control Questionnaire</a>).<ul><li>Additionally, assess asthma control using closed questions such as &quot;do you use your blue inhaler (reliever) every day?&quot;</li></ul></li><li>Growth (height and weight centiles).</li></ul></li><li><strong>In adults, specific factors that should be monitored and recorded include:</strong><ul><li>Symptomatic asthma control (best assessed using directive questions such as <a class=\"topic-reference internal-reference\" href=\"#d8eac3dc-356d-439a-9658-a7a700c440ce\">The Royal College of Physicians 3 Questions</a>&nbsp;or the <a href=\"https://www.asthma.com/content/dam/NA_Pharma/Country/US/Unbranded/Consumer/Common/Images/MPY/documents/80108R0_AsthmaControlTest_ICAD.pdf\" data-hyperlink-id=\"2b380e42-e788-4ec8-ba8e-a8f7015a5a1b\">Asthma Control Test</a>, or <a href=\"https://www.qoltech.co.uk/acq.html\" data-hyperlink-id=\"c8437fde-c451-46c7-bd1d-a8f7015a5a4f\">Asthma Control Questionnaire</a>).<ul><li>Additionally, assess asthma control using closed questions such as &ldquo;how many days a week do you use your reliever (blue) inhaler?&rdquo;</li></ul></li><li>Lung function.</li><li>Bronchodilator overuse, especially more than 12 short-acting beta-<sub>2</sub> agonist (SABA) inhalers per year.</li><li>Smoking status.</li><li>The possibility of occupational asthma.</li></ul></li><li><strong>People on long-term steroid tablets (for example, longer than three months) or requiring frequent courses of steroid tablets (for example three to four per year)&nbsp;should be offered monitoring of:</strong><ul><li>Blood pressure.</li><li>Urine or&nbsp;blood sugar (measured by HbA1c).</li><li>Cholesterol.</li><li>Bone mineral density.</li><li>Vision (to assess for cataracts and glaucoma).&nbsp;</li></ul></li><li><strong>If medication&nbsp;is adjusted, review the response to treatment in 4&nbsp;to&nbsp;8&nbsp;weeks.</strong></li></ul><!-- end field 7e5fce9e-5997-41fa-94cd-a6be0107cf94 --><!-- end item 045c7ab2-0640-464c-b6e7-a6be0107cf94 -->",
              "containerElement": "scenarioRecommendation",
              "children": [
                {
                  "itemId": "d8eac3dc-356d-439a-9658-a7a700c440ce",
                  "parentId": "045c7ab2-0640-464c-b6e7-a6be0107cf94",
                  "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
                  "fullItemName": "The Royal College of Physicians 3 Questions",
                  "htmlHeader": "<!-- begin field 6e2cef1b-fffd-4e5b-8940-a7a700c442cb --><h4>The Royal College of Physicians 3 Questions</h4><!-- end field 6e2cef1b-fffd-4e5b-8940-a7a700c442cb -->",
                  "htmlStringContent": "<!-- begin item d8eac3dc-356d-439a-9658-a7a700c440ce --><!-- begin field de016cf2-8104-429c-a016-a7a700c442cb --><ul><li><strong>The &#39;Royal College of Physicians (RCP) 3&nbsp;questions&#39; is simple to use in every day clinical practice, but has not been validated in children.</strong></li><li>Answering &#39;no&#39; to all three questions is consistent with controlled asthma. The three questions are:<ul><li>Have you had difficulty sleeping because of your asthma symptoms (including cough)?</li><li>Have you had your usual asthma symptoms during the day (e.g. cough, wheeze, chest tightness, or breathlessness)?</li><li>Has your asthma interfered with your usual activities (e.g. housework, work, school)?</li></ul></li></ul><!-- end field de016cf2-8104-429c-a016-a7a700c442cb --><!-- end item d8eac3dc-356d-439a-9658-a7a700c440ce -->",
                  "containerElement": "scenarioClarification",
                  "children": [],
                  "depth": 4,
                  "pos": 0
                },
                {
                  "itemId": "a9caa51d-275b-4563-ad2b-a6be0107cf98",
                  "parentId": "045c7ab2-0640-464c-b6e7-a6be0107cf94",
                  "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
                  "fullItemName": "Basis for recommendation",
                  "htmlHeader": "<!-- begin field 9a59ef93-9b14-447f-bc67-a6be0107cf98 --><h4>Basis for recommendation</h4><!-- end field 9a59ef93-9b14-447f-bc67-a6be0107cf98 -->",
                  "htmlStringContent": "<!-- begin item a9caa51d-275b-4563-ad2b-a6be0107cf98 --><!-- begin field 10fd0bd5-0c6f-4913-9572-a6be0107cf98 --><p>The information on how to follow-up a person with asthma is based on expert opinion in the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines&nbsp;Network (SIGN)&nbsp;<em>British guideline on the management of asthma&nbsp;</em>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>]&nbsp;and the National Institute of Health and Care Excellence Guideline&nbsp;<em>Asthma: diagnosis, monitoring and chronic asthma management </em>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>].</p><!-- end field 10fd0bd5-0c6f-4913-9572-a6be0107cf98 --><!-- end item a9caa51d-275b-4563-ad2b-a6be0107cf98 -->",
                  "containerElement": "scenarioBasis",
                  "children": [],
                  "depth": 4,
                  "pos": 1
                }
              ],
              "depth": 3,
              "pos": 0
            }
          ],
          "depth": 2,
          "pos": 2
        },
        {
          "itemId": "ce4b7218-e5ce-4b55-a34e-a6be0108fcc6",
          "parentId": "07e98755-62cf-4a2d-96c0-a297468b1000",
          "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
          "fullItemName": "Scenario: Acute exacerbation of asthma",
          "htmlHeader": "<!-- begin field 2e95bcac-99c0-4c70-bbe0-a6be0108fd95 --><h2>Scenario: Acute exacerbation of asthma</h2><!-- end field 2e95bcac-99c0-4c70-bbe0-a6be0108fd95 -->",
          "htmlStringContent": "<!-- begin item ce4b7218-e5ce-4b55-a34e-a6be0108fcc6 --><!-- begin field 4f17f178-c176-4511-83eb-aa5b00cd8497 --><p>From age 1 month onwards.</p><!-- end field 4f17f178-c176-4511-83eb-aa5b00cd8497 --><!-- end item ce4b7218-e5ce-4b55-a34e-a6be0108fcc6 -->",
          "containerElement": "scenario",
          "children": [
            {
              "itemId": "06c7a78e-2664-4c30-8fe3-a6be0108fd9a",
              "parentId": "ce4b7218-e5ce-4b55-a34e-a6be0108fcc6",
              "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
              "fullItemName": "How should I manage an acute exacerbation of asthma?",
              "htmlHeader": "<!-- begin field ba69fb3d-b276-4729-baa1-a6be0108fd9a --><h3>How should I manage an acute exacerbation of asthma?</h3><!-- end field ba69fb3d-b276-4729-baa1-a6be0108fd9a -->",
              "htmlStringContent": "<!-- begin item 06c7a78e-2664-4c30-8fe3-a6be0108fd9a --><!-- begin field 894e3abb-5565-458f-ae05-a6be0108fd9a --><ul><li><strong>Determine the severity of the exacerbation, bearing in mind that people with a severe or life-threatening exacerbation sometimes do not appear to be distressed.</strong><ul><li>Note the person&#39;s degree of agitation&nbsp;and consciousness. Agitation and behavioural changes in a child may be a sign of hypoxia.&nbsp;</li><li>Look for signs of exhaustion (inability to complete sentences), cyanosis (bluish lips or extremities), and use of accessory muscles while the person is at rest.</li><li>Examine the person&#39;s chest, and record their respiratory rate, pulse, and blood pressure.&nbsp;</li><li>Record the person&#39;s peak expiratory flow rate (if they are old and well&nbsp;enough to comply) and use the best of three recordings compared to the person&#39;s best &nbsp;(if measured within the last two years) or predicted PEFR value.&nbsp;</li><li>Measure the person&#39;s oxygen saturation in room air using pulse oximetry (if available).&nbsp;</li><li><strong>The severity of an exacerbation&nbsp;is graded as follows:</strong><ul><li>Moderate &ndash; PEFR more than 50&ndash;75% best or predicted (at least 50% best or predicted in children) and normal speech, with no features of acute severe or life-threatening asthma.</li><li>Acute severe &ndash;&nbsp;PEFR 33&ndash;50% best or predicted, (less than 50% best or predicted in children)&nbsp;<em>or</em> respiratory rate of at least 25/min in people over the age of 12 years, 30/min in children between the ages of 5 and 12 years, and 40/min in children between 2 and 5 years old, <em>or </em>pulse rate&nbsp;of at least 110/min&nbsp;in people over the age of 12 years, 125/min&nbsp;in children between the ages of 5 and 12 years, and 140/min&nbsp;in children between 2 and 5 years old, <em>or</em> inability to complete sentences in one breath, or accessory muscle use,&nbsp;<em>or</em> inability to feed (infants), with oxygen saturation of at least 92%.</li><li>Life-threatening &ndash; PEFR less than 33% best or predicted, <em>or</em> oxygen saturation of less than 92%, <em>or</em> altered consciousness, <em>or</em> exhaustion, <em>or</em> cardiac arrhythmia, <em>or</em> hypotension, <em>o</em>r cyanosis, <em>or</em> poor respiratory effort, <em>or</em> silent chest, <em>or</em> confusion.</li></ul></li></ul></li><li><strong>Review the person&#39;s history,</strong> paying particular attention to compliance with medication, and details of any previous exacerbations.&nbsp;</li><li><strong>Consider the need for hospital admission:</strong><ul><li>Admit all people with features of a life-threatening asthma exacerbation.</li><li>Admit people with any feature of a severe asthma attack persisting after initial bronchodilator&nbsp;treatment.</li><li>Admit people with a moderate&nbsp;asthma exacerbation with worsening symptoms despite initial bronchodilator treatment and/or who have had a previous near-fatal asthma attack. People with a moderate&nbsp;exacerbation may also require admission if they have factors that warrant&nbsp;a lower threshold for admission, such as:<ul><li>Age under 18 years.</li><li>Poor treatment adherence.</li><li>Living alone/social isolation.</li><li>Psychological problems such as depression, and alcohol or drug misuse.</li><li>Physical or learning disability.</li><li>Previous severe asthma attack.</li><li>Exacerbation despite an adequate dose of oral corticosteroids before presentation.</li><li>Presentation in the afternoon or at night.</li><li>Recent nocturnal symptoms.</li><li>Recent hospital admission.</li><li>Pregnancy.</li></ul></li></ul></li><li><strong>While awaiting admission to hospital:</strong><ul><li>Give controlled supplementary oxygen to all people with hypoxia using a face mask, Venturi mask, or nasal cannulae. Adjust flow rates as necessary to maintain an oxygen saturation of 94&ndash;98% but do not delay oxygen administration in the absence of pulse oximetry.</li><li>Treat with a short-acting beta-<sub>2</sub> agonist:<ul><li>For life-threatening or severe asthma, give nebulized salbutamol (5 mg to all people aged over 5 years, and 2.5 mg to children aged &nbsp;2&ndash;5 years). &nbsp;Ideally, nebulizers should be oxygen driven (flow rate of 6 L /min usually needed) to avoid worsening hypoxia. If an oxygen-driven nebulizer is unavailable, deliver by air-driven nebulizer, although be alert that oxygen desaturation may occur. Continuous nebulization is preferred in severe obstruction, but not all nebulizer systems can do this. When using intermittent nebulization, repeat salbutamol&nbsp;administration every 20&ndash;30 minutes. When using a continuous nebulizer, give the dose&nbsp;over 30&ndash;60 minutes.</li><li>If a nebulizer is not available, or if the attack is of moderate severity, use a pressurized metered-dose inhaler with a large-volume spacer. Children under the age of three years are likely to require a face mask connected&nbsp;to the mouthpiece of a spacer for successful drug delivery. A short pause between puffs may be necessary to avoid hyperventilation with puffs given one at a time and inhaled with five tidal breaths. For an adult, give 4 puffs initially, followed by 2&nbsp;puffs every 2&nbsp;minutes according to response, up to 10&nbsp;puffs. Repeat&nbsp;every 10-20 minutes if clinically necessary. For a child, give a puff every 30&ndash;60 seconds, up to 10&nbsp;puffs. If the response is poor, give further doses while awaiting hospital admission, and switch to a nebulizer if available.</li></ul></li><li>For people with life-threatening or severe asthma, and those with a poor initial response to salbutamol, consider the addition of nebulized ipratropium&nbsp;bromide (500 micrograms for adults and 250 micrograms for children aged&nbsp;2&ndash;12 years, do not repeat within 4 hours).</li><li>For attacks of all severities, give the first dose of a course of prednisolone (40&ndash;50 mg for adults, 30&ndash;40 mg for children over 5 years, 20 mg for children aged 2&ndash;5 years, and 10 mg for children aged under 2 years). If medication cannot be swallowed, consider intramuscular methylprednisolone 160 mg as an alternative in adults, or IV hydrocortisone 100 mg in people aged over 5 years, and 50 mg in children aged 2&ndash;5 years.</li><li>Monitor peak expiratory flow rate (if the person can comply) and oxygen saturation (if available) to assess response to treatment.</li></ul></li><li><strong>If the person does not require hospital admission:</strong><ul><li>Use a&nbsp;short-acting beta-<sub>2</sub> agonist via a large-volume spacer to relieve acute symptoms. For an adult, give 4 puffs initially, followed by 2&nbsp;puffs every 2&nbsp;minutes according to response, up to 10&nbsp;puffs. For a child, give a puff every 30&ndash;60 seconds, up to 10 puffs. Each puff should be given one at a time and inhaled with five tidal breaths. Repeat every 10&ndash;20&nbsp;minutes according to clinical response.</li><li>Prescribe a short course of oral prednisolone. For further details including doses, see the section <a class=\"topic-reference internal-reference\" href=\"#694b34de-6f64-4504-b957-a6da01622a27\">Which oral corticosteroids are used to treat asthma?</a>.</li><li>Do not prescribe antibiotics routinely, unless symptoms and signs suggest a bacterial infection. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/473ddaff-d0fe-4ba6-950d-21174782d383\">Chest infections - adult</a>&nbsp;and&nbsp;<a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/6f239a86-8a9f-4fc1-85b2-df045fbf9477\">Cough - acute with chest signs in children</a>.</li><li>Once symptoms have subsided, advise the person (or their parent/carer) to return to using their short-acting beta-<sub>2&nbsp;</sub>agonist as required, up to four times a day (not exceeding 4-hourly).</li><li>The dose of inhaled corticosteroids (ICS) does not need to be altered&nbsp;during an exacerbation. Treatment with ICS should not be used as an alternative to oral corticosteroids.</li><li>Advise the person or their parent/carer to monitor their peak expiratory flow rate (PEFR) and symptoms, and to seek medical advice if&nbsp;symptoms worsen, or PEFR decreases.</li><li>Consider initiating montelukast in children aged over 2&nbsp;years with a mild asthma exacerbation&nbsp;early after the onset of symptoms.</li></ul></li><li><strong>Follow-up a person within 48&nbsp;hours of presentation, if not admitted to hospital. Follow-up all people admitted to hospital within 2 working days of discharge.</strong><ul><li>Review symptoms and check peak expiratory flow.</li><li>Check inhaler technique.</li><li>Consider stepping-up treatment by increasing inhaled corticosteroids or adding in new preventive therapy.</li><li>Address potentially preventable contributors to the exacerbation, such as exposure to trigger factors and non-compliance with treatment.</li><li>Provide advice on lifestyle, vaccinations, diet, exercise, and smoking. If the person or parent/carer of the child smokes, advise them to stop.</li><li>Advise on&nbsp;recognizing poor asthma control (worsening symptoms or peak flow readings), early signs of an exacerbation (sudden persistent worsening symptoms), what to do at the early signs of an exacerbation (increasing&nbsp;beta-<sub>2</sub> agonist and starting oral corticosteroids), and seeking medical help&nbsp;if symptoms are not controlled.</li><li>Consider prescribing a supply of oral corticosteroids for the person to keep at home and provide written information advising the person to start taking them during early signs of an exacerbation, and to contact a primary healthcare professional if they start treatment or are uncertain about whether to start treatment.</li><li>Ensure that the person has received self-management education and a <a data-hyperlink-id=\"7564fe20-4cc1-4d95-b294-a8f7015ccd02\" href=\"https://www.asthma.org.uk/advice/manage-your-asthma/action-plan/\">personalised asthma action plan</a>.</li><li>For&nbsp;people over the age of 18 years with a history of asthma attacks, who are not well-controlled with either medium dose ICS or a combination ICS/LABA inhaler,&nbsp;a combined LABA/ICS&nbsp;can be used as reliever therapy when required, in addition to a regular preventer. However, people taking rescue doses of their combination inhaler once a day or more on a regular basis should have their treatment reviewed.<br>Not all combination products are licensed for maintenance and reliever therapy. See the <a data-hyperlink-id=\"2d2eed34-66ba-470d-99e0-a8f7015ccd78\" href=\"https://www.evidence.nhs.uk/formulary/bnf/current\">British National Formulary</a> for further details.</li><li>Consider referral to a respiratory physician if the person has experienced 2 asthma attacks within 12 months.</li></ul></li></ul><!-- end field 894e3abb-5565-458f-ae05-a6be0108fd9a --><!-- end item 06c7a78e-2664-4c30-8fe3-a6be0108fd9a -->",
              "containerElement": "scenarioRecommendation",
              "children": [
                {
                  "itemId": "299f1fb7-b91b-4868-8db1-a6be0108fd9a",
                  "parentId": "06c7a78e-2664-4c30-8fe3-a6be0108fd9a",
                  "rootId": "07e98755-62cf-4a2d-96c0-a297468b1000",
                  "fullItemName": "Basis for recommendation",
                  "htmlHeader": "<!-- begin field 15df3f3c-0b84-4be3-8649-a6be0108fd9a --><h4>Basis for recommendation</h4><!-- end field 15df3f3c-0b84-4be3-8649-a6be0108fd9a -->",
                  "htmlStringContent": "<!-- begin item 299f1fb7-b91b-4868-8db1-a6be0108fd9a --><!-- begin field 23f57c80-4074-4131-b825-a6be0108fd9a --><p>The information on how to manage&nbsp;a person with an acute exacerbation of&nbsp;asthma is largely based on expert opinion in the in the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) B<em>ritish guideline on the management of asthma</em>&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>]<em>.</em></p><p><strong>Prescribing oral corticosteroids to keep at home</strong></p><ul><li>The advice on prescribing oral corticosteroids for a person to keep at home following an asthma exacerbation is extrapolated from information contained within Asthma UK&#39;s adult personal asthma action plan [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Asthma UK, 2018</a>].</li></ul><!-- end field 23f57c80-4074-4131-b825-a6be0108fd9a --><!-- end item 299f1fb7-b91b-4868-8db1-a6be0108fd9a -->",
                  "containerElement": "scenarioBasis",
                  "children": [],
                  "depth": 4,
                  "pos": 0
                }
              ],
              "depth": 3,
              "pos": 0
            }
          ],
          "depth": 2,
          "pos": 3
        }
      ],
      "depth": 1,
      "pos": 6
    },
    {
      "itemId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
      "parentId": null,
      "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
      "fullItemName": "Prescribing information",
      "htmlHeader": "<!-- begin field 61908f46-1a0d-48e6-9764-4111c9794a99 --><h1>Prescribing information</h1><!-- end field 61908f46-1a0d-48e6-9764-4111c9794a99 -->",
      "htmlStringContent": "<!-- begin item baacfbc5-ee97-4d5f-a5a3-b492048eebab --><!-- begin field 010f5fa8-810b-4536-ba00-a6f800e52b6a --><p>Important aspects of prescribing information relevant to primary healthcare are covered in this section specifically for the drugs recommended in this CKS&nbsp;topic. For further information on contraindications, cautions, drug interactions, and adverse effects, see the&nbsp;<a data-hyperlink-id=\"958827eb-8af0-4479-9ef2-a8f7015a73d1\" href=\"http://www.medicines.org.uk/emc\">electronic Medicines Compendium</a>&nbsp;(eMC), or the&nbsp;<a data-hyperlink-id=\"e266a900-1512-40bd-a0d7-a8f7015a7459\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a>&nbsp;(BNF).</p><!-- end field 010f5fa8-810b-4536-ba00-a6f800e52b6a --><!-- end item baacfbc5-ee97-4d5f-a5a3-b492048eebab -->",
      "containerElement": "prescribingInfo",
      "children": [
        {
          "itemId": "be2c12ab-d9dd-4ccf-bbda-a6d7016a5f43",
          "parentId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "fullItemName": "Beta-2 agonists",
          "htmlHeader": "<!-- begin field cbd78448-fb44-4e1b-ae6b-a6d7016a65e8 --><h2>Beta-2 agonists</h2><!-- end field cbd78448-fb44-4e1b-ae6b-a6d7016a65e8 -->",
          "htmlStringContent": "<!-- begin item be2c12ab-d9dd-4ccf-bbda-a6d7016a5f43 --><!-- begin field d18b91d7-0383-466f-b13e-a6d7016a65e8 --><ul><li><strong>Beta-<sub>2</sub> agonists &mdash; act directly on beta-<sub>2</sub> receptors, causing smooth muscle relaxation and dilatation of the airways.</strong></li><li><strong>Short-acting beta-<sub>2</sub>&nbsp;agonists (SABAs),</strong> such as salbutamol and terbutaline, have a rapid onset of action (15 minutes) and their effects last for up to 4&nbsp;hours.<ul><li>Doses vary depending on the person&#39;s age, response to treatment and the preparation prescribed. For more details, see the <a href=\"https://www.evidence.nhs.uk/formulary/bnf/current\" data-hyperlink-id=\"02946b15-5a02-4ace-bedc-a8f7014ed320\">British National Formulary</a> and the manufacturers&#39; Summaries of Product Characteristics.</li><li>Use of a SABA as required is at least as effective as regular (four times daily) use.&nbsp;</li></ul></li><li><strong>Long-acting beta-<sub>2</sub> agonists (LABAs)</strong> have prolonged receptor occupancy. Salmeterol and formoterol are relatively lipophilic and have a duration of action of 12&nbsp;hours.<ul><li>They should only be used in people who regularly use an inhaled corticosteroid.</li><li>An LABA should be introduced at a low dose and the effect monitored before considering a dose increase.</li><li>The recommended doses vary depending on the person&#39;s age, response to treatment&nbsp;and&nbsp;the preparation prescribed. For more details, see the <a href=\"https://www.evidence.nhs.uk/formulary/bnf/current\" data-hyperlink-id=\"2399ef73-433e-4b8c-aa53-a8f7014ed329\">British National Formulary</a>&nbsp;and the manufacturers&#39; Summaries of Product Characteristics.</li><li>Combination products that include an LABA and an inhaled corticosteroid are available, such as formoterol plus budesonide, formoterol plus beclometasone, and salmeterol plus fluticasone propionate. Some preparations of&nbsp;formoterol plus budesonide are licensed for use in people over the age of 12 years,&nbsp;and&nbsp;formoterol plus beclometasone are licensed for use in people over the age of 18 years, as maintenance and reliever therapy. The appropriate inhaler should be prescribed by brand name. For more details, see the&nbsp;<a href=\"https://www.evidence.nhs.uk/formulary/bnf/current\" data-hyperlink-id=\"c9f36305-50ff-49d6-8864-a8f7014ed329\">British National Formulary</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>]</p><!-- end field d18b91d7-0383-466f-b13e-a6d7016a65e8 --><!-- end item be2c12ab-d9dd-4ccf-bbda-a6d7016a5f43 -->",
          "containerElement": "prescribingInfoSub",
          "children": [
            {
              "itemId": "07fffe25-13a0-42f9-a8ba-a6d80145d84d",
              "parentId": "be2c12ab-d9dd-4ccf-bbda-a6d7016a5f43",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Contraindications and cautions",
              "htmlHeader": "<!-- begin field 8dc3d133-50f9-43fb-9d07-a6d80145dc41 --><h3>Contraindications and cautions</h3><!-- end field 8dc3d133-50f9-43fb-9d07-a6d80145dc41 -->",
              "htmlStringContent": "<!-- begin item 07fffe25-13a0-42f9-a8ba-a6d80145d84d --><!-- begin field 180a99d0-e5b4-4be4-bc6e-a6d80145dc41 --><ul><li><strong>Beta-<sub>2</sub> agonists should be used with caution in people with:</strong><ul><li>Hyperthyroidism &mdash; beta-<sub>2</sub> agonists may stimulate thyroid activity.</li><li>Diabetes mellitus &mdash; there is a rare risk of ketoacidosis (especially after intravenous beta-<sub>2 </sub>agonist administration). Additional blood glucose measurements are recommended when treatment with a beta-<sub>2</sub> agonist is commenced.</li><li>Cardiovascular disease (including hypertension) &mdash; beta-<sub>2</sub> agonists may cause an increased risk of arrhythmias and significant changes to blood pressure and heart rate.</li><li>Susceptibility to QT-interval prolongation.</li><li>Hypokalaemia &mdash; plasma potassium concentration may be reduced by beta-<sub>2</sub> agonists (particularly high doses).</li><li>Convulsive disorders.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>] </p><!-- end field 180a99d0-e5b4-4be4-bc6e-a6d80145dc41 --><!-- end item 07fffe25-13a0-42f9-a8ba-a6d80145d84d -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 0
            },
            {
              "itemId": "2c669cbf-22b0-4a0b-b734-a6d80145f3f9",
              "parentId": "be2c12ab-d9dd-4ccf-bbda-a6d7016a5f43",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Adverse effects",
              "htmlHeader": "<!-- begin field b4c3fcba-15cb-4e25-a9e5-a6d80145f98c --><h3>Adverse effects</h3><!-- end field b4c3fcba-15cb-4e25-a9e5-a6d80145f98c -->",
              "htmlStringContent": "<!-- begin item 2c669cbf-22b0-4a0b-b734-a6d80145f3f9 --><!-- begin field cb56f451-8c91-4e37-9cba-a6d80145f98c --><ul><li><strong>Adverse effects of short-acting and long-acting beta-<sub>2</sub> agonists are similar. They are usually dose related and include:</strong><ul><li>Fine tremor &mdash; occurs particularly in the hands and is usually worse in the first few days of treatment.</li><li>Palpitations.</li><li>Headache.</li><li>Seizure.</li><li>Anxiety.</li><li>Hypokalaemia.</li><li>Cardiac arrhythmia and paradoxical bronchospasm (rare).</li><li>Acute angle-closure glaucoma has been reported in people using nebulized short-acting beta-<sub>2</sub> agonists.<ul><li>Advise people using nebulized short-acting beta-<sub>2</sub> agonists to use a mouthpiece rather than a mask to minimize exposure of the eyes to the drug.</li></ul></li></ul></li><li>Advise people who are using terbutaline turbohaler to rinse their mouth with water after each use. A fraction of the dose will always be deposited in the mouth and rinsing will minimize the amount of drug that is absorbed systemically.</li><li><strong>The risk of adverse events may be higher in people with a predisposition to arrhythmias and in people with pre-existing cardiovascular disease, or hypertension.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field cb56f451-8c91-4e37-9cba-a6d80145f98c --><!-- end item 2c669cbf-22b0-4a0b-b734-a6d80145f3f9 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 1
            },
            {
              "itemId": "a4504b51-f61f-44a4-b090-a6d80146157d",
              "parentId": "be2c12ab-d9dd-4ccf-bbda-a6d7016a5f43",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Drug interactions",
              "htmlHeader": "<!-- begin field 4f0957d3-c135-4a3f-b034-a6d80146193f --><h3>Drug interactions</h3><!-- end field 4f0957d3-c135-4a3f-b034-a6d80146193f -->",
              "htmlStringContent": "<!-- begin item a4504b51-f61f-44a4-b090-a6d80146157d --><!-- begin field 3d94e210-56c8-423f-81dd-a6d80146193f --><ul><li><strong>Corticosteroids, diuretics, and xanthine derivatives such as theophylline</strong> &mdash; monitor potassium levels.<ul><li>Beta-<sub>2 </sub>agonists can cause hypokalaemia (particularly at high doses), and this can be increased by other potassium-depleting drugs, such as corticosteroids, loop diuretics, and xanthine derivatives.</li></ul></li><li><strong>Digoxin </strong>&mdash; monitor potassium levels and be alert to signs of digoxin toxicity, such as loss of appetite, nausea, vomiting, bradycardia, visual disturbance, and drowsiness.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field 3d94e210-56c8-423f-81dd-a6d80146193f --><!-- end item a4504b51-f61f-44a4-b090-a6d80146157d -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 2
            }
          ],
          "depth": 2,
          "pos": 0
        },
        {
          "itemId": "2941a4c0-4c3b-40cd-8090-a6d7016a8eeb",
          "parentId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "fullItemName": "Inhaled corticosteroids",
          "htmlHeader": "<!-- begin field 749ec473-1ed5-4f2f-a593-a6d7016a940e --><h2>Inhaled corticosteroids&nbsp;</h2><!-- end field 749ec473-1ed5-4f2f-a593-a6d7016a940e -->",
          "htmlStringContent": "<!-- begin item 2941a4c0-4c3b-40cd-8090-a6d7016a8eeb --><!-- begin field e29ad118-38c1-4b2d-83e9-a6d7016a940e --><ul><li><strong>Inhaled corticosteroids (ICS) used in the treatment of asthma include beclometasone, budesonide, ciclesonide, fluticasone, and mometasone.</strong><ul><li>Note: for detailed prescribing information on inhaled corticosteroids, see the CKS topic on&nbsp;<a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/702fbe32-706c-43c3-bc60-c5cc8f25f0a7\">Corticosteroids - inhaled</a>.</li></ul></li><li>Consider issuing a steroid treatment card [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">CHM, 2006</a>]&nbsp;to:<ul><li>People using prolonged high doses of inhaled corticosteroids.</li><li>People taking inhaled corticosteroids plus drugs that inhibit their metabolism (for example cytochrome P450 inhibitors, such as HIV protease inhibitors).</li></ul></li><li>ICS can be given via a pressurized metered dose inhaler (PMDI) or a dry powder inhaler (DPI). For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"#d697784b-2cbb-4b02-b96d-a7a700c380d7\">delivery systems</a>.&nbsp;</li><li>Combination inhalers which deliver an ICS in combination with a long-acting beta-<sub>2</sub> agonist (LABA) are also available.</li><li><strong>Use the lowest dose of inhaled corticosteroid (ICS) that maintains effective control of asthma and start ICS at a dose appropriate to the severity of symptoms.</strong> For more information, see the section&nbsp;<a class=\"topic-reference internal-reference\" href=\"#44f59cc7-25d8-4bb0-b726-a6be01067965\">How should I manage someone with newly-diagnosed asthma?</a>.</li><li><strong>NICE has&nbsp;have&nbsp;issued&nbsp;the following guidance on ICS dosages for adults aged 17 and over:</strong><ul><li>More than 800&nbsp;micrograms budesonide or equivalent would be considered a high dose.</li><li>More than 400&nbsp;micrograms to 800&nbsp;micrograms budesonide or equivalent would be considered a moderate dose.</li><li>Less than or equal to 400&nbsp;micrograms budesonide or equivalent would be considered a low dose.<ul><li>Note: BTS/SIGN use the same terminology as NICE to define these three dosage categories for adults, as in table 1 below.</li></ul></li></ul></li><li><strong>NICE has issued the following guidance on ICS dosages for children and young people aged 16 and under:</strong><ul><li>Less than or equal to 200&nbsp;micrograms budesonide or equivalent would be considered a paediatric low dose (Note: BTS/SIGN classify this dose range as &#39;very low dose&#39;, as in table 2 below).</li><li>More than 200&nbsp;micrograms to 400 micrograms budesonide or equivalent would be considered a paediatric moderate dose (Note: BTS/SIGN classify this dose range as &#39;low dose&#39; as in table 2 below).</li><li>More than 400&nbsp;micrograms budesonide or equivalent would be considered a paediatric high dose&nbsp;(Note: BTS/SIGN classify this dose range as &#39;medium&nbsp;dose&#39; as in table 2 below).</li></ul></li><li><strong>For information about dose equivalance between different steroid preparations, please see tables 1 and 2 below.</strong></li></ul><p><strong>Table 1.</strong> Categorization of inhaled corticosteroids by dose in adults (N.B. different products are licensed for different age groups and some may also be applicable to older children. Before prescribing, consult the manufacturer&#39;s summary of product characteristics) [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>].</p><table><tbody><tr><td>&nbsp;</td><td>Low dose</td><td>Medium dose</td><td>High dose&nbsp;</td></tr><tr><td colspan=\"4\"><strong>Pressurized metered dose inhalers</strong></td></tr><tr><td colspan=\"4\">Beclometasone dipropionate</td></tr><tr><td>Non-proprietary</td><td>100 micrograms, two puffs twice a day</td><td>200 micrograms, two puffs twice a day</td><td>200 micrograms, four puffs twice a day</td></tr><tr><td>Clenil Modulite&nbsp;</td><td>100 micrograms, two puffs twice a day</td><td>200 micrograms, two puffs twice a day</td><td><p>250 micrograms, two puffs twice a day, <em>or</em></p><p>250 micrograms, four puffs twice a day</p></td></tr><tr><td>Qvar (extrafine) Qvar autohaler Qvar Easi-breathe</td><td>50 micrograms, two puffs twice a day</td><td>100 micrograms, two puffs twice a day</td><td>100 micrograms, four puffs twice a day</td></tr><tr><td colspan=\"4\">Ciclesonide</td></tr><tr><td>Alvesco Aerosol inhaler</td><td>80 micrograms, two puffs twice a day</td><td>160 micrograms, two puffs twice a day</td><td>&nbsp;</td></tr><tr><td colspan=\"4\">Fluticasone propionate</td></tr><tr><td>Flixotide Evohaler</td><td>50 micrograms, two puffs twice a day</td><td>125 micrograms, two puffs twice a day</td><td>250 micrograms, two puffs twice a day</td></tr><tr><td colspan=\"4\"><strong>Dry powder inhalers</strong></td></tr><tr><td colspan=\"4\">Beclometasone</td></tr><tr><td>Non-proprietary Easyhaler</td><td>200 micrograms, one&nbsp;puff twice a day</td><td>200 micrograms, two&nbsp;puffs twice a day</td><td>&nbsp;</td></tr><tr><td>Asmabec</td><td>100 micrograms, one&nbsp;puff twice a day</td><td>100 micrograms, two&nbsp;puffs twice a day</td><td>&nbsp;</td></tr><tr><td colspan=\"4\">Budesonide</td></tr><tr><td>Non-proprietary&nbsp;Easyhaler</td><td>100 micrograms, two&nbsp;puffs twice a day</td><td>200 micrograms, two&nbsp;puffs twice a day</td><td>400 micrograms, two&nbsp;puffs twice a day</td></tr><tr><td>Budelin Novolizer</td><td>&nbsp;</td><td>200 micrograms, two&nbsp;puffs twice a day</td><td>200 micrograms, four&nbsp;puffs twice a day</td></tr><tr><td>Pulmicort Turbohaler</td><td>100 micrograms, two&nbsp;puffs twice a day, <em>or</em> 200 micrograms, one&nbsp;puff twice a day</td><td>200 micrograms, two&nbsp;puffs twice a day, <em>or</em> 400 micrograms, one&nbsp;puff twice a day</td><td>400 micrograms, two&nbsp;puffs twice a day</td></tr><tr><td colspan=\"4\">Fluticasone propionate</td></tr><tr><td>Flixotide Accuhaler</td><td>100 micrograms, one&nbsp;puff twice a day</td><td>250 micrograms, one&nbsp;puff twice a day</td><td>500 micrograms, one&nbsp;puff twice a day</td></tr><tr><td colspan=\"4\">Mometasone</td></tr><tr><td>Asmanex Twisthaler</td><td>200 micrograms, one&nbsp;puff twice a day</td><td>400 micrograms, one&nbsp;puff twice a day</td><td>&nbsp;</td></tr><tr><td colspan=\"4\"><strong>Combination inhalers</strong></td></tr><tr><td colspan=\"4\">Beclometasone dipropionate (extrafine) with formoterol</td></tr><tr><td>Fostair (pMDI)</td><td>100/6, one puff twice&nbsp;a day</td><td>100/6, two puffs twice&nbsp;a day</td><td>200/6, two puffs twice&nbsp;a day</td></tr><tr><td>Fostair (NEXThaler)</td><td>100/6, one puff twice&nbsp;a day</td><td>100/6, two puffs twice&nbsp;a day</td><td>200/6, two puffs twice&nbsp;a day</td></tr><tr><td colspan=\"4\">Budesonide with formoterol</td></tr><tr><td>DuoResp Spiromax</td><td>200/6, one puff twice&nbsp;a day</td><td>200/6, two puffs twice&nbsp;a day, <em>or</em> 400/12, one puff twice&nbsp;a day</td><td>400/12, two puffs&nbsp;twice a day</td></tr><tr><td>Symbicort Turbohaler</td><td><p>100/6, one puff twice&nbsp;a day,&nbsp;<em>or</em></p><p>200/6, one puff twice&nbsp;a day</p></td><td>200/6, two puffs twice&nbsp;a day, <em>or</em> 400/12, one puff twice&nbsp;a day</td><td>400/12, two puffs&nbsp;twice a day</td></tr><tr><td colspan=\"4\">Fluticasone propionate with formoterol</td></tr><tr><td>Flutiform</td><td>50/5, two puffs twice&nbsp;a day</td><td>125/5, two puffs twice&nbsp;a day</td><td>250/10, two puffs twice&nbsp;a day</td></tr><tr><td colspan=\"4\">Fluticasone propionate with salmeterol</td></tr><tr><td>Seretide Accuhaler</td><td>100/50, one puff twice&nbsp;a day</td><td>250/50, one puff twice&nbsp;a day</td><td>500/50 one puff twice&nbsp;a day</td></tr><tr><td>Seretide Evohaler</td><td>50/25, two puffs twice&nbsp;a day</td><td>125/25, two puffs twice&nbsp;a day</td><td>250/25, two puffs twice&nbsp;a day</td></tr><tr><td colspan=\"4\">Fluticasone furoate with vilanterol</td></tr><tr><td>Relvar</td><td>&nbsp;</td><td>92/22, one puff once a day</td><td>184/22, one puff once a day</td></tr></tbody></table><p><strong>Table 2.&nbsp;</strong>Categorization of inhaled corticosteroids by dose in children (N.B. different products are licensed for different age groups. Before prescribing, consult the manufacturer&#39;s summary of product characteristics)&nbsp;[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>].</p><table><tbody><tr><td>&nbsp;</td><td>Very low dose</td><td>Low dose</td><td>Medium dose&nbsp;</td></tr><tr><td colspan=\"4\"><strong>Pressurized metered dose inhalers</strong></td></tr><tr><td colspan=\"4\">Beclometasone dipropionate</td></tr><tr><td>Non-proprietary</td><td>50 micrograms, two puffs twice a day</td><td>100 micrograms, two puffs twice a day</td><td>200 micrograms, two puffs twice a day</td></tr><tr><td>Clenil Modulite&nbsp;</td><td>50 micrograms, two puffs twice a day</td><td>100 micrograms, two puffs twice a day</td><td><p>200 micrograms, two puffs twice a day</p></td></tr><tr><td><p>Qvar (extrafine)</p><p>Qvar autohaler</p><p>Qvar Easi-breathe</p></td><td>&nbsp;</td><td>50 micrograms, two puffs twice a day</td><td>100 micrograms, two puffs twice a day</td></tr><tr><td colspan=\"4\">Ciclesonide</td></tr><tr><td>Alvesco Aerosol inhaler</td><td>&nbsp;</td><td>80 micrograms, two puffs once a day</td><td>160 micrograms, two puffs once a day</td></tr><tr><td colspan=\"4\">Fluticasone propionate</td></tr><tr><td>Flixotide Evohaler</td><td>50 micrograms, one puff twice a day</td><td>50 micrograms, two puffs twice a day</td><td>125 micrograms, two puffs twice a day</td></tr><tr><td colspan=\"4\"><strong>Dry powder inhalers</strong></td></tr><tr><td colspan=\"4\">Beclometasone</td></tr><tr><td>Asmabec</td><td>&nbsp;</td><td>100 micrograms, one&nbsp;puff twice a day</td><td>100 micrograms, two&nbsp;puffs twice a day</td></tr><tr><td colspan=\"4\">Budesonide</td></tr><tr><td>Non-proprietary&nbsp;Easyhaler</td><td>&nbsp;</td><td>100 micrograms, two&nbsp;puffs twice a day</td><td>200 micrograms, two&nbsp;puffs twice a day</td></tr><tr><td>Pulmicort Turbohaler</td><td>100 micrograms, one puff twice a day</td><td>100 micrograms, two&nbsp;puffs twice a day, <em>or</em> 200 micrograms, one&nbsp;<br>puff twice a day</td><td>200 micrograms, two&nbsp;puffs twice a day, <em>or</em><br>400 micrograms, one&nbsp;puff twice a day</td></tr><tr><td colspan=\"4\">Fluticasone propionate</td></tr><tr><td>Flixotide Accuhaler</td><td>50 micrograms, one&nbsp;puff twice a day</td><td>100 micrograms, one&nbsp;puff twice a day</td><td>250 micrograms, one&nbsp;puff twice a day</td></tr><tr><td colspan=\"4\">Mometasone</td></tr><tr><td>Asmanex Twisthaler</td><td>&nbsp;</td><td>200 micrograms, one&nbsp;puff twice a day</td><td>&nbsp;</td></tr><tr><td colspan=\"4\"><strong>Combination inhalers</strong></td></tr><tr><td colspan=\"4\">Budesonide with formoterol</td></tr><tr><td>Symbicort Turbohaler</td><td><p>100/6, one puff twice&nbsp;a day&nbsp;</p></td><td>100/6, two puffs twice&nbsp;a day, <em>or</em> 200/6, one puff twice&nbsp;a day</td><td>&nbsp;</td></tr><tr><td colspan=\"4\">Fluticasone propionate with salmeterol</td></tr><tr><td>Seretide Accuhaler</td><td>&nbsp;</td><td>100/50, one puff twice&nbsp;a day</td><td>&nbsp;</td></tr><tr><td>Seretide Evohaler</td><td>&nbsp;</td><td>50/25, two puffs twice&nbsp;a day</td><td>&nbsp;</td></tr></tbody></table><!-- end field e29ad118-38c1-4b2d-83e9-a6d7016a940e --><!-- end item 2941a4c0-4c3b-40cd-8090-a6d7016a8eeb -->",
          "containerElement": "prescribingInfoSub",
          "children": [],
          "depth": 2,
          "pos": 1
        },
        {
          "itemId": "694b34de-6f64-4504-b957-a6da01622a27",
          "parentId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "fullItemName": "Oral corticosteroids",
          "htmlHeader": "<!-- begin field 6af0217d-1d1d-4a2e-a5bf-a6da0162305a --><h2>Oral corticosteroids&nbsp;</h2><!-- end field 6af0217d-1d1d-4a2e-a5bf-a6da0162305a -->",
          "htmlStringContent": "<!-- begin item 694b34de-6f64-4504-b957-a6da01622a27 --><!-- begin field 7888988c-602b-49ad-9fe3-a6da0162305a --><ul><li>Prednisolone is the most widely used steroid for maintenance therapy in people&nbsp;with chronic asthma. There is no evidence that other steroids offer an advantage over prednisolone. The dose should be kept at the lowest which provides adequate control.</li><li>Short courses of prednisolone are also used for acute exacerbations of asthma. Doses are usually as follows:<ul><li>Adult or child over the age of&nbsp;12 years &mdash; 40&ndash;50&nbsp;mg once a day for 5&nbsp;days.</li><li>Child 6 to 12 years &mdash; 30&ndash;40 mg once a day for 3 days.</li><li>Child 2 to 5 years &mdash; 20 mg once a day for 3 days.</li><li>Child&nbsp;under 2 years &mdash; 10 mg once a day for 3 days.</li></ul></li><li>People on long-term treatment with oral corticosteroids should be given a steroid treatment&nbsp;card, which gives guidance on minimizing the risk of adverse effects&nbsp;and provides details of prescriber, drug, dosage, and duration of treatment.</li><li>For detailed prescribing information on oral corticosteroids, see the CKS&nbsp;topic on&nbsp;<a class=\"topic-reference external-reference\" href=\"/Topic/ViewTopic/72c594bc-4c91-4d24-acdb-dda9812ea656\">Corticosteroids - oral</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">CHM, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>].</p><!-- end field 7888988c-602b-49ad-9fe3-a6da0162305a --><!-- end item 694b34de-6f64-4504-b957-a6da01622a27 -->",
          "containerElement": "prescribingInfoSub",
          "children": [],
          "depth": 2,
          "pos": 2
        },
        {
          "itemId": "2626bec7-75d5-4caa-9158-a6d7016b9de8",
          "parentId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "fullItemName": "Leukotriene receptor antagonists",
          "htmlHeader": "<!-- begin field 6af39be8-c628-4a9b-ba85-a6d7016ba4be --><h2>Leukotriene receptor antagonists&nbsp;</h2><!-- end field 6af39be8-c628-4a9b-ba85-a6d7016ba4be -->",
          "htmlStringContent": "<!-- begin item 2626bec7-75d5-4caa-9158-a6d7016b9de8 --><!-- end item 2626bec7-75d5-4caa-9158-a6d7016b9de8 -->",
          "containerElement": "prescribingInfoSub",
          "children": [
            {
              "itemId": "9882fc1f-1f03-47cf-b33d-a6f700ee82cd",
              "parentId": "2626bec7-75d5-4caa-9158-a6d7016b9de8",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Dose",
              "htmlHeader": "<!-- begin field 43415854-9c8d-4e86-8774-a6f700ee84ab --><h3>Which dose should be given?</h3><!-- end field 43415854-9c8d-4e86-8774-a6f700ee84ab -->",
              "htmlStringContent": "<!-- begin item 9882fc1f-1f03-47cf-b33d-a6f700ee82cd --><!-- begin field f2730f2c-fc9b-4a2f-bc7f-a6f700ee84ab --><p><strong>Montelukast and zafirlukast are leukotriene receptor antagonists&nbsp;taken orally in the treatment of asthma. Doses are as follows:</strong></p><ul><li><strong>Montelukast</strong> &mdash;&nbsp;10 mg once daily in adults and children aged 15 years and older, 5 mg once daily in children aged 6&ndash;14 years, and 4 mg once daily in children aged 6 months to 5 years. Doses to be taken in the evening.</li><li><strong>Zafirlukast</strong> &mdash; 20 mg twice daily in adults and children aged 12 years and older. Not licensed for use in younger children.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>] </p><!-- end field f2730f2c-fc9b-4a2f-bc7f-a6f700ee84ab --><!-- end item 9882fc1f-1f03-47cf-b33d-a6f700ee82cd -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 0
            },
            {
              "itemId": "694198d3-855f-458d-8ff8-a6da00fba1c8",
              "parentId": "2626bec7-75d5-4caa-9158-a6d7016b9de8",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Contraindications and cautions",
              "htmlHeader": "<!-- begin field b211a1ee-1b42-4fb8-833d-a6da00fba44d --><h3>Contraindications and cautions</h3><!-- end field b211a1ee-1b42-4fb8-833d-a6da00fba44d -->",
              "htmlStringContent": "<!-- begin item 694198d3-855f-458d-8ff8-a6da00fba1c8 --><!-- begin field 5c3a7fef-0b0b-4f73-8d7f-a6da00fba44d --><ul><li>There are no noted contraindications or cautions for montelukast.</li><li>Zafirlukast is&nbsp;contraindicated in people&nbsp;with hepatic impairment or cirrhosis.</li><li>The use of Zafirlukast&nbsp;in children under 12 years is contraindicated until safety information becomes available.&nbsp;</li><li>Zafirlukast should be used with caution in people with mild to severe renal impairment. Experience of use in these groups is limited, and clear dose recommendations can therefore not&nbsp;be given.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2018a</a>]</p><!-- end field 5c3a7fef-0b0b-4f73-8d7f-a6da00fba44d --><!-- end item 694198d3-855f-458d-8ff8-a6da00fba1c8 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 1
            },
            {
              "itemId": "71556ea0-c4d4-488a-87c3-a6da00fbd25c",
              "parentId": "2626bec7-75d5-4caa-9158-a6d7016b9de8",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Adverse effects",
              "htmlHeader": "<!-- begin field a9c279f3-9001-4fc6-a85c-a6da00fbd4ae --><h3>Adverse effects</h3><!-- end field a9c279f3-9001-4fc6-a85c-a6da00fbd4ae -->",
              "htmlStringContent": "<!-- begin item 71556ea0-c4d4-488a-87c3-a6da00fbd25c --><!-- begin field 068be596-c6e1-4a90-890b-a6da00fbd4ae --><ul><li><strong>Adverse effects of montelukast include:</strong><ul><li>Arthralgia.</li><li>Bruising.</li><li>Dyspepsia.</li><li>Excessive thirst.</li><li>Gastrointestinal upset.</li><li>Headache.</li><li>Hyperkinesia (in young children).</li><li>Infections.</li><li>Malaise.</li><li>Myalgia.</li><li>Nose bleeds.</li><li>Nervous system disorders (dizziness, drowsiness, paraesthesia/hypoesthesia, seizure).</li><li>Oedema.</li><li>Psychiatric disorders (dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity [including irritability, restlessness and tremor]).&nbsp;</li><li>Rash.</li><li>Thrombocytopaenia.</li><li>Tic.</li><li>Enuresis in children.</li></ul></li><li><strong>Adverse effects of zafirlukast include:</strong><ul><li>Arthralgia.</li><li>Bruising.</li><li>Gastrointestinal upset.</li><li>Headache.</li><li>Hepatic disorder.<ul><li>The person or their parent/carer should be advised&nbsp;to be alert for&nbsp;signs and symptoms of hepatic disorder (persistent nausea, vomiting, malaise, or jaundice) and to seek medical attention if they develop.</li></ul></li><li>Hyperbilirubinemia.</li><li>Infections.</li><li>Insomnia.</li><li>Malaise.</li><li>Muscle cramps.</li><li>Myalgia.</li><li>Rash.</li></ul></li><li><strong>Very rarely, leukotriene receptor antagonists have been associated with&nbsp;systemic eosinophilia, eosinophilic pneumonia, or with clinical features of systemic vasculitis, consistent with Churg-Strauss syndrome.</strong><ul><li>If a person&nbsp;develops an eosinophilic condition, or a Churg-Strauss syndrome-type illness, the leukotriene receptor antagonist&nbsp;should be stopped.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field 068be596-c6e1-4a90-890b-a6da00fbd4ae --><!-- end item 71556ea0-c4d4-488a-87c3-a6da00fbd25c -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 2
            },
            {
              "itemId": "56ba43d7-0d5e-418e-9118-a6da00fbb7dd",
              "parentId": "2626bec7-75d5-4caa-9158-a6d7016b9de8",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Drug interactions",
              "htmlHeader": "<!-- begin field efd42eb5-fc2b-4ea5-a798-a6da00fbba64 --><h3>Drug interactions</h3><!-- end field efd42eb5-fc2b-4ea5-a798-a6da00fbba64 -->",
              "htmlStringContent": "<!-- begin item 56ba43d7-0d5e-418e-9118-a6da00fbb7dd --><!-- begin field 8fd32c1f-45fc-44ac-bf44-a6da00fbba64 --><ul><li><strong>Phenytoin, phenobarbital and rifampicin</strong> &mdash; These are inducers of CYP 3A4, 2C8 and 2C9 which also metabolise montelukast. Caution should be exercised, particularly in children as plasma levels of montelukast may be reduced with co-administration.</li><li><strong>Aspirin</strong> &mdash; Co-administration of zafirlukast and aspirin 650 mg four times a day may result in approximately 45% increased zafirlukast levels.</li><li><strong>Warfarin&nbsp;</strong>&mdash;&nbsp;Zafirlukast co-administration results in an approximately 35%&nbsp;increase in maximum prothrombin time. Prothrombin time should therefore be closely monitored in people receiving both drugs.</li><li><strong>Theophylline</strong> &mdash; Zafirlukast co-administered with theophylline has been observed rarely to result in increased theophylline levels. Theophylline levels should therefore be monitored in people receiving both drugs.</li><li><strong>Erythromycin</strong> &mdash; Zafirlukast co-administered with erythromycin results in 40% decreased plasma level of zafirlukast.&nbsp;</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2018a</a>]</p><!-- end field 8fd32c1f-45fc-44ac-bf44-a6da00fbba64 --><!-- end item 56ba43d7-0d5e-418e-9118-a6da00fbb7dd -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 3
            }
          ],
          "depth": 2,
          "pos": 3
        },
        {
          "itemId": "d75dbb2f-d5be-417d-89a7-a6d7016bd4e4",
          "parentId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "fullItemName": "Muscarinic agents",
          "htmlHeader": "<!-- begin field 8d3b4dd9-fbd8-45eb-b748-a6d7016bd965 --><h2>Muscarinic agents</h2><!-- end field 8d3b4dd9-fbd8-45eb-b748-a6d7016bd965 -->",
          "htmlStringContent": "<!-- begin item d75dbb2f-d5be-417d-89a7-a6d7016bd4e4 --><!-- end item d75dbb2f-d5be-417d-89a7-a6d7016bd4e4 -->",
          "containerElement": "prescribingInfoSub",
          "children": [
            {
              "itemId": "53e471be-e5af-49a1-b25c-a6f700eeef83",
              "parentId": "d75dbb2f-d5be-417d-89a7-a6d7016bd4e4",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Dose",
              "htmlHeader": "<!-- begin field a6ce26d4-10af-4c82-8acb-a6f700eef0f6 --><h3>Which dose should be given?</h3><!-- end field a6ce26d4-10af-4c82-8acb-a6f700eef0f6 -->",
              "htmlStringContent": "<!-- begin item 53e471be-e5af-49a1-b25c-a6f700eeef83 --><!-- begin field f3684bab-bde8-4435-9262-a6f700eef0f6 --><p>Ipratropium bromide is a muscarinic agent&nbsp;that can be used to treat asthma in all age groups, with tiotropium&nbsp;licensed as an add-on therapy for&nbsp;adults&nbsp;who have experienced one or more severe asthma exacerbations in the past year. Both are delivered via pressurized metered dose inhalers. Doses are as follows:</p><ul><li><strong>Ipratropium bromide.</strong><ul><li>Adults and children aged 12 years and older &mdash;&nbsp;20 to 40 micrograms 3 to 4 times daily.</li><li>Children aged 6 to 11 years &mdash;&nbsp;20 to 40 micrograms 3&nbsp;times daily.</li><li>Children aged 1 month to 5 years &mdash;&nbsp;20&nbsp;micrograms 3&nbsp;times daily.</li></ul></li><li><strong>Tiotropium.</strong><ul><li>Adults&nbsp;&mdash; 5&nbsp;micrograms once&nbsp;daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field f3684bab-bde8-4435-9262-a6f700eef0f6 --><!-- end item 53e471be-e5af-49a1-b25c-a6f700eeef83 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 0
            },
            {
              "itemId": "d4647cc1-a535-464a-a4c0-a6da011636a1",
              "parentId": "d75dbb2f-d5be-417d-89a7-a6d7016bd4e4",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Contraindications and cautions",
              "htmlHeader": "<!-- begin field 1da2bb7e-d81b-4a52-8826-a6da01163926 --><h3>Contraindications and cautions</h3><!-- end field 1da2bb7e-d81b-4a52-8826-a6da01163926 -->",
              "htmlStringContent": "<!-- begin item d4647cc1-a535-464a-a4c0-a6da011636a1 --><!-- begin field db81a163-fc6f-45a6-83f3-a6da01163926 --><ul><li>Do not prescribe ipratropium bromide or tiotropium to people with a known hypersensitivity to atropine or its derivatives.</li><li>Prescribe ipratropium bromide and tiotropium with caution to people with:<ul><li>Narrow-angle glaucoma or a pre-disposition to narrow-angle glaucoma.</li><li>Urinary outflow tract obstruction (such as prostatic hyperplasia or bladder outflow obstruction).&nbsp;</li><li>Cystic fibrosis.</li></ul></li><li>Prescribe tiotropium&nbsp;with caution to people with:<ul><li>A history of myocardial infarction within the previous 6 months, any unstable or life-threatening cardiac arrhythmia, or cardiac arrhythmia requiring intervention or a change in drug therapy in the past year, or hospitalisation due to heart failure (NYHA Class III or IV) within the past year.</li><li>Moderate to severe renal impairment (creatinine clearance &le; 50 ml/min).<ul><li>Plasma concentration of tiotropium increases with decreasing&nbsp;renal function.&nbsp;Use in people with renal impairment only if&nbsp;the expected benefit outweighs the potential risk.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2018c</a>]</p><!-- end field db81a163-fc6f-45a6-83f3-a6da01163926 --><!-- end item d4647cc1-a535-464a-a4c0-a6da011636a1 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 1
            },
            {
              "itemId": "7d573498-98be-4fc6-a869-a6da01164ac3",
              "parentId": "d75dbb2f-d5be-417d-89a7-a6d7016bd4e4",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Adverse effects",
              "htmlHeader": "<!-- begin field 208a63b3-f42a-4533-bdaf-a6da01164d2d --><h3>Adverse effects</h3><!-- end field 208a63b3-f42a-4533-bdaf-a6da01164d2d -->",
              "htmlStringContent": "<!-- begin item 7d573498-98be-4fc6-a869-a6da01164ac3 --><!-- begin field 987ca17a-ee36-4338-a545-a6da01164d2d --><p><strong>Adverse effects of ipratropium bromide and tiotropium include:</strong></p><ul><li>Constipation.</li><li>Cough.</li><li>Diarrhoea.&nbsp;</li><li>Nausea</li><li>Dry mouth.&nbsp;</li><li>Gastro-intestinal motility disorder.</li><li>Headache.</li><li>Sinusitis.</li><li>Stomatitis.</li><li>Narrow angle glaucoma.<ul><li>Should the person develop eye pain or discomfort, blurred vision, visual halos, or coloured images in association with red eyes from conjunctival congestion and corneal oedema, treat with miotic drops and seek urgent specialist advice.</li><li>Ocular complications are more likely if the product comes into direct contact with the eyes. Instruct&nbsp;the person on the correct administration of their inhaler and warn&nbsp;against the accidental release of its contents into the eye.</li></ul></li></ul><p><strong>Other adverse effects of iptratropium include:</strong></p><ul><li>Laryngospasm</li><li>Pharyngeal oedema.</li><li>Vomiting.</li><li>Ocular accommodation disorder (rarely).</li></ul><p><strong>Other adverse effects of tiptropium include:</strong></p><ul><li>Gingivitis.</li><li>Glossitis.</li><li>Insomnia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field 987ca17a-ee36-4338-a545-a6da01164d2d --><!-- end item 7d573498-98be-4fc6-a869-a6da01164ac3 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 2
            },
            {
              "itemId": "7e7e1d8b-c6d3-4acf-92e2-a6da01165d9d",
              "parentId": "d75dbb2f-d5be-417d-89a7-a6d7016bd4e4",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Drug interactions",
              "htmlHeader": "<!-- begin field 6379b02c-6b1a-42c6-bdeb-a6da01165fe1 --><h3>Drug interactions</h3><!-- end field 6379b02c-6b1a-42c6-bdeb-a6da01165fe1 -->",
              "htmlStringContent": "<!-- begin item 7e7e1d8b-c6d3-4acf-92e2-a6da01165d9d --><!-- begin field c6ba620a-35a2-4531-a7eb-a6da01165fe1 --><ul><li><strong>Beta-<sub>2</sub> agonists and xanthines</strong> &mdash; may produce an additive bronchodilatory effect with ipratropium bromide.</li><li><strong>Other anticholinergic drugs</strong> &mdash; are not recommended to be co-administered with&nbsp;tiotropium bromide as the effects of this have not been studied.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI Medicines Compendium, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 72, 2016</a>]</p><!-- end field c6ba620a-35a2-4531-a7eb-a6da01165fe1 --><!-- end item 7e7e1d8b-c6d3-4acf-92e2-a6da01165d9d -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 3
            }
          ],
          "depth": 2,
          "pos": 4
        },
        {
          "itemId": "b3de6f3f-00cd-4aee-af3c-a6d7016bfc35",
          "parentId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "fullItemName": "Theophylline",
          "htmlHeader": "<!-- begin field 673f7884-2f0e-447d-b672-a6d7016c014b --><h2>Theophylline</h2><!-- end field 673f7884-2f0e-447d-b672-a6d7016c014b -->",
          "htmlStringContent": "<!-- begin item b3de6f3f-00cd-4aee-af3c-a6d7016bfc35 --><!-- end item b3de6f3f-00cd-4aee-af3c-a6d7016bfc35 -->",
          "containerElement": "prescribingInfoSub",
          "children": [
            {
              "itemId": "e221ba2a-d7b0-437a-b49a-a6f700ed2055",
              "parentId": "b3de6f3f-00cd-4aee-af3c-a6d7016bfc35",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Dose",
              "htmlHeader": "<!-- begin field 75dd1359-a62c-44db-a45e-a6f700ed2168 --><h3>Which dose should be given?&nbsp;</h3><!-- end field 75dd1359-a62c-44db-a45e-a6f700ed2168 -->",
              "htmlStringContent": "<!-- begin item e221ba2a-d7b0-437a-b49a-a6f700ed2055 --><!-- begin field 62f41d46-b8dd-4fc4-8c43-a6f700ed2168 --><ul><li><strong>Theophylline can be used as an add-on therapy in the treatment of asthma.</strong></li><li>Theophylline is taken orally and all available brands&nbsp;are modified release preparations.</li><li><strong>When prescribing theophylline, the brand should be specified on the prescription.</strong> Because of differences in bioavailability among brands, people should be maintained on the same brand of theophylline.</li><li><strong>Doses are as follows:</strong><ul><li>Nuelin SA<sup>&reg;&nbsp;</sup>175 tablets &mdash; 175 mg to 350 mg every 12 hours in adults and children aged 12 years and over, 175 mg every 12 hours in children aged 6 to 11 years.</li><li>Nuelin SA<sup>&reg;&nbsp;</sup>250 tablets &mdash; 250 mg to 500 mg every 12 hours in adults and children aged 12 years and over, 125 mg to 250 mg every 12 hours in children aged 6 to 11 years.</li><li>Slo-Phyllin<sup>&reg;</sup> capsules &mdash; 250 mg to 500 mg every 12 hours in adults and children aged 12 years and over, 125&nbsp;mg to 250&nbsp;mg every 12 hours in children aged 6 to 11 years, 60&nbsp;mg to 120&nbsp;mg every 12 hours in children aged 2&nbsp;to 5&nbsp;years.</li><li>Uniphyllin Continus<sup>&reg;</sup> tablets &mdash;200 mg every 12 hours, titrated to a maximum of 400 mg in adults and children aged 12 years and over, 9&nbsp;mg/kg every 12 hours, titrated to a maximum of 200 mg per dose&nbsp;in children aged 2 to 11 years. In some children with chronic asthma, doses can be increased to 10-16 mg/kg every 12 hours, titrated to a maximum of 400 mg per dose.&nbsp;<ul><li>Consider prescribing a larger evening or morning dose to achieve optimum therapeutic effect when symptoms are most severe.</li><li>In people not currently receiving theophylline whose night-time or daytime symptoms persist despite other treatment, the total daily requirement may be given as a single evening or morning dose.</li></ul></li></ul></li><li><strong>Before starting theophylline, check:</strong><ul><li>Urea and electrolyte levels (paying particular attention to potassium levels).</li><li>Liver function.</li></ul></li><li><strong>In most individuals, a plasma-theophylline concentration of 10&ndash;20 mg/litre (55&ndash;110 micromol/litre) is required for satisfactory bronchodilation</strong>, although a lower plasma-theophylline concentration of 5&ndash;15 mg/litre may be effective. Adverse effects can occur within the range 10&ndash;20 mg/litre and both the frequency and severity increase at concentrations above 20 mg/litre.</li><li><strong>Check drug plasma levels:</strong><ul><li>Five days after starting oral treatment.</li><li>Routinely every 6&ndash;12 months. Check more regularly in older people or those with heart failure or hepatic impairment.</li><li>At least 3 days after any dose adjustments.</li><li>If an enzyme-inhibiting drug (such as erythromycin, clarithromycin, allopurinol, or cimetidine) is prescribed (raises plasma levels) or if an enzyme-inducing drug (such as carbamazepine, rifampicin, or St John&#39;s Wort) is prescribed (lowers plasma levels).</li><li>If the person starts or stops smoking &mdash; a dose adjustment may be needed because tobacco can lower the plasma levels of theophylline.</li></ul></li><li><strong>Check potassium levels regularly in people taking theophylline alongside beta-<sub>2 </sub>agonists, corticosteroids, or diuretics, and in all people with severe asthma.</strong> Plasma potassium concentrations may be reduced by beta-<sub>2</sub> agonists, corticosteroids, and diuretics. This effect may be potentiated by theophylline, and further exacerbated by hypoxia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">London and South East Medicines Information Service et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field 62f41d46-b8dd-4fc4-8c43-a6f700ed2168 --><!-- end item e221ba2a-d7b0-437a-b49a-a6f700ed2055 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 0
            },
            {
              "itemId": "00f6def4-a536-422a-b46e-a6da0175b4ba",
              "parentId": "b3de6f3f-00cd-4aee-af3c-a6d7016bfc35",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Contraindications and cautions",
              "htmlHeader": "<!-- begin field 772be6f2-c788-42be-8211-a6da0175bc1e --><h3>Contraindications and cautions</h3><!-- end field 772be6f2-c788-42be-8211-a6da0175bc1e -->",
              "htmlStringContent": "<!-- begin item 00f6def4-a536-422a-b46e-a6da0175b4ba --><!-- begin field 560849bf-d1ce-4715-8c64-a6da0175bc1e --><ul><li><strong>Do not prescribe theophylline to:</strong><ul><li>People with porphyria.</li><li>People with hypersensitivity to xanthines.</li><li>Children concomitantly receiving ephedrine.</li><li>Infants under 6 months of age.</li></ul></li><li><strong>Use theophylline with caution in people with:</strong><ul><li>Cardiovascular disease, including cardiac arrhythmias.</li><li>Hepatic impairment.</li><li>Hyperkalaemia risk.</li><li>Hypertension.</li><li>Hyperthyroidism.</li><li>Peptic ulcers.</li><li>Epilepsy.</li></ul></li><li><strong>Fever decreases the clearance of theophylline.</strong> It may be necessary to decrease the dose in people with acute febrile illness to avoid intoxication.</li><li><strong>The half-life of theophylline may be prolonged in older people, and in those with heart failure, or hepatic impairment.</strong> A reduction in&nbsp;dosage may be necessary to avoid toxic accumulation.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field 560849bf-d1ce-4715-8c64-a6da0175bc1e --><!-- end item 00f6def4-a536-422a-b46e-a6da0175b4ba -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 1
            },
            {
              "itemId": "7f7a7b1b-16bb-4fb6-96a2-a6da0175e626",
              "parentId": "b3de6f3f-00cd-4aee-af3c-a6d7016bfc35",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Adverse effects",
              "htmlHeader": "<!-- begin field d475ca26-c87d-44d7-8881-a6da0175edd0 --><h3>Adverse effects</h3><!-- end field d475ca26-c87d-44d7-8881-a6da0175edd0 -->",
              "htmlStringContent": "<!-- begin item 7f7a7b1b-16bb-4fb6-96a2-a6da0175e626 --><!-- begin field d55c37ff-7a73-493d-9cdf-a6da0175edd0 --><ul><li>The adverse effects of theophylline include nausea (most common), vomiting, tremor, headache, central nervous system stimulation, insomnia, palpitations, arrhythmias, and convulsion (rare).</li><li>Adverse effects can occur with plasma theophylline concentrations of 10 mg/L to 20 mg/L. However, a plasma concentration in this range is required in most people to achieve a satisfactory clinical effect.</li><li>Both the frequency and severity of adverse effects increase when plasma concentrations of theophylline is above 20 mg/L.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field d55c37ff-7a73-493d-9cdf-a6da0175edd0 --><!-- end item 7f7a7b1b-16bb-4fb6-96a2-a6da0175e626 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 2
            },
            {
              "itemId": "e70d47e7-baba-4afa-8066-a6da01761270",
              "parentId": "b3de6f3f-00cd-4aee-af3c-a6d7016bfc35",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Drug interactions",
              "htmlHeader": "<!-- begin field 5f705f3c-ecf5-4240-91cc-a6da017619d0 --><h3>Drug interactions</h3><!-- end field 5f705f3c-ecf5-4240-91cc-a6da017619d0 -->",
              "htmlStringContent": "<!-- begin item e70d47e7-baba-4afa-8066-a6da01761270 --><!-- begin field e0b549e5-b592-4d95-ac25-a6da017619d0 --><ul><li><strong>The key drug interactions with theophylline include:</strong><ul><li><strong>Beta-<sub>2</sub> agonists, corticosteroids, diuretics</strong> &mdash; hypokalaemia may be potentiated.<ul><li>Check serum potassium levels regularly.</li></ul></li><li><strong>Lithium</strong> &mdash; excretion of lithium may be potentiated.<ul><li>Check plasma lithium levels and alter dose if necessary.</li></ul></li><li><strong>Fluvoxamine</strong> &mdash; can raise the plasma level of theophylline.<ul><li>Avoid concomitant use if possible, or halve the theophylline dose and monitor plasma levels.</li></ul></li><li><strong>Plasma levels of theophylline can be altered by concomitant use with liver enzyme-inhibiting drugs</strong> such as verapamil, ciprofloxacin, fluconazole, erythromycin, clarithromycin, allopurinol, or cimetidine, or liver enzyme-inducing drugs such as primidone, phenobarbital, carbamazepine, phenytoin, ritonavir, rifampicin, or St John&#39;s Wort.<ul><li>Check drug plasma levels if any of these are used concomitantly.</li></ul></li></ul></li><li>The person should be made aware that over-the-counter cough and decongestant preparations that contain theophylline (such as Do-Do Chesteze<sup>&reg;</sup>, Franol<sup>&reg;</sup>, and Franol Plus<sup>&reg;</sup>) should be avoided.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field e0b549e5-b592-4d95-ac25-a6da017619d0 --><!-- end item e70d47e7-baba-4afa-8066-a6da01761270 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 3
            }
          ],
          "depth": 2,
          "pos": 5
        },
        {
          "itemId": "acd10a80-cd5b-46a0-8c0b-a6d7016c3582",
          "parentId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
          "fullItemName": "Cromones",
          "htmlHeader": "<!-- begin field 3fa170a2-44a5-42a0-9123-a6d7016c3ae0 --><h2>Cromones</h2><!-- end field 3fa170a2-44a5-42a0-9123-a6d7016c3ae0 -->",
          "htmlStringContent": "<!-- begin item acd10a80-cd5b-46a0-8c0b-a6d7016c3582 --><!-- end item acd10a80-cd5b-46a0-8c0b-a6d7016c3582 -->",
          "containerElement": "prescribingInfoSub",
          "children": [
            {
              "itemId": "b3d0888e-10c5-404b-9f41-a6f700ecf915",
              "parentId": "acd10a80-cd5b-46a0-8c0b-a6d7016c3582",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Dose",
              "htmlHeader": "<!-- begin field ae78eeb7-0265-4d94-aa6f-a6f700ecff0f --><h3>What dose should be given?</h3><!-- end field ae78eeb7-0265-4d94-aa6f-a6f700ecff0f -->",
              "htmlStringContent": "<!-- begin item b3d0888e-10c5-404b-9f41-a6f700ecf915 --><!-- begin field 707749f2-81fc-4a73-bf98-a6f700ecff0f --><ul><li><strong>Cromones (sodium cromoglicate and nedocromil sodium) can be considered as add-on treatments for asthma. They are delivered via pressurized metered dose inhalers</strong>.<ul><li>Advise people that inhaled sodium cromoglicate or nedocromil sodium should be used regularly. Doses are as follows for children aged over 5 years and adults.<ul><li>Sodium cromoglicate - Initially 10 mg four times a day, additional dose may also be taken before exercise, increased if necessary to 10 mg six&nbsp;to eight&nbsp;times a day. Maintenance dose is&nbsp;5 mg four times a day (5 mg is equivalent to one puff).</li><li>Nedocromil sodium- Initially 4 mg four times a day, when control achieved, may be possible to reduce to twice daily (4 mg is equivalent to 2 puffs).&nbsp;</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>] </p><!-- end field 707749f2-81fc-4a73-bf98-a6f700ecff0f --><!-- end item b3d0888e-10c5-404b-9f41-a6f700ecf915 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 0
            },
            {
              "itemId": "7924c31f-2be2-4c22-b1d7-a6db00b60ac0",
              "parentId": "acd10a80-cd5b-46a0-8c0b-a6d7016c3582",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Contraindications and cautions",
              "htmlHeader": "<!-- begin field 9bcd825d-0b99-4a2a-b271-a6db00b60fe9 --><h3>Contraindications and cautions</h3><!-- end field 9bcd825d-0b99-4a2a-b271-a6db00b60fe9 -->",
              "htmlStringContent": "<!-- begin item 7924c31f-2be2-4c22-b1d7-a6db00b60ac0 --><!-- begin field 25023564-d199-475d-9117-a6db00b60fe9 --><ul><li>Cromone therapy should be discontinued if the person develops&nbsp;eosinophilic pneumonia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field 25023564-d199-475d-9117-a6db00b60fe9 --><!-- end item 7924c31f-2be2-4c22-b1d7-a6db00b60ac0 -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 1
            },
            {
              "itemId": "12b79e14-cec9-46d8-8246-a6db00b40fbd",
              "parentId": "acd10a80-cd5b-46a0-8c0b-a6d7016c3582",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Adverse effects",
              "htmlHeader": "<!-- begin field 7fe150e4-d1ad-4efb-9132-a6db00b41505 --><h3>Adverse effects</h3><!-- end field 7fe150e4-d1ad-4efb-9132-a6db00b41505 -->",
              "htmlStringContent": "<!-- begin item 12b79e14-cec9-46d8-8246-a6db00b40fbd --><!-- begin field 200b1977-df16-40de-9570-a6db00b41505 --><ul><li><strong>Adverse effects of cromones include:</strong><ul><li>Mild throat irritation, coughing, and bronchospasm.<ul><li>If inhalation of a cromone causes bronchospasm, advise the person to use their short-acting beta<sub>2</sub>-agonist inhaler (salbutamol or terbutaline) and discontinue cromone treatment.</li></ul></li><li>Headache and rhinitis have also been reported in clinical trials.</li><li>Hypersensitivity reactions, including angioedema, bronchospasm, hypotension and collapse have been reported extremely rarely&nbsp;in patients using inhaled sodium cromoglicate.</li><li>Very rare cases of eosinophilic pneumonia have been reported.</li></ul></li><li><strong>Adverse effects of nedocromil sodium also include:</strong><ul><li>Abdominal pain, vomiting, nausea.</li><li>Dyspepsia.</li><li>Altered sense of taste.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">ABPI, 2014b</a>]</p><!-- end field 200b1977-df16-40de-9570-a6db00b41505 --><!-- end item 12b79e14-cec9-46d8-8246-a6db00b40fbd -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 2
            },
            {
              "itemId": "970d1bf1-38c5-4df6-8d17-a6db00b6427f",
              "parentId": "acd10a80-cd5b-46a0-8c0b-a6d7016c3582",
              "rootId": "baacfbc5-ee97-4d5f-a5a3-b492048eebab",
              "fullItemName": "Drug interactions",
              "htmlHeader": "<!-- begin field 45aede2c-1ada-4760-863d-a6db00b6471c --><h3>Drug interactions</h3><!-- end field 45aede2c-1ada-4760-863d-a6db00b6471c -->",
              "htmlStringContent": "<!-- begin item 970d1bf1-38c5-4df6-8d17-a6db00b6427f --><!-- begin field 028321b5-a47e-4fcc-9f03-a6db00b6471c --><ul><li>No harmful drug interactions have been observed with cromones.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BNF 75, 2018</a>]</p><!-- end field 028321b5-a47e-4fcc-9f03-a6db00b6471c --><!-- end item 970d1bf1-38c5-4df6-8d17-a6db00b6427f -->",
              "containerElement": "prescribingInfoSub",
              "children": [],
              "depth": 3,
              "pos": 3
            }
          ],
          "depth": 2,
          "pos": 6
        }
      ],
      "depth": 1,
      "pos": 7
    },
    {
      "itemId": "f7bb5e69-1969-4ede-80be-360b30138104",
      "parentId": null,
      "rootId": "f7bb5e69-1969-4ede-80be-360b30138104",
      "fullItemName": "Supporting evidence",
      "htmlHeader": "<!-- begin field 192daf12-d46c-46bb-9b4f-fa3db6f8dc83 --><h1>Supporting evidence</h1><!-- end field 192daf12-d46c-46bb-9b4f-fa3db6f8dc83 -->",
      "htmlStringContent": "<!-- begin item f7bb5e69-1969-4ede-80be-360b30138104 --><!-- begin field 60590230-02c1-4120-bbdf-0d8c7f849c48 --><p>This CKS&nbsp;topic is largely based on the&nbsp;British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines&nbsp;Network (SIGN)&nbsp;<em>British guideline on the management of asthma </em>[<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">BTS/SIGN, 2016</a>], and the National Institute of Health and Care Excellence guideline <em>Asthma: diagnosis, monitoring and chronic asthma management</em> [<a class=\"bibliography-reference internal-reference\" href=\"#4292b777-4c53-411b-ad77-95f72ba7bc7b\">NICE, 2017a</a>]. The recommendations relevant to primary care were mostly developed from the expert opinion of the guideline development group following narrative reviews of the evidence, where available. The evidence for specialist management strategies is not discussed as they are beyond the scope of this CKS topic.</p><!-- end field 60590230-02c1-4120-bbdf-0d8c7f849c48 --><!-- end item f7bb5e69-1969-4ede-80be-360b30138104 -->",
      "containerElement": "evidence",
      "children": [],
      "depth": 1,
      "pos": 8
    },
    {
      "itemId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
      "parentId": null,
      "rootId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
      "fullItemName": "How this topic was developed",
      "htmlHeader": "<!-- begin field 10a248d3-4252-4303-bcb1-a7f201453858 --><h1>How this topic was developed</h1><!-- end field 10a248d3-4252-4303-bcb1-a7f201453858 -->",
      "htmlStringContent": "<!-- begin item 8e8a8d5c-a47d-4361-988a-a7f201442a8d --><!-- begin field 2085cd39-718a-482d-8c29-a7f201453858 --><p>This section briefly describes the processes used in developing and updating this topic. Further details on the full process can be found in the <a href=\"http://cks.nice.org.uk/development\" data-hyperlink-id=\"45dd8ecd-d177-47e0-be7e-a8f70154ffca\">About Us</a> section and on the <a href=\"https://clarity.co.uk/\" data-hyperlink-id=\"bbc3a7f1-98d5-4675-9fb5-a8f70154ffd5\">Clarity Informatics</a> website.</p><!-- end field 2085cd39-718a-482d-8c29-a7f201453858 --><!-- end item 8e8a8d5c-a47d-4361-988a-a7f201442a8d -->",
      "containerElement": "howthistopicwasdeveloped",
      "children": [
        {
          "itemId": "bb41dc52-89c2-4208-860e-a7f2014ba6a8",
          "parentId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "rootId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "fullItemName": "Search strategy",
          "htmlHeader": "<!-- begin field cbbd085d-0c88-48a9-bc4a-a7f2014cf031 --><h2>Search strategy</h2><!-- end field cbbd085d-0c88-48a9-bc4a-a7f2014cf031 -->",
          "htmlStringContent": "<!-- begin item bb41dc52-89c2-4208-860e-a7f2014ba6a8 --><!-- begin field aa93b85b-12d9-457c-a7cf-a7f2014cf031 --><h2>Scope of search</h2><!-- end field aa93b85b-12d9-457c-a7cf-a7f2014cf031 --><!-- begin field 910002f3-9448-423d-b867-a7f2014cf031 --><p>A literature search was conducted for guidelines, systematic reviews and randomized controlled trials on primary care management of asthma.</p><!-- end field 910002f3-9448-423d-b867-a7f2014cf031 --><!-- begin field b5d2a1d3-339b-4c4d-aeef-a7f2014cf031 --><h2>Search dates</h2><!-- end field b5d2a1d3-339b-4c4d-aeef-a7f2014cf031 --><!-- begin field efd179b7-87c0-4892-909d-a7f2014cf031 --><p>December 2016 - March 2018</p><!-- end field efd179b7-87c0-4892-909d-a7f2014cf031 --><!-- begin field 466b0438-9139-4c09-88b7-a7f2014cf031 --><h2>Key search terms</h2><!-- end field 466b0438-9139-4c09-88b7-a7f2014cf031 --><!-- begin field 81e34ddc-d32f-4c34-8aff-a7f2014cf031 --><p>Various combinations of searches were carried out. The terms listed below are the core search terms that were used for EBSCO Medline.</p><ul><li>(MH &quot;Asthma+&quot;)</li><li>(AB asthma* OR TI asthma*)</li></ul><!-- end field 81e34ddc-d32f-4c34-8aff-a7f2014cf031 --><!-- begin field fe009f36-c183-4812-a29a-a7f2014cf031 --><h2>Sources of guidelines</h2><!-- end field fe009f36-c183-4812-a29a-a7f2014cf031 --><!-- begin field 7ed1dffe-617e-480c-a8d9-a7f2014cf031 --><ul>    <li><a href=\"http://www.nice.org.uk/\" data-hyperlink-id=\"bb81c0ce-5bf9-46f2-bd5e-a8f701597323\">National Institute for Health and Care Excellence (NICE)</a></li>    <li><a href=\"http://www.sign.ac.uk/\" data-hyperlink-id=\"27e70c9c-d026-4d69-bfb3-a8f70159732c\">Scottish Intercollegiate Guidelines Network (SIGN)</a></li>    <li><a href=\"http://www.rcplondon.ac.uk/\" data-hyperlink-id=\"c0d451d9-69f9-4312-9760-a8f701597330\">Royal College of Physicians</a></li>    <li><a href=\"http://www.rcgp.org.uk/\" data-hyperlink-id=\"471d3c3d-4d22-4603-b66a-a8f701597368\">Royal College of General Practitioners</a></li>    <li><a href=\"http://www.rcn.org.uk/development/practice/clinicalguidelines\" data-hyperlink-id=\"176d1c87-5343-49ee-a6c7-a8f7015973e2\">Royal College of Nursing</a></li>    <li><a href=\"https://www.evidence.nhs.uk/topics/\" data-hyperlink-id=\"38c143d4-af0f-42bd-8095-a8f70159744a\">NICE Evidence</a></li>    <li><a href=\"http://www.hpa.org.uk/\" data-hyperlink-id=\"7cea9d17-ed31-43da-8e11-a8f701597482\">Health Protection Agency</a></li>    <li><a href=\"http://www.who.int/\" data-hyperlink-id=\"716fb4fd-37c0-41f7-b067-a8f7015974a7\">World Health Organization</a></li>    <li><a href=\"http://www.guideline.gov/\" data-hyperlink-id=\"11b4bf0e-6bf0-4d08-8fc4-a8f7015974ac\">National Guidelines Clearinghouse</a></li>    <li><a href=\"http://www.g-i-n.net/\" data-hyperlink-id=\"d7753fbf-8489-46a9-941d-a8f70159754b\">Guidelines International Network</a></li>    <li><a href=\"http://www.tripdatabase.com/\" data-hyperlink-id=\"1e8f2d8c-7452-4bcd-96ae-a8f701597588\">TRIP database</a></li>    <li><a href=\"http://www.gain-ni.org/index.php/audits/guidelines\" data-hyperlink-id=\"0844ac30-f229-489a-8157-a8f701597597\">GAIN</a></li>    <li><a href=\"http://www.pathways.scot.nhs.uk/\" data-hyperlink-id=\"a7e202ed-db37-4e72-9eb2-a8f7015975ea\">NHS Scotland National Patient Pathways</a></li>    <li><a href=\"http://www.nzgg.org.nz/\" data-hyperlink-id=\"077dce47-474d-46f5-8a4a-a8f7015975f3\">New Zealand Guidelines Group</a></li>    <li><a href=\"http://www.ahrq.gov/\" data-hyperlink-id=\"f67ad398-d6ee-49e5-bc13-a8f7015976e3\">Agency for Healthcare Research and Quality</a></li>    <li><a href=\"http://www.icsi.org/\" data-hyperlink-id=\"a3ec76b3-3e9d-4d71-8c0f-a8f7015976f5\">Institute for Clinical Systems Improvement</a></li>    <li><a href=\"http://www.nhmrc.gov.au/publications/index.htm\" data-hyperlink-id=\"4b5b2cd3-a026-4382-976d-a8f7015977ad\">National Health and Medical Research Council (Australia)</a></li>    <li><a href=\"http://www.racgp.org.au/your-practice/guidelines/\" data-hyperlink-id=\"f99b96e3-ff75-467b-a8aa-a8f701597c9e\">Royal Australian College of General Practitioners</a></li>    <li><a href=\"http://www.health.gov.bc.ca/gpac/index.html\" data-hyperlink-id=\"7349d343-bc42-4e2c-b887-a8f701597e52\">British Columbia Medical Association</a></li>    <li><a href=\"http://www.cma.ca/index.php/ci_id/54316/la_id/1.htm\" data-hyperlink-id=\"a4eb22de-5eb1-4654-b2aa-a8f701597fe5\">Canadian Medical Association</a></li>    <li><a href=\"http://www.topalbertadoctors.org/cpgs.php\" data-hyperlink-id=\"c6913518-e882-4554-bd91-a8f701598117\">Alberta Medical Association</a></li>    <li><a href=\"http://ocpd.med.umich.edu/cme/self-study/\" data-hyperlink-id=\"b55f0374-ea36-451c-b55b-a8f7015981e4\">University of Michigan Medical School</a></li>    <li><a href=\"http://mqic.org/guidelines.htm\" data-hyperlink-id=\"647ba059-a7dc-4664-a223-a8f701598225\">Michigan Quality Improvement Consortium</a></li>    <li><a href=\"http://www.moh.gov.sg/content/moh_web/home/Publications/guidelines/cpg.html\" data-hyperlink-id=\"ac39a977-0778-4714-90f9-a8f701598262\">Singapore Ministry of Health</a></li>    <li><a href=\"http://www.nric.org.uk/\" data-hyperlink-id=\"d6ee7884-91e2-4d6c-be35-a8f7015984ba\">National Resource for Infection Control</a></li>    <li><a href=\"http://www.patient.co.uk/guidelines.asp\" data-hyperlink-id=\"4b716c3c-da67-47c6-9b4d-a8f7015984c9\">Patient UK Guideline links</a></li>    <li><a href=\"http://www2.warwick.ac.uk/fac/med/research/hsri/emergencycare/jrcalc_2006/guidelines/\" data-hyperlink-id=\"9ea846b6-b888-4c31-9ce1-a8f7015984fc\">UK Ambulance Service Clinical Practice Guidelines</a></li>    <li><a href=\"http://www.refhelp.scot.nhs.uk/index.php?option=com_content&amp;task=view&amp;id=490&amp;Itemid=104\" data-hyperlink-id=\"4fcf86cd-8b5c-410b-8d27-a8f701598551\">RefHELP NHS Lothian Referral Guidelines</a></li>    <li>Medline (with guideline filter)</li>    <li><a href=\"http://www.dft.gov.uk/dvla/medical/ataglance.aspx\" data-hyperlink-id=\"e8b468e1-8c19-4d27-b74d-a8f7015985d5\">Driver and Vehicle Licensing Agency</a></li>    <li><a href=\"http://www.nhshealthatwork.co.uk/oh-guidelines.asp\" data-hyperlink-id=\"fb3109c5-b1f7-4fc7-ae70-a8f7015985f4\">NHS Health at Work</a>(occupational health practice)</li></ul><!-- end field 7ed1dffe-617e-480c-a8d9-a7f2014cf031 --><!-- begin field 68f20566-aba6-4095-ad79-a7f2014cf031 --><h2>Sources of systematic reviews and meta-analyses</h2><!-- end field 68f20566-aba6-4095-ad79-a7f2014cf031 --><!-- begin field 9ffe9b58-a21c-4fd5-b70e-a7f2014cf031 --><ul>    <li><a href=\"http://www.thecochranelibrary.com/\" data-hyperlink-id=\"cd8bbc46-b901-4174-889b-a8f7015140fd\">The Cochrane Library</a>:    <ul>        <li>Systematic reviews</li>        <li>Protocols</li>        <li>Database of Abstracts of Reviews of Effects</li>    </ul>    </li>    <li>Medline (with systematic review filter)</li>    <li>EMBASE (with systematic review filter)</li></ul><!-- end field 9ffe9b58-a21c-4fd5-b70e-a7f2014cf031 --><!-- begin field 34c8e647-e3d6-4169-b723-a7f2014cf031 --><h2>Sources of health technology assessments and economic appraisals</h2><!-- end field 34c8e647-e3d6-4169-b723-a7f2014cf031 --><!-- begin field d9967046-da2b-45aa-b2be-a7f2014cf031 --><ul>    <li><a href=\"http://www.hta.ac.uk/\" data-hyperlink-id=\"d78355f0-cce3-4c05-911c-a8f701566e4b\">NIHR Health Technology Assessment programme</a></li>    <li><a href=\"http://www.thecochranelibrary.com/\" data-hyperlink-id=\"e349f8c1-0b89-479f-8365-a8f701566e4b\">The Cochrane Library</a>:    <ul>        <li>NHS Economic Evaluations</li>        <li>Health Technology Assessments</li>    </ul>    </li>    <li><a href=\"http://www.cadth.ca/\" data-hyperlink-id=\"ef36fd7e-d06c-4d3d-acdb-a8f701566f11\">Canadian Agency for Drugs and Technologies in Health</a></li>    <li><a href=\"http://www.inahta.org/\" data-hyperlink-id=\"532271f8-b46c-4736-865b-a8f701566fcf\">International Network of Agencies for Health Technology Assessment</a></li></ul><!-- end field d9967046-da2b-45aa-b2be-a7f2014cf031 --><!-- begin field b8ea0141-6f1f-4c5d-9d7a-a7f2014cf031 --><h2>Sources of randomized controlled trials</h2><!-- end field b8ea0141-6f1f-4c5d-9d7a-a7f2014cf031 --><!-- begin field c40bb5e1-8ad6-4944-afd4-a7f2014cf031 --><ul>    <li><a href=\"http://www.thecochranelibrary.com/\" data-hyperlink-id=\"c5002ac0-ba43-4966-b5a6-a8f7015f5f64\">The Cochrane Library</a>:    <ul>        <li>Central Register of Controlled Trials</li>    </ul>    </li>    <li>Medline (with randomized controlled trial filter)</li>    <li>EMBASE (with randomized controlled trial filter)</li></ul><!-- end field c40bb5e1-8ad6-4944-afd4-a7f2014cf031 --><!-- begin field c5c63dcf-0d4f-4bcb-8646-a7f2014cf031 --><h2>Sources of evidence based reviews and evidence summaries</h2><!-- end field c5c63dcf-0d4f-4bcb-8646-a7f2014cf031 --><!-- begin field 85963c77-ade5-4bfc-8a28-a7f2014cf031 --><ul>    <li><a href=\"http://www.medicine.ox.ac.uk/bandolier/\" data-hyperlink-id=\"a7582de5-eef6-45e1-b921-a8f701508481\">Bandolier</a></li>    <li><a href=\"http://dtb.bmj.com/\" data-hyperlink-id=\"ef2466ed-9794-4c3f-8c9b-a8f701508486\"> Drug & amp; Therapeutics Bulletin</a></li>    <li><a href=\"http://www.tripdatabase.com/\" data-hyperlink-id=\"b2dc6e1c-5b1a-4830-a9f8-a8f70150848a\"> TRIP database</a></li>    <li><a href=\"http://www.medicinesni.com/courses/type.asp?ID=CN\" data-hyperlink-id=\"e9c7e620-873b-43ac-8203-a8f701508495\"> Central Services Agency COMPASS Therapeutic Notes</a></li></ul><!-- end field 85963c77-ade5-4bfc-8a28-a7f2014cf031 --><!-- begin field 561a89c2-ab1d-43a0-82bc-a7f2014cf031 --><h2>Sources of national policy</h2><!-- end field 561a89c2-ab1d-43a0-82bc-a7f2014cf031 --><!-- begin field d56f2771-a762-47c9-98a1-a7f2014cf031 --><ul>    <li><a href=\"http://www.dh.gov.uk/\" data-hyperlink-id=\"9193cbff-c791-44b6-904e-a8f70152e39c\">Department of Health</a></li>    <li>Health Management Information Consortium(HMIC)</li></ul><!-- end field d56f2771-a762-47c9-98a1-a7f2014cf031 --><!-- begin field e6cfac38-a5ee-438d-b988-a7f2014cf031 --><h2>Patient experiences</h2><!-- end field e6cfac38-a5ee-438d-b988-a7f2014cf031 --><!-- begin field 9e82097e-ba8f-4316-96e2-a7f2014cf031 --><ul>    <li><a href=\"http://www.healthtalkonline.org/\" data-hyperlink-id=\"9ff8b875-a711-48ff-9f27-a8f7015da924\">Healthtalkonline</a></li>    <li><a href=\"http://www.bmj.com/bmj-series/patient-journeys\" data-hyperlink-id=\"18b80b12-2ea0-4819-b3ff-a8f7015dad28\"> BMJ - Patient Journeys</a></li>    <li><a href=\"http://www.patient.co.uk/selfhelp.asp\" data-hyperlink-id=\"2cea52cd-27a3-4129-91d6-a8f7015dad6d\"> Patient.co.uk - Patient Support Groups</a></li></ul><!-- end field 9e82097e-ba8f-4316-96e2-a7f2014cf031 --><!-- begin field 230b9c7f-4d24-41d3-868c-a7f2014cf031 --><h2>Sources of medicines information</h2><!-- end field 230b9c7f-4d24-41d3-868c-a7f2014cf031 --><!-- begin field 3057e7d0-693e-4403-bf32-a7f2014cf031 --><p>The following sources are used by CKS pharmacists and are not necessarily searched by CKS information specialists for all topics. Some of these resources are not freely available and require subscriptions to access content.</p><ul>    <li><a href=\"http://www.evidence.nhs.uk/formulary/bnf/current\" data-hyperlink-id=\"8a812faa-0403-43cf-832d-a8f7015d277c\">British National Formulary</a>(BNF)</li>    <li><a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"3c711c8e-77b1-4877-867d-a8f7015d2781\">electronic Medicines Compendium</a>(eMC)</li>    <li><a href=\"http://www.ema.europa.eu/ema/\" data-hyperlink-id=\"b016dc55-0a25-4cc0-89e4-a8f7015d2817\">European Medicines Agency</a>(EMEA)</li>    <li><a href=\"http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT\" data-hyperlink-id=\"b0687b86-58e4-40ed-9f5c-a8f7015d2820\">LactMed</a></li>    <li><a href=\"http://www.mhra.gov.uk/index.htm\" data-hyperlink-id=\"15e3e40a-fc85-4202-9dd6-a8f7015d2abe\">Medicines and Healthcare products Regulatory Agency</a>(MHRA)</li>    <li><a href=\"http://www.reprotox.org/Default.aspx\" data-hyperlink-id=\"a09aad85-88bd-4ca4-bdf1-a8f7015d2acd\">REPROTOX</a></li>    <li><a href=\"http://www.scottishmedicines.org.uk/Home\" data-hyperlink-id=\"b29a92d3-8d70-4862-87d2-a8f7015d2ce3\">Scottish Medicines Consortium</a></li>    <li><a href=\"https://www.medicinescomplete.com/mc/stockley/current/login.htm?uri=http%3A%2F%2Fwww.medicinescomplete.com%2Fmc%2Fstockley%2Fcurrent%2F\" data-hyperlink-id=\"e74d619b-8693-4bbe-9e26-a8f7015d2e1d\">Stockley&#39;s Drug Interactions</a></li>    <li><a href=\"http://depts.washington.edu/terisweb/teris/\" data-hyperlink-id=\"9380c21f-f06e-4a3b-bf9c-a8f7015d3046\">TERIS</a></li>    <li><a href=\"http://www.toxbase.org/\" data-hyperlink-id=\"40caac46-2b39-41c7-9919-a8f7015d310c\">TOXBASE</a></li>    <li><a href=\"http://www.micromedex.com/products/hcs/\" data-hyperlink-id=\"de806832-3cf9-45e8-a381-a8f7015d311e\">Micromedex</a></li>    <li><a href=\"http://www.ukmi.nhs.uk/\" data-hyperlink-id=\"d9d0d555-2ebb-4bd3-ab0c-a8f7015d31ed\">UK Medicines Information</a></li></ul><!-- end field 3057e7d0-693e-4403-bf32-a7f2014cf031 --><!-- end item bb41dc52-89c2-4208-860e-a7f2014ba6a8 -->",
          "containerElement": "searchstrategy",
          "children": [],
          "depth": 2,
          "pos": 0
        },
        {
          "itemId": "3750f351-26f8-49a9-9b36-a7f20174d91e",
          "parentId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "rootId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "fullItemName": "Stakeholder engagement",
          "htmlHeader": "<!-- begin field af2edf48-ef87-4ba6-93de-a7f20176245a --><h2>Stakeholder engagement</h2><!-- end field af2edf48-ef87-4ba6-93de-a7f20176245a -->",
          "htmlStringContent": "<!-- begin item 3750f351-26f8-49a9-9b36-a7f20174d91e --><!-- begin field b11f4790-c3c4-4eca-9f55-a7f20176245a --><h2>Our policy</h2><!-- end field b11f4790-c3c4-4eca-9f55-a7f20176245a --><!-- begin field ce35c257-f9c7-4590-999d-a7f20176245a --><p>The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:</p><ul><li>Clinical accuracy.</li><li>Consistency with other providers of clinical knowledge for primary care.</li><li>Accuracy of implementation of national guidance (in particular NICE guidelines).</li><li>Usability.</li></ul><!-- end field ce35c257-f9c7-4590-999d-a7f20176245a --><!-- begin field 06dea246-8452-49b2-8cc4-a7f20176245a --><h2>Principles of the consultation process</h2><!-- end field 06dea246-8452-49b2-8cc4-a7f20176245a --><!-- begin field 2f8cd627-c6d9-41a7-8464-a7f20176245a --><ul><li>The process is inclusive and any individual may participate.</li><li>To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.</li><li>Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.</li><li>Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.</li><li>External reviewers are not paid for commenting on the draft topics.</li><li>Discussion with an individual or an organization about the CKS&nbsp;response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).</li><li>All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.</li><li>All reviewers are invited to be acknowledged on the website.All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.</li></ul><!-- end field 2f8cd627-c6d9-41a7-8464-a7f20176245a --><!-- begin field 32889156-bc80-4c6d-b7df-a7f20176245a --><h2>Stakeholders</h2><!-- end field 32889156-bc80-4c6d-b7df-a7f20176245a --><!-- begin field bcb18501-134e-4d82-be1d-a7f20176245a --><ul><li>Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the <a href=\"http://cks.clarity.co.uk/get-involved/\" data-hyperlink-id=\"3c2d5a86-d30a-4aae-8fed-a8f70163c117\">Getting involved</a> section of the <a href=\"https://clarity.co.uk/\" data-hyperlink-id=\"7f0a22f6-202b-4a9d-841b-a8f70163c53b\">Clarity Informatics</a> website.</li><li>Stakeholders identified from the following groups are invited to review draft topics:<ul><li>Experts in the topic area.</li><li>Professional organizations and societies(for example, Royal Colleges).</li><li>Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer&rsquo;s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.</li><li>Guideline development groups where the topic is an implementation of a guideline.</li><li>The British National Formulary team.</li><li>The editorial team that develop MeReC Publications.</li></ul></li><li>Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.</li></ul><!-- end field bcb18501-134e-4d82-be1d-a7f20176245a --><!-- begin field 03b0d49b-c4c1-459a-9530-a7f20176245a --><h2>Patient engagement</h2><!-- end field 03b0d49b-c4c1-459a-9530-a7f20176245a --><!-- begin field b31428de-b72f-4223-9cab-a7f20176245a --><p>Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:</p><ul><li>Topic selection</li><li>Scoping of topic</li><li>Selection of clinical scenarios</li><li>First draft internal review</li><li>Second draft internal review</li><li>External review</li><li>Final draft and pre-publication</li></ul><p>Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.</p><!-- end field b31428de-b72f-4223-9cab-a7f20176245a --><!-- end item 3750f351-26f8-49a9-9b36-a7f20174d91e -->",
          "containerElement": "stakeholderengagement",
          "children": [],
          "depth": 2,
          "pos": 1
        },
        {
          "itemId": "f7167159-db69-48c2-9dd8-a7f20187a3cf",
          "parentId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "rootId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "fullItemName": "Evidence exclusion criteria",
          "htmlHeader": "<!-- begin field 2ad3fb1b-00f7-4c03-84a1-a7f20188f336 --><h2>Evidence exclusion criteria</h2><!-- end field 2ad3fb1b-00f7-4c03-84a1-a7f20188f336 -->",
          "htmlStringContent": "<!-- begin item f7167159-db69-48c2-9dd8-a7f20187a3cf --><!-- begin field d946b25e-9a91-4b96-89f5-a7f20188f336 --><h2>Our policy</h2><!-- end field d946b25e-9a91-4b96-89f5-a7f20188f336 --><!-- begin field 18dcd72c-8915-4ea9-97aa-a7f20188f336 --><p>Scoping a literature search, and reviewing the evidence for CKS is a methodical and systematic process that is carried out by the lead clinical author for each topic. Relevant evidence is gathered in order that the clinical author can make fully informed decisions and recommendations. It is important to note that some evidence may be excluded for a variety of reasons. These reasons may be applied across all CKS topics or may be specific to a given topic.</p><p>Studies identified during literature searches are reviewed to identify the most appropriate information to author a CKS topic, ensuring any recommendations are based on the best evidence. We use the principles of the GRADE and PICOT approaches to assess the quality of published research. We use the principles of AGREE II to assess the quality of published guidelines.</p><!-- end field 18dcd72c-8915-4ea9-97aa-a7f20188f336 --><!-- begin field 5175732d-0983-47e5-9885-a7f20188f336 --><h2>Standard exclusions for scoping literature:</h2><!-- end field 5175732d-0983-47e5-9885-a7f20188f336 --><!-- begin field a003b96c-ba4b-4330-abfe-a7f20188f336 --><ul><li>Animal studies</li><li>Original research is not written in English</li></ul><!-- end field a003b96c-ba4b-4330-abfe-a7f20188f336 --><!-- begin field 2a74cb39-3dd6-443a-ab4a-a7f20188f336 --><h2>Possible exclusions for reviewed literature:</h2><!-- end field 2a74cb39-3dd6-443a-ab4a-a7f20188f336 --><!-- begin field 6be7b24e-9c32-418a-aa7e-a7f20188f336 --><ul><li>Sample size too small or study underpowered</li><li>Bias evident or promotional literature</li><li>Population not relevant</li><li>Intervention/treatment not relevant</li><li>Outcomes not relevant</li><li>Outcomes have no clear evidence of clinical effectiveness</li><li>Setting not relevant</li><li>Not relevant to UK</li><li>Incorrect study type</li><li>Review article</li><li>Duplicate reference</li></ul><!-- end field 6be7b24e-9c32-418a-aa7e-a7f20188f336 --><!-- end item f7167159-db69-48c2-9dd8-a7f20187a3cf -->",
          "containerElement": "evidenceexclusioncriteria",
          "children": [],
          "depth": 2,
          "pos": 2
        },
        {
          "itemId": "3555b547-2c4a-4bf9-9de6-a7f3000c45d5",
          "parentId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "rootId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "fullItemName": "Organizational, behavioural and financial barriers",
          "htmlHeader": "<!-- begin field 2126aa0b-55d8-4090-9003-a7f3000d97ea --><h2>Organizational, behavioural and financial barriers</h2><!-- end field 2126aa0b-55d8-4090-9003-a7f3000d97ea -->",
          "htmlStringContent": "<!-- begin item 3555b547-2c4a-4bf9-9de6-a7f3000c45d5 --><!-- begin field afb652ab-c693-4d89-ae13-a7f3000d97ea --><h2>Our policy</h2><!-- end field afb652ab-c693-4d89-ae13-a7f3000d97ea --><!-- begin field 6d4ce1b0-33d3-4e6e-9b3c-a7f3000d97ea --><p>The CKS&nbsp;literature searches take into consideration the following concepts, which are discussed at the initial scoping of the topic.</p><ul><li>Feasibility<ul><li>Studies are selected depending on whether the intervention under investigation is available in the NHS and can be practically and safely undertaken in primary care.</li></ul></li><li>Organizational and Financial Impact Analysis</li><li>Studies are selected and evaluated on whether the intervention under investigations may have an impact on local clinical service provision or national impact on cost for the NHS. The principles of clinical budget impact analysis are adhered to, evaluated and recorded by the author. The following factors are considered when making this assessment and analysis.<ul><li>Eligible population</li><li>Current interventions</li><li>Likely uptake of new intervention or recommendation</li><li>Cost of the current or new intervention mix</li><li>Impact on other costs</li><li>Condition-related costs</li><li>In-direct costs and service impacts</li><li>Time dependencies</li></ul></li><li>Cost-effectiveness or cost-benefit analysis studies are identified where available.&nbsp;</li></ul><p>We also evaluate and include evidence from NICE accredited sources which provide economic evaluations of recommendations, such as NICE guidelines.&nbsp;When a recommended action may not be possible because of resource constraints, this is explicitly indicated to healthcare professionals by the wording of the CKS recommendation.</p><!-- end field 6d4ce1b0-33d3-4e6e-9b3c-a7f3000d97ea --><!-- end item 3555b547-2c4a-4bf9-9de6-a7f3000c45d5 -->",
          "containerElement": "organizationalbehaviouralandfinancialbarriers",
          "children": [],
          "depth": 2,
          "pos": 3
        },
        {
          "itemId": "6548d842-46f1-46dc-8cad-a7f30015bd73",
          "parentId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "rootId": "8e8a8d5c-a47d-4361-988a-a7f201442a8d",
          "fullItemName": "Declarations of interest",
          "htmlHeader": "<!-- begin field e69f8993-aaa4-413a-a691-a7f3001729a3 --><h2>Declarations of interest</h2><!-- end field e69f8993-aaa4-413a-a691-a7f3001729a3 -->",
          "htmlStringContent": "<!-- begin item 6548d842-46f1-46dc-8cad-a7f30015bd73 --><!-- begin field 4ff5fbdc-b6f3-4857-9f1b-a7f3001729a3 --><h2>Our policy</h2><!-- end field 4ff5fbdc-b6f3-4857-9f1b-a7f3001729a3 --><!-- begin field 020565fe-6d37-4b7e-bc80-a7f3001729a3 --><p>Clarity Informatics requests that all those involved in the writing and reviewing of topics, and those involved in the external review process to declare any competing interests. Signed copies are securely held by Clarity Informatics and are available on request with the permission of the individual. A copy of the declaration of interest form which participants are asked to complete annually is also available on request. A brief outline of the declarations of interest policy is described here and full details of the policy is available on the <a href=\"https://cks.clarity.co.uk/\" data-hyperlink-id=\"c897429b-dd48-4f95-b6d1-a8f701510b5b\">Clarity Informatics website</a>. Declarations of interests of the authors are not routinely published, however competing interests of all those involved in the topic update or development are listed below. Competing interests include:</p><ul><li>Personal financial interests</li><li>Personal family interest</li><li>Personal non-financial interest</li><li>Non-personal financial gain or benefit</li></ul><p>Although particular attention is given to interests that could result in financial gains or losses for the individual, competing interests may also arise from academic competition or for political, personal, religious, and reputational reasons.An individual is not obliged to seek out knowledge of work done for, or on behalf of, the healthcare industry within the departments for which they are responsible if they would not normally expect to be informed.</p><!-- end field 020565fe-6d37-4b7e-bc80-a7f3001729a3 --><!-- begin field e6dc89f7-ff11-4df6-987d-a7f3001729a3 --><h2>Who should declare competing interests?</h2><!-- end field e6dc89f7-ff11-4df6-987d-a7f3001729a3 --><!-- begin field 040eed27-384e-400c-bc14-a7f3001729a3 --><p>Any individual (or organization) involved in developing, reviewing, or commenting on clinical content, particularly the recommendations should declare competing interests. This includes the authoring team members, expert advisers, external reviewers of draft topics, individuals providing feedback on published topics, and Editorial Steering Group members. Declarations of interest are completed annually for authoring team and editorial steering group members, and are completed at the start of the topic update and development process for external stakeholders.</p><!-- end field 040eed27-384e-400c-bc14-a7f3001729a3 --><!-- begin field 92ec902f-cfb6-4858-809a-a7f3001729a3 --><h2>Competing interests declared for this topic:</h2><!-- end field 92ec902f-cfb6-4858-809a-a7f3001729a3 --><!-- begin field 74269d00-b9b5-4d6d-9457-a7f3001729a3 --><p>None.</p><!-- end field 74269d00-b9b5-4d6d-9457-a7f3001729a3 --><!-- end item 6548d842-46f1-46dc-8cad-a7f30015bd73 -->",
          "containerElement": "declarationsofinterest",
          "children": [],
          "depth": 2,
          "pos": 4
        }
      ],
      "depth": 1,
      "pos": 10
    },
    {
      "itemId": "4292b777-4c53-411b-ad77-95f72ba7bc7b",
      "parentId": null,
      "rootId": "4292b777-4c53-411b-ad77-95f72ba7bc7b",
      "fullItemName": "References",
      "htmlHeader": "<!-- begin field 3e8069dd-18bc-44dc-bb07-cd9684dc869d --><h1>References</h1><!-- end field 3e8069dd-18bc-44dc-bb07-cd9684dc869d -->",
      "htmlStringContent": "<!-- begin item 4292b777-4c53-411b-ad77-95f72ba7bc7b --><!-- begin field 024827b7-afdb-4e29-ba76-8b7b1c808b6b --><ul class=\"bibliography\"><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2015a</span>) <em><span property=\"dc:title\">SPC for Bricanyl Turbohaler, 0.5mg/dose, inhalation powder.</span></em> <em property=\"dc:publisher\">AstraZeneca UK Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"http://www.medicines.org.uk\" target=\"_blank\" class=\"website\">www.medicines.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/medicine/160\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2015b</span>) <em><span property=\"dc:title\">SPC for Atrovent Inhaler CFC-Free.</span></em> <em property=\"dc:publisher\">Boehringer Ingelheim Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"http://www.medicines.org.uk\" target=\"_blank\" class=\"website\">www.medicines.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/medicine/14332\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2015c</span>) <em><span property=\"dc:title\">SPC for Spiriva Respimat 2.5 microgram, inhalation solution.</span></em> <em property=\"dc:publisher\">Boehringer Ingelheim Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"http://www.medicines.org.uk\" target=\"_blank\" class=\"website\">www.medicines.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/medicine/20134\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2014a</span>) <em><span property=\"dc:title\">SPC for Tilade CFC-Free Inhaler.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"http://www.medicines.org.uk/emc/medicine/17175/SPC/Tilade+CFC-Free+Inhaler\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2014b</span>)  <i><span property=\"dc:title\">SPC for Intal CFC-free Inhaler 5mg Pressurised Inhalation, Suspension.</span></i> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span> <i property=\"dc:publisher\">Datapharm Communications Ltd.</i>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2015</span>) <em><span property=\"dc:title\">SPC for Formoterol Easyhaler 12 micrograms per dose inhalation powder.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/product/312\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2016a</span>) <em><span property=\"dc:title\">SPC for Easyhaler Salbutamol 200mcg.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/product/6340\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2016b</span>) <em><span property=\"dc:title\">SPC for Accolate 20mg Film-coated Tablets.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/medicine/2269\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2016c</span>) <em><span property=\"dc:title\">SPC for Slo-Phyllin 60mg, 125mg, 250mg Capsules.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/product/7760\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2017a</span>) <em><span property=\"dc:title\">SPC for Nuelin SA 250 mg Tablets.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/product/1329\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2017b</span>) <em><span property=\"dc:title\">SPC for Uniphyllin Continus 200 mg, 300 mg and 400 mg prolonged release tablets.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/product/7719\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2018a</span>) <em><span property=\"dc:title\">SPC for Montelukast 10 mg film coated tablets.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/product/1243\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2018b</span>) <em><span property=\"dc:title\">SPC for Atrovent Inhaler CFC-Free.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/product/61\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">ABPI</span> (<span property=\"dcterms:issued\">2018c</span>) <em><span property=\"dc:title\">SPC for Spiriva 18 microgram inhalation powder, hard capsule.</span></em> <span property=\"bibo:Collection\">Electronic Medicines Compendium.</span>  <em property=\"dc:publisher\">Datapharm Communications Ltd.</em>. <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc/\" target=\"_blank\" class=\"website\">www.medicines.org.uk/emc/</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/product/1693\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">Asthma UK</span> (<span property=\"dcterms:issued\">2018</span>) <em><span property=\"dc:title\">Your Asthma Action Plan.</span></em> <em property=\"dc:publisher\">Asthma UK</em>. <span rel=\"bibo:Website\"><a href=\"http://www.asthma.org.uk\" target=\"_blank\" class=\"website\">www.asthma.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.asthma.org.uk/globalassets/health-advice/resources/adults/adult-asthma-action-plan.pdf\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">BMA and NHS Employers</span> (<span property=\"dcterms:issued\">2017</span>) <em><span property=\"dc:title\">Summary of changes to QOF 2017/18.</span></em> <em property=\"dc:publisher\">NHS</em>. <span rel=\"bibo:Website\"><a href=\"http://www.nhsemployers.org\" target=\"_blank\" class=\"website\">www.nhsemployers.org</a></span></span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">BNF 72</span> (<span property=\"dcterms:issued\">2016</span>) <em><span property=\"dc:title\">British National Formulary.</span></em> <em property=\"dc:publisher\">British Medical Association and Royal Pharmaceutical Society of Great Britain.</em>.</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">BNF</span> (2018) <em><span property=\"dc:title\">British National Formulary.</span></em>75th edn. London:  British Medical Association and Royal Pharmaceutical Society.</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">British Lung Foundation</span> (<span property=\"dcterms:issued\">2018</span>) <em><span property=\"dc:title\">Asthma Statistics.</span></em> <em property=\"dc:publisher\">BLF</em>. <span rel=\"bibo:Website\"><a href=\"http://www.blf.org.uk\" target=\"_blank\" class=\"website\">www.blf.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://statistics.blf.org.uk/asthma?_ga=2.62730156.1266003558.1521461087-1489201466.1521461087\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">British Thoracic Society and Scottish Intercollegiate Guidelines Network</span> (<span property=\"dcterms:issued\">2016</span>) <em><span property=\"dc:title\">British guideline on the management of asthma.</span></em> <em property=\"dc:publisher\">British Thoracic Society and Scottish Intercollegiate Guidelines Network.</em>. <span rel=\"bibo:Website\"><a href=\"http://www.brit-thoracic.org.uk\" target=\"_blank\" class=\"website\">www.brit-thoracic.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">CHM</span> (<span property=\"dcterms:issued\">2006</span>) <span property=\"dc:title\">High dose inhaled steroids: new advice on supply of steroid treatment cards.</span> <em property=\"dc:publisher\">Current Problems in Pharmacovigilence.</em> <strong property=\"bibo:volume\">31</strong>(<span property=\"bibo:Issue\">May</span>), <span property=\"bibo:pageStart\">5</span><span property=\"bibo:pageEnd\"></span>.</span></li><li><span property=\"bibo:Article\">  <span property=\"bibo:authorList\">DynaMed Plus</span> (<span property=\"dcterms:issued\">2016</span>) <em><span property=\"dc:title\">Asthma in adults and adolescents.</span></em> <em property=\"dc:publisher\">DynaMed Plus</em>.</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">GINA</span> (<span property=\"dcterms:issued\">2016</span>) <em><span property=\"dc:title\">Global strategy for asthma management and prevention.</span></em> <em property=\"dc:publisher\">Global Initiative for Asthma.</em>. <span rel=\"bibo:Website\"><a href=\"http://www.ginasthma.org\" target=\"_blank\" class=\"website\">www.ginasthma.org</a></span></span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">Horak, E., Lanigan, A. and Roberts, M. et al</span> (<span property=\"dcterms:issued\">2003</span>) <span property=\"dc:title\">Longitudinal study of childhood wheezy bronchitis and asthma: outcome at age 42.</span> <em property=\"dc:publisher\">British Medical Journal.</em> <strong property=\"bibo:volume\">326</strong>(<span property=\"bibo:Issue\">7386</span>), <span property=\"bibo:pageStart\">422</span>-<span property=\"bibo:pageEnd\">423</span>. [<span rel=\"bibo:Abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/12595380\" target=\"_blank\" class=\"abstract\">Abstract</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">London and South East Medicines Information Service, South West Medicines Information Service, Croydon Clinical Commissioning Group</span> (<span property=\"dcterms:issued\">2014</span>)  <i><span property=\"dc:title\">Suggestions for drug monitoring in adults in primary care.</span></i> <i property=\"dc:publisher\">UK Medicines Information.</i>. <span rel=\"bibo:Website\"><a href=\"http://www.ukmi.nhs.uk\" target=\"_blank\" class=\"website\">www.ukmi.nhs.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"http://www.ukmi.nhs.uk\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">Mukherjee, M., Stoddart, A. and Gupta, R.P. et al</span> (<span property=\"dcterms:issued\">2016</span>) <span property=\"dc:title\">The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases.</span> <em property=\"dc:publisher\">BMC Med.</em> <strong property=\"bibo:volume\">14</strong>(<span property=\"bibo:Issue\">1</span>), <span property=\"bibo:pageStart\">113</span><span property=\"bibo:pageEnd\"></span>. [<span rel=\"bibo:Abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27568881\" target=\"_blank\" class=\"abstract\">Abstract</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">National Institute of Health and Care Excellence</span> (<span property=\"dcterms:issued\">2013</span>) <em><span property=\"dc:title\">Quality Standard [QS43]: Smoking.</span></em> <em property=\"dc:publisher\">NICE</em>. <span rel=\"bibo:Website\"><a href=\"http://www.nice.org.uk\" target=\"_blank\" class=\"website\">www.nice.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.nice.org.uk/guidance/qs43\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">National Institute of Health and Care Excellence</span> (<span property=\"dcterms:issued\">2017a</span>) <em><span property=\"dc:title\">Asthma: diagnosis, monitoring and chronic asthma management.</span></em> <em property=\"dc:publisher\">NICE</em>. <span rel=\"bibo:Website\"><a href=\"http://www.nice.org.uk\" target=\"_blank\" class=\"website\">www.nice.org.uk</a></span></span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">National Institute of Health and Care Excellence</span> (<span property=\"dcterms:issued\">2017b</span>) <em><span property=\"dc:title\">Quality Standard [QS25]: Asthma.</span></em> <em property=\"dc:publisher\">NICE</em>. <span rel=\"bibo:Website\"><a href=\"http://www.nice.org.uk\" target=\"_blank\" class=\"website\">www.nice.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.nice.org.uk/guidance/qs25\" target=\"_blank\" class=\"fulltextlink\">Free Full-text</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">Olin, J.T. and Wechsler, M.</span> (<span property=\"dcterms:issued\">2014</span>) <span property=\"dc:title\">Asthma: pathogenesis and novel drugs for treatment.</span> <em property=\"dc:publisher\">British Medical Journal.</em> <strong property=\"bibo:volume\">349</strong><span property=\"bibo:Issue\"></span>, <span property=\"bibo:pageStart\">g5517</span><span property=\"bibo:pageEnd\"></span>.</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">Phelan P.D., Robertson C.F. and and Olinsky A.</span> (<span property=\"dcterms:issued\">2002</span>)  <span property=\"dc:title\">The Melbourne Asthma Study: 1964-1999.</span> <i property=\"dc:publisher\">J Allergy Clin Immunol.</i> <b property=\"bibo:volume\">109</b>(<span property=\"bibo:Issue\">2</span>), <span property=\"bibo:pageStart\">189</span>-<span property=\"bibo:pageEnd\">194</span>.</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:editorList\">Preston,C.L.</span> (Eds.) (<span property=\"dcterms:issued\">2016</span>) <em><span property=\"dc:title\">Stockley's drug interactions 2015: pocket companion.</span></em><span property=\"bibo:edition\"></span> London: <span property=\"bibo:publisher\">Pharmaceutical Press.</span>.</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">Subbarao, P., Anand, S.S. and Becker, A.B. et al</span> (<span property=\"dcterms:issued\">2015</span>) <span property=\"dc:title\">The Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining developmental origins of allergy and asthma.</span> <em property=\"dc:publisher\">Thorax.</em> <strong property=\"bibo:volume\">70</strong>(<span property=\"bibo:Issue\">10</span>), <span property=\"bibo:pageStart\">998</span>-<span property=\"bibo:pageEnd\">1000</span>. [<span rel=\"bibo:Abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26069286\" target=\"_blank\" class=\"abstract\">Abstract</a></span>]</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">Warner,J.</span> (2006) <em>Personal communication.<span property=\"dc:title\"></span></em> Consultant in Paediatrics, Imperial College, St Mary's Hospital: London.</span></li><li><span property=\"bibo:Article\">\n  <span property=\"bibo:authorList\">White,J.,  Paton, J.Y., Niven, R. and and Pinnock, H.</span> (<span property=\"dcterms:issued\">2017</span>) <span property=\"dc:title\">Guidelines for the diagnosis and management of asthma: a look at the key differences between BTS/ SIGN and NICE.</span> <em property=\"dc:publisher\">Thorax</em> <strong property=\"bibo:volume\">doi:10.1136</strong><span property=\"bibo:Issue\"></span>.</span></li></ul><!-- end field 024827b7-afdb-4e29-ba76-8b7b1c808b6b --><!-- end item 4292b777-4c53-411b-ad77-95f72ba7bc7b -->",
      "containerElement": "references",
      "children": [],
      "depth": 1,
      "pos": 11
    }
  ],
  "latestChanges": [
    {
      "dateFrom": "2018-04-01T00:00:00+01:00",
      "dateTo": "2018-04-30T23:59:59+01:00",
      "title": "Minor update",
      "body": "New product availability Spiriva Respimat is now licensed as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year."
    },
    {
      "dateFrom": "2018-03-01T00:00:00+00:00",
      "dateTo": "2018-03-31T23:59:59+01:00",
      "title": "Reviewed and updated",
      "body": "A literature search was conducted in March 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made."
    }
  ]
}
